

ORCA - Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/110818/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., Warris, A., Ader, F., Akova, M., Arendrup, M. C., Barnes, R. A., Beigelman-Aubry, C., Blot, S., Bouza, E., Brüggemann, R. J. M., Buchheidt, D., Cadranel, J., Castagnola, E., Chakrabarti, A., Cuenca-Estrella, M., Dimopoulos, G., Fortun, J., Gangneux, J.-P., Garbino, J., Heinz, W. J., Herbrecht, R., Heussel, C. P., Kibbler, C. C., Klimko, N., Kullberg, B. J., Lange, C., Lehrnbecher, T., Löffler, J., Lortholary, O., Maertens, J., Marchetti, O., Meis, J.F., Pagano, L., Ribaud, P., Richardson, M., Roilides, E., Ruhnke, M., Sanguinetti, M., Sheppard, D. C., Sinkó, J., Skiada, A., Vehreschild, M. J. G. T., Viscoli, C. and Cornely, O. A. 2018. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection 24 (Supple), e1-e38. 10.1016/j.cmi.2018.01.002

Publishers page: http://dx.doi.org/10.1016/j.cmi.2018.01.002

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Diagnosis and Management of Aspergillus Diseases: Executive Summary of the 2017 ESCMID-ECMM-ERS Guideline

-		
4	An	drew J. Ullmann ^{1,61,62} , Jose M. Aguado ^{2,61,62} , Sevtap Arikan-Akdagli ^{3,61,62} , David W. Denning ^{4,5,6,62} ,
5	An	dreas H. Groll ^{7,61,62} , Katrien Lagrou ^{8,61,62} , Cornelia Lass-Flörl ^{9,61,62} , Russel E. Lewis ^{10,61} , Patricia
6	Μι	Inoz ^{11,12,13,61,64} , Paul E. Verweij ^{14,61,62} , Adilia Warris ^{15,61,62} , Florence Ader ^{16,17,63} , Murat Akova ^{18,61,62} ,
7	Ma	iken C. Arendrup ^{19,61,62} , Rosemary A. Barnes ^{20,,62} , Catherine Beigelman-Aubry ^{21,63} , Stijn
8	Blo	ot ^{22,23,63} , Emilio Bouza ^{11,12, 13,61,62} , Roger J. M. Brüggemann ^{24,61} , Dieter Buchheidt ^{25,61,62} , Jacques
9	Ca	dranel ^{26,63} , Elio Castagnola ^{27,61} , Arunaloke Chakrabarti ^{28,62} , Manuel Cuenca-Estrella ^{29,61,62} , George
10	Dir	nopoulos ^{30,63} , Jesus Fortun ^{31,61,62} , Jean-Pierre Gangneux ^{32,61,62} , Jorge Garbino ^{33,61,62} , Werner J.
11	He	inz ^{1,61,62} , Raoul Herbrecht ^{34,61} , Claus P. Heussel ³⁵² , Christopher C. Kibbler ^{36,62} , Nikolai Klimko ^{37,62} ,
12	Bai	rt Jan Kullberg ^{24,61,62} , Christoph Lange ^{38,39,40,63} , Thomas Lehrnbecher ^{41,62} , Jürgen Löffler ^{1,61,62} ,
13	Oli	vier Lortholary ^{42,61,62} , Johan Maertens ^{43,61,62} , Oscar Marchetti ^{44,61,62} , Jacques F. Meis ^{45,61,62} , Livio
14	Pa	gano ^{46,62} , Patricia Ribaud ⁴⁷ , Malcolm Richardson ^{4,61,62} , Emmanuel Roilides ^{48,49,61,62} , Markus
15	Ru	hnke ^{50,61,62} , Maurizio Sanguinetti ^{51,61,62} , Donald C. Sheppard ^{52,61,62} , János Sinkó ^{53,61} , Anna
16	Ski	ada ^{54,61,62} , Maria J. G. T. Vehreschild ^{55,56,57,62} , Claudio Viscoli ^{58,61,62} , Oliver A. Cornely ^{55,57,59,60,61,62,64}
17		
18		
	1	Department of Infectious Diseases, Hematology and Oncology, University Hospital Wuerzburg,
19	1	Department of Infectious Diseases, Hematology and Oncology, University Hospital Wuerzburg, Wuerzburg, Germany
19 20	1 2	
		Wuerzburg, Germany
20	2	Wuerzburg, Germany Infectious Diseases Unit, University Hospital Madrid, Madrid, Spain
20 21	2 3	Wuerzburg, Germany Infectious Diseases Unit, University Hospital Madrid, Madrid, Spain Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey
20 21 22	2 3	Wuerzburg, Germany Infectious Diseases Unit, University Hospital Madrid, Madrid, Spain Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey The National Aspergillosis Centre, Wythenshawe Hospital, ECMM Excellence Center of Medical
20 21 22 23	2 3 4	Wuerzburg, Germany Infectious Diseases Unit, University Hospital Madrid, Madrid, Spain Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey The National Aspergillosis Centre, Wythenshawe Hospital, ECMM Excellence Center of Medical Mycology, Manchester, United Kingdom

- 26 7 Department of Paediatric Hematology/Oncology, Center for Bone Marrow Transplantation,
- 27 University Children's Hospital Münster, Münster, Germany
- 28 8 Department of Microbiology and Immunology, ECMM Excellence Center of Medical Mycology,
- 29 University Hospital Leuven, Leuven, Belgium
- 30 9 Institute of Hygiene, Microbiology and Social Medicine, ECMM Excellence Center of Medical
- 31 Mycology, Medical University Innsbruck, Innsbruck, Austria
- 32 10 Infectious Diseases Clinic, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- 33 11 Department of Medical Microbiology and Infectious Diseases, Hospital General Universitario
- 34 Gregorio Marañón, Madrid, Spain
- 35 12 CIBER Enfermedades Respiratorias CIBERES (CB06/06/0058), Madrid Spain
- 36 13 Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
- 37 14 Department of Medical Microbiology, Radboud University Medical Centre, Center of Expertise in
- 38 Mycology Radboudumc/CWZ, ECMM Excellence Center of Medical Mycology, Nijmegen,
- 39 Netherlands
- 40 15 MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen,
- 41 Aberdeen, United Kingdom
- 42 16 Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France
- 43 17 Inserm 1111, French International Centre for Infectious Diseases Research (CIRI), Université
- 44 Claude Bernard Lyon 1, Lyon, France
- 45 18 Department of Medicine, Section of Infectious Diseases, Hacettepe University Medical School,
- 46 Ankara, Turkey
- 47 19 Department Microbiological Surveillance and Research, Statens Serum Institute, Copenhagen,
- 48 Denmark
- 49 20 Department of Medical Microbiology and Infectious Diseases, Institute of Infection and
- 50 Immunity, School of Medicine, Cardiff University, Cardiff, UK

- 51 21 Department of Diagnostic and Interventional Radiology, Centre Hospitalier Universitaire Vaudois
- 52 (CHUV), Lausanne, Switzerland
- 53 22 Department of Internal Medicine, Ghent University, Ghent, Belgium
- 54 23 Burns, Trauma and Critical Care Research Centre, University of Queensland, Brisbane, Australia
- 55 24 Radboud Center for Infectious Diseases, Radboud University Medical Centre, Center of Expertise
- 56 in Mycology Radboudumc/CWZ, ECMM Excellence Center of Medical Mycology, Nijmegen,
- 57 Netherlands
- 58 25 Medical Clinic III, University Hospital Mannheim, Mannheim, Germany
- 59 26 Department of Pneumology, University Hospital of Tenon and Sorbonne, University of Paris,
- 60 Paris, France
- 61 27 Infectious Diseases Unit, Istituto Giannina Gaslini Children's Hospital, Genoa, Italy
- 62 28 Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research,
- 63 Chandigarh, India
- 64 29 Instituto de Salud Carlos III, Madrid, Spain
- 65 30 Department of Critical Care Medicine, Attikon University Hospital, National and Kapodistrian
- 66 University of Athens, Medical School, Athens, Greece
- 67 31 Infectious Diseases Service, Ramón y Cajal Hospital, Madrid, Spain
- 68 32 Univ Rennes, CHU Rennes, Inserm, Irset (Institut de Recherche en santé, environnement et
- 69 travail) UMR_S 1085, Rennes, France
- 70 33 Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
- 71 34 Department of Hematology and Oncology, University Hospital of Strasbourg, Strasbourg, France
- 72 35 Diagnostic and Interventional Radiology, Thoracic Clinic, University Hospital Heidelberg,
- 73 Heidelberg, Germany
- 74 36 Centre for Medical Microbiology, University College London, London, UK
- 75 37 Department of Clinical Mycology, Allergy and Immunology, North Western State Medical
- 76 University, St. Petersburg, Russia

77	38	International Health and Infectious Diseases, University of Lübeck, Lübeck, Germany
78	39	Clinical Infectious Diseases, Research Center Borstel, Leibniz Center for Medicine & Biosciences,
79		Borstel, Germany
80	40	German Center for Infection Research (DZIF), Tuberculosis Unit, Hamburg-Lübeck-Borstel-Riems
81		Site, Lübeck, Germany
82	41	Division of Paediatric Haematology and Oncology, Hospital for Children and Adolescents, Johann
83		Wolfgang Goethe-University, Frankfurt, Germany
84	42	Department of Infectious and Tropical Diseases, Children's Hospital, University of Paris, Paris,
85		France
86	43	Department of Haematology, ECMM Excellence Center of Medical Mycology, University Hospital
87		Leuven, Leuven, Belgium
88	44	Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne,
89		Switzerland
90	45	Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital,
91		Center of Expertise in Mycology Radboudumc/CWZ, ECMM Excellence Center of Medical
92		Mycology, Nijmegen, Netherlands
93	46	Department of Hematology, Universita Cattolica del Sacro Cuore, Roma, Italy
94	47	Quality Unit, Pôle Prébloc, Saint-Louis and Lariboisière Hospital Group, Assistance Publique-
95		Hôpitaux de Paris, Paris, France
96	48	Infectious Diseases Unit, 3rd Department of Paediatrics, Faculty of Medicine, Aristotle University
97		School of Health Sciences, Thessaloniki, Greece
98	49	Hippokration General Hospital, Thessaloniki, Greece
99	50	Department of Hematology and Oncology, Paracelsus Hospital, Osnabrück, Germany
100	51	Institute of Microbiology, Fondazione Policlinico Universitario A. Gemelli – Università Cattolica
101		del Sacro Cuore, Rome, Italy

102 52 Division of Infectious Diseases, Department of Medicine, Microbiology and Immunology, McGill

103 University, Montreal, Canada

104 53 Department of Hematology and Stem Cell Transplantation, Szent István and Szent László

105 Hospital, Budapest, Hungary

106 54 First Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens,

107 Athens, Greece

- 108 55 Department I of Internal Medicine, ECMM Excellence Center of Medical Mycology, University
- 109 Hospital of Cologne, Cologne, Germany
- 110 56 Center for Integrated Oncology, Cologne-Bonn, University of Cologne, Cologne, Germany
- 111 57 German Centre for Infection Research (DZIF) partner site Bonn-Cologne, Cologne, Germany
- 112 58 Ospedale Policlinico San Martino and University of Genova (DISSAL), Genova, Italy
- 113 59 CECAD Cluster of Excellence, University of Cologne, Cologne, Germany
- 114 60 Clinical Trials Center Cologne, University Hospital of Cologne, Cologne, Germany
- 115 61 ESCMID Fungal Infection Study Group (EFISG)
- 116 62 European Confederation of Medical Mycology (ECMM)
- 117 63 European Respiratory Society (ERS)
- 118 64 ESCMID European Study Group for Infections in Compromised Hosts (ESGICH)
- 119

Acknowledgement: Professor William Hope was a member of the TDM group, however, he stepped down during the process of guideline development due to his new post as guideline director of ESCMID to avoid any conflicts of interest. His contributions were very much appreciated to the entry guideline group. We are thankful for his help. We also thank Dr Vincent Dunet (Department of Diagnostic and Interventional Radiology, CHUV, Lausanne, Switzerland) and Dr Frédéric Lamoth (Department of Infectious Disease, CHUV, Lausanne, Switzerland) for their help and contribution to this guideline. We are indebted to Kerstin Albus, MSc, for her critical review and corrections of the manuscript.

- 128 **Funding:** European Society of Clinical Microbiology and Infectious Diseases (ESCMID), European
- 129 Confederation of Medical Mycology (ECMM) and European Respiratory Society (ERS)
- 130

131 Corresponding author

- 132 Prof. Oliver A. Cornely, MD, FECMM, FIDSA, FAAM, FACP
- 133 Department I for Internal Medicine
- 134 ECMM Excellence Center of Medical Mycology
- 135 University Hospital
- 136 Kerpener Str. 62
- 137 50937 Cologne
- 138 Germany
- 139 Tel. +49 221 478 85523
- 140 Fax +49 221 478 1421 445
- 141 E-mail: Oliver.cornely@uk-koeln.de

142 Abstract

143 The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation 144 of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis 145 and management of aspergillosis. Of the numerous recommendations a few are summarized here. 146 Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients 147 with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct 148 microscopy preferably using optical brighteners, histopathology and culture are strongly 149 recommended. Serum and BAL galactomannan is recommended as markers for the diagnosis of IA. 150 PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species 151 complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal 152 susceptibility testing should be done in patients with invasive disease in regions with resistance found 153 in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents 154 for first line treatment of pulmonary IA, while liposomal amphotericin B is moderately supported. 155 Combinations of antifungals as primary treatment options are not recommended. TDM is strongly 156 recommended for patients receiving posaconazole suspension or any form of voriconazole for IA 157 treatment, and in refractory disease, where a personalized approach considering reversal of 158 predisposing factors, switching drug class and surgical intervention is also strongly recommended. 159 Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous 160 leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is 161 strongly recommended in high-risk patients. We strongly recommend treatment duration based on 162 clinical improvement, degree of immunosuppression and response on imaging.

164 Introduction

165 This is the third fungal diagnosis and management clinical guideline published in cooperation with 166 various European scientific societies [1-9]. This part of the guideline regarding invasive and chronic 167 aspergillosis is a condensation of all the recommendations made by the guideline subcommittees and 168 presented in tables for easier and faster reading. More details on how the recommendations were 169 arrived at are planned in supplementary publications. This Aspergillus guideline will follow the style of 170 other guidelines by including diagnostic and therapeutic guidance. Other scientific groups have 171 published guidelines on this topic previously and all follow the common goal to provide clinicians with 172 best guidance in their everyday working environment. Our goal was to provide a comprehensive 173 European guideline focusing on the life-threatening diseases caused by *Aspergillus* spp.

174

175 Methods

176 Author panel recruitment and organisation was similar to what was done previously [10]. In brief, 177 experts in the field were nominated by the three societies ESCMID, ECMM, and ERS. The total 53 178 authors were grouped into their special fields of expertise. Subgroup coordinators were responsible 179 for the first draft of recommendations. There were two face-to-face meetings followed by numerous 180 electronic exchanges. Some of the first recommendations were presented at ECCMID 2014. This 181 summary was reviewed and approved by all authors and sent to the ESCMID guideline director for 182 public review. Then the final version was submitted to Clinical Microbiology and Infection for 183 additional peer review and subsequent publication. Only the rationale of the chronic pulmonary 184 aspergillosis (CPA) guideline was published ahead of time [11].

Questions were predefined and modified where appropriate and the strength of recommendation and quality of evidence was slightly modified (Table 1) [12]. Diagnostic tests are regarded as interventions.

187

188 Summary of Recommendations

189 Diagnostic Procedures

Early diagnosis of invasive aspergillosis (IA) is a challenge and should be based on the integration ofclinical, radiological and microbiological data.

192

193 Thoracic Imaging

194 In patients at risk for IA with fever of unknown origin or clinical symptoms of lower respiratory tract 195 infection who remain febrile despite broad-spectrum antibacterial treatment, thin-section chest 196 computed tomography (multidetector (MDCT), multislice (MSCT), spiral CT, high resolution CT) at 197 optimized dose (according to ALARA "As Low As Reasonably Achievable" principle) is the imaging 198 modality of choice (AII) [13-23]. Pulmonary CT angiography may be of interest in the early diagnosis of 199 IA by depicting directly vessel occlusion at the level of a suspicious fungal lesion with a potential high 200 negative predictive value regarding imaging evaluation [24-26], and is required in case of haemoptysis 201 (AII). In selected patients where CT is not wanted or feasible, MRI of the lungs may represent an 202 alternative imaging to thin-section MSCT [27-32], PET-CT being of modest interest in the diagnostics 203 of IA [33, 34].

204 No CT scanning technique is 100% sensitive or specific for pulmonary IA [35-37]: Classical CT findings 205 of angioinvasive aspergillosis include macronodule(s) >1 cm, which may be surrounded by a halo of 206 ground-glass attenuation (halo sign, early phase, inconstant) [36, 38-40], pleural based wedge-shaped 207 areas of consolidation [41], alveolar consolidations [36, 42, 43], masses (especially in SOT recipients) 208 [15, 38], internal low attenuation[44], reverse halo sign [45], cavity or air-crescent sign (delayed 209 finding), ground glass opacities and pleural effusion [17, 35, 46]. Bronchoinvasive forms may appear 210 as tracheal or bronchial wall thickening, centrilobular nodules with tree in bud appearance [14] in a 211 patchy distribution, predominant peribronchial areas of consolidation [47] or bronchopneumonia [46] (Table 2). 212

213

214 Bronchoalveolar Lavage and Biopsies

Other diagnostic procedures include early bronchoalveolar lavage (BAL) (AII) [48-54], guided by CTfindings [55, 56], and less frequently CT-guided transthoracic biopsies, video-assisted thoracoscopic surgery (VATS), open lung biopsies, transbronchial biopsies or convex endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), the latter technique appearing to be a promising procedure in this setting [28, 57-72]. Contraindications to these techniques need to be considered.

220

221 Imaging of other Sites

Moreover, according to clinical symptoms, paranasal CT, CT or MRI of the CNS as well as abdominal CT may also be required. In particular, findings of sinusitis with bone erosion may be observed, intracranial and/or intraorbital extension of the disease being best evaluated by MRI [73-75]. In the brain, due to direct spread from paranasal sinuses or haematogenous dissemination, meningeal enhancement or empyema, cerebral abscess, mycotic aneurysms as well as haemorrhagic lesions and rarely stroke may be seen [76-79].

228

229 Microscopy and Culture

230 Both microscopy and culture should be attempted on appropriate specimens from patients at risk for 231 IA (AII) with a priority for culture in most cases where insufficient material is available. Demonstrating 232 tissue invasion by hyphae through microscopic examination of biopsy or autopsy material provides a 233 diagnosis of proven invasive fungal infection. However, the sensitivity of microscopy for IA is 50% at 234 best [80]. Specimens may be examined as a wet mount preparation with or without the addition of 235 10% potassium hydroxide. Fluorescent dyes such as Calcofluor White™ or Blancophor™ have the 236 advantages of increased sensitivity, rapid turnaround time, and broad applicability but are not specific 237 for Aspergillus (AII). Gomori's methenamine silver stain (GMS) and periodic acid-Schiff (PAS) can be 238 applied to histological sections and smears and should be conducted in all cases in which IA is 239 considered a possibility (Table 3). Respiratory secretions from patients with suspected aspergillosis 240 must be processed rapidly for culture to prevent overgrowth by bacteria and yeasts. To achieve

optimal recovery of *Aspergillus* from BAL fluid, centrifugation of the sample is advised with investigation of the sediment **(AIII)**. It is recommended that cultures of high volume untreated sputum and BAL should be performed as opposed to culturing small volumes of digested, liquefied samples [81] (Table 4). Specific media to support fungal growth are recommended. Species identification to the complex level should be done for clinically relevant isolates from patients who need antifungal treatment, and for epidemiological purposes (AIII) (Table 5).

247

248 Non-Culture Based Assays

Galactomannan (GM) detection in fluids (especially BAL) is more sensitive than culture for diagnosis of IA. GM is reported as optical density index (ODI). In serum samples an ODI cut-off of 0.5 results in high sensitivity in haematological patients in the absence of mould-active prophylaxis (AI) (Table 6). Serial screening for serum GM in prolonged neutropenia and in allogeneic stem cell transplantation recipients during the early engraftment phase has a high sensitivity and negative predictive value (NPV) for IA (AII) [82]. Serial screening is not recommended in patients on mould-active prophylaxis [83].

Sensitivity of serum GM testing is significantly lower in non-neutropenic versus neutropenic patients [84]. Decrease of the ODI during the first two weeks of antifungal therapy is a reliable predictor of a satisfactory response in cancer patients [85]. GM detection in BAL specimens has an excellent performance with evidence that ODI of 0.5–1.0 has decreased predictive values compared with results of >1.0 [86] (AII) (Table 7). The test also has diagnostic value in patients undergoing lung transplantation or who are in intensive care [87-89]; a sensitivity of 100% and a specificity of 90.4% was defined at cut-off of 1.5 [87].

(1-3)-β-D-glucan (BDG) is a constituent of the cell wall of many species and genera of fungi and is
released into body fluids in association with fungal infection. A limited role is given for the exclusive
testing of the BDG in diagnosing IA (BII) (Table 8), however, the combination with GM or PCR improves
specific detection [90].

The *Aspergillus* lateral flow LFD assay can be performed on serum and on BAL samples, but at the timeof writing this assay is not commercially available [91] (Table 9).

Aspergillus PCR has been applied mostly to blood and BAL fluid. For both sample types, a combination with other biomarkers increases the likelihood of IA [92, 93]. The performance of serum PCR is not significantly different from that of whole blood [94-97]. Prospective screening of high-risk haematological patients by a combination of GM and PCR improves the diagnostic accuracy and is associated with an earlier diagnosis [98, 99] (Table 10 and 11).

273 On hyphal positive biopsy samples molecular detection of fungi is strongly recommended **(AII)**. If no 274 hyphae are visible the diagnostic yield of molecular methods is lower (Table 12). Recommendations 275 for storage of original samples and isolates are given in table 13. Antibody detection tests are not 276 supported for the diagnosis of IA **(CII)** (Table 14).

277

278 Antifungal Susceptibility Testing

279 Resistance to antifungal agents is an increasing problem in Aspergillus diseases [100-102]. Aspergillus 280 species can be intrinsically resistant to polyenes and azoles [103], or may acquire resistance following 281 exposure to azole compounds [104]. Acquired resistance to azoles is mainly found in Aspergillus 282 fumigatus and is reported globally [100, 101, 105-108]. Resistance may also develop through exposure 283 to azole fungicides in the environment [109-112]. As resistant spores are present in ambient air, 284 patients may present with azole-resistant Aspergillus disease without previous azole therapy [113, 285 114]. Individual Aspergillus colonies from a single specimen may harbour different resistance profiles 286 [117], hence multiple colony testing (up to 5 colonies) is recommended to increase sensitivity for azole-287 resistance detection (BIII).

In clinical laboratories, species identification to complex level is recommended for all clinically
 significant isolates (BIII). Some species are intrinsically resistant to either azoles or amphotericin B
 (AmB) (Tables 5, 15, 16 and 17).

291 Antifungal susceptibility testing of Aspergillus isolates should be performed in patients with invasive 292 disease with the exception of azole naïve patients in regions with no resistance found in contemporary 293 surveillance programmes and regularly for epidemiological purposes including \geq 100 isolates. This is 294 particularly important in patients who are unresponsive to antifungal treatment, or in patients who 295 are clinically suspected having an azole-resistant pathogen (AIII) (Table 15). If MIC-testing is not 296 available, routine agar screening can be used to detect azole resistance (Table 16) [118]. However, 297 such isolate should be referred to a mycology reference laboratory for MIC testing. Clinical breakpoints 298 for interpretation of azole and AmB MICs against Aspergillus are currently available for European 299 Committee on Antimicrobial Susceptibility Testing (EUCAST) microdilution method but remain 300 undetermined for Clinical & Laboratory Standards Institute (CLSI) methodology. Accordingly, EUCAST 301 (AII) or CLSI broth microdilution methods (BII) can be used for determination of routine MICs for 302 clinical guidance and for epidemiological resistance surveillance (AII). Both itraconazole and 303 voriconazole (AII) should be tested to ensure detection of the voriconazole-resistance mutation 304 TR₄₆/Y121F/T289A [118]. Posaconazole resistance without itraconazole resistance has not been 305 reported (Table 17). EUCAST (BIII) or CLSI broth microdilution methods (CIII) can be used to determine 306 AmB MICs but although a correlation between MIC and clinical outcome exist for A. terreus and A. 307 flavus it remains to be documented for A. fumigatus due to the scarcity of resistant isolates (Table 308 17).

309 Voriconazole and isavuconazole are recommended for the treatment of IA due to species showing high 310 AmB MICs (Table 19). Liposomal AmB (L-AmB) or AmB lipid complex (ABLC) are recommended for 311 species with intrinsic high azole MICs (Table 18 and 20). In aspergillosis due to A. fumigatus specifically, 312 voriconazole or isavuconazole are recommended if the isolate is voriconazole susceptible (EUCAST MIC 313 ≤1 mg/l) (AI). If resistant (voriconazole MIC >2 mg/l), L-AmB therapy is recommended (AII_u). It is 314 unknown if patients infected with A. fumigatus with voriconazole MIC 2 mg/l (intermediate), respond 315 less well to voriconazole monotherapy. These patients may have an increased probability of failing 316 voriconazole monotherapy, and combination therapy with an echinocandin or L-AmB monotherapy

should be considered for invasive disease (AIII) (Table 20). In azole-resistant CPA, L-AmB or micafungin
can be considered (BII) if surgical intervention is precluded [11]. In settings with environmental azole
resistance, no change to the primary regimen for IA is recommended when resistance rates are <10%
(AIII). If azole resistance rates are >10%, first line therapy with voriconazole plus echinocandin (BIII) or
L-AmB (BIII) is recommended.

322

323 Therapeutic Drug Monitoring (TDM)

324 Patients with IA often have multiple conditions associated with their underlying disease and its 325 treatment that affects the absorption, distribution, metabolism, and clearance of antifungal 326 medications [119]. As a result, standardized dosing recommendations for antifungals used in the 327 prevention or treatment of IA may not achieve effective or safe drug exposures in all patients. 328 Moreover, a subset of patients with severe infections or difficult to treat sites (e.g. CNS) or infections 329 caused by Aspergillus spp. with elevated MICs may require higher drug exposures. Therapeutic drug 330 monitoring (TDM) is often the most direct laboratory approach for identifying patients at jeopardy for 331 treatment failure or toxicity because of inadequate or excessive drug exposures, and can be used to 332 fine-tune antifungal dosing to improve the probability of optimal outcomes (Table 21).

333

334 Itraconazole

335 For itraconazole, a serum trough of 0.5-4 mg/L (measured by HPLC) is recommended for prophylaxis 336 (All [efficacy], Bll [safety]) and a trough of 1-4 mg/L is recommended during the treatment of IA (All 337 [efficacy], BII [safety]) [120-125]. Itraconazole has an active metabolite, OH-itraconazole that is 338 present in similar (1:1) concentrations as the parent itraconazole compound when patients are at 339 pharmacokinetic steady state. OH-itraconazole concentrations may be reported separately when 340 samples are analysed by HPLC or LC/MS/MS, but will included in the overall report of "itraconazole" 341 concentrations if samples are analysed by bioassay [126, 127]. Therefore, the target range for 342 itraconazole is higher when reported by bioassay (i.e. 3-17 mg/L) but may vary by lab depending on

the reference standards used. Samples should be acquired within 5-7 days of starting therapy. Repeat TDM is recommended the following week to confirm the patient remains in the therapeutic range, and repeated thereafter as clinically indicated if there are changes in the patient's clinical condition, concomitant medications known to interact, or suspected toxicity (Table 22). Steady-state concentrations can often be predicted from earlier (non-steady) state samples through pharmacokinetic models or computerized dosage-assistance. In centres where these tools are available, sampling before day 5-7 may be preferable.

350

351 Voriconazole

352 A plasma trough concentration of 1-5.5 mg/L is considered adequate for most patients receiving 353 voriconazole prophylaxis or treatment (All, safety and efficacy) [128-133]. However, a trough of 2-354 6 mg/L (All, safety and efficacy) is recommended in patients treated for severe infections (multifocal 355 or disseminated disease, CNS infections, infection with pathogen with elevated MICs, e.g. an MIC of 2 356 ml/L) [130, 131]. TDM is strongly recommended in children due to the much higher rates of drug 357 elimination and potential for underdosing, especially with the lower voriconazole doses recommended 358 in the past (AII) [134, 135]. Plasma levels should be monitored between 2-5 days after initiation of 359 therapy, and repeated the following week to confirm the patient remains in the therapeutic range. 360 Repeated monitoring is indicated until steady state level in the therapeutic range is confirmed, if there 361 are changes in the patient's clinical condition, concomitant medications, or suspected toxicity (Table 362 23).

363

364 Posaconazole

For patients receiving posaconazole suspension, a plasma trough of >0.7 mg/L is recommended during prophylaxis (**BII efficacy**) [136, 137]; and a trough of >1 mg/L is recommended if the patient is receiving treatment for suspected or documented IA (**AII efficacy**) [138]. Currently, no studies have defined an upper plasma target that is associated with toxicity, although pharmacokinetic studies supporting the

369 registration of the new posaconazole tablet and intravenous formulations with the EMA used a 370 provisional cut-off of 3.75 mg/L [139-141]. Posaconazole plasma trough levels should be monitored on 371 day 5 of therapy or soon thereafter, and repeated as clinically indicated.

372 For most patients prescribed posaconazole, we recommend using the newer tablet formulation (or 373 intravenous formulation, if tablet formulation is contraindicated) rather than the suspension (AII), as 374 tablets are more likely to consistently achieve target plasma levels and are less affected by GI-375 dependent drug interactions [139]. Currently, there is limited evidence to suggest that all patients 376 receiving posaconazole tablets or IV formulation for prophylaxis require routine TDM; however, our 377 opinion is that when treating suspected or documented Aspergillus infections, TDM could still be useful 378 if the pathogen has elevated MICs, is unresponsive to treatment, or in the event of unexplained toxicity 379 (BIII). Until further data are available, we recommend using TDM monitoring strategies and plasma 380 trough targets as detailed above suggested for the suspension formulation (Table 24).

381

382 Isavuconazole

383 Although dose-response and plasma concentration-response relationships for isavuconazole have 384 been reported in animal models, limited data are currently available to define a target therapeutic 385 range or support the need for routine TDM for this agent [142]. Our opinion is that TDM could still be 386 useful in the clinical assessment or monitoring of patients receiving isavuconazole therapy (CIII) if 387 patients are unresponsive to treatment, have unexpected toxicity, pharmacokinetic drug-drug 388 interactions, or if isavuconazole is being used to treat pathogens with elevated MICs or sanctuary sites 389 such as the CNS. In the absence of well-defined therapeutic targets, documentation of a plasma trough 390 in the range of 2-3 mg/L (mean concentration range from phase II/III clinical studies) after day 5 391 (including loading doses) suggests adequate drug exposure (Table 25).

392

393 Flucytosine

In rare circumstances, flucytosine may be used in combination with other antifungals for the treatment of triazole-resistant *Aspergillus* spp. In this scenario, weekly measurement of peak serum concentrations 2 hours following an oral dose (AII) are needed to confirm that peak concentrations are 50-100 mg/L in order to reduce the risk of toxicity. Trough concentrations required for efficacy are unknown but a level of 25-50 mg/mL is recommended based upon experience from cryptococcosis [143, 144].

400

401 Hospital Environment

402 Standards for the hospital environment in immunosuppressed adults and children requires special 403 attention. Patients need to be segregated from construction or renovation (All_h), potted plants (BII), 404 and flowers in wards and in patients' rooms (CIII) [145-150]. Published data support the 405 recommendation to accommodate patients in special hospital rooms with positive air pressure and 406 HEPA filters (BII) or laminar airflow (BII_h). However, data were with historical controls, underpowered, 407 or described by multivariate analysis describing high-risk situations for IA [151-154]. Protective masks 408 for patients are proven not to be effective outside of the protected area (CII) [155]. Filters for water 409 supply, especially in showers, are recommended (BII) [156-160]. No data are available to support 410 regular environmental air sampling to prevent infections. However, indoor sampling is advisable to 411 monitor filter efficacy (BIII) [161, 162].

412

413 Treatment Strategies

Two strategies are accepted for managing patients with haematological malignancy at risk for IA: 1) the patient receives primary prophylaxis or 2) the patient receives no prophylaxis but is monitored at least twice weekly using biomarkers. The decision between the two strategies depends on local epidemiology, access to rapid diagnostics and patient characteristics. Breakthrough fungal diseases may appear through either symptoms or a disease-identifying biomarker or imaging result. Figure 1 depicts a consensus algorithm for patient management.

420

421 **Primary Prophylaxis**

422 At least three studies describe a number of patients who succumbed with IA missed prior to death 423 [163-165]. Although diagnostic procedures improved since then, they are not satisfactory. For this 424 reason, patients known to be at high risk for IA may receive primary prophylaxis, especially patients 425 with profound and prolonged neutropenia or with active graft-versus-host disease (GvHD) (Table 26).

426

427 Aspergillosis in Haematological Malignancy and Haematopoietic Stem Cell Transplantation

In patients treated for haematological diseases, prolonged severe neutropenia is the most important risk factor for the development of IA. T cell depleted grafts, glucocorticosteroids and other immune suppressive drugs have been identified as further risk factors for IA in the later course after HSCT, even in non-neutropenic patients [166]. In fact, up to two thirds of patients with IA diagnosed after allogeneic HSCT are not neutropenic [167], and the median time of diagnosis of IA after allogeneic HSCT is 82 days (range, 3 - 6542 days) [168].

434

435 Treatment

436 Providing a definite diagnosis of IA is a continuously challenging endeavour for clinicians. The 437 EORTC/MSG definitions are only designed for clinical studies. For clinical decision-making, these 438 definitions could have a deleterious outcome since confirmation of a proven or probable diagnosis 439 would delay the start of therapy [169]. Any patient at risk considered by the responsible clinician as 440 having IA should receive antifungal therapy (AIII) (Tables 27-28). Physicians should consider IV to oral 441 switch in stable and PK-reliable patients. Treatment duration depends on clinical response and on 442 immune reconstitution or recovery from GvHD. Good partial or complete remission requires no 443 persistent clinical, including imaging (scarring allowed) or microbiological evidence of disease. The 444 range of the duration of treatment (3 to >50 weeks) is huge and the evidence base to support any particular recommendation is weak [170-173]. Close monitoring (e.g. non-enhanced CT or, if
applicable, biomarkers) is suggested once antifungal treatment is discontinued.

447 Additional adjunctive therapy such as the administration of G-CSF or G-CSF-primed granulocyte 448 infusions (data mainly from paediatric populations) received only a weak supportive recommendation 449 (CIII). In refractory cases, G-CSF (or IFNγ) has immunomodulatory effects [174-179]. No controlled trials 450 have been performed and only anecdotal data with small numbers of patients exist. Persistent 451 neutropenia is related with treatment failure, recovery from neutropenia enhances the efficacy of 452 antifungal agents. A recent Cochrane review investigating the efficacy of granulocyte transfusions 453 indicated no mortality difference for any kind of infection in patients with neutropenia [180].

454

455 Fever-driven ("Empiric"), and Diagnosis-driven ("Pre-emptive") Therapy

456 As an alternative to prophylaxis, patients could receive the classical empirical administration of 457 antifungal agents during fever refractory to broad-spectrum antibacterial agents. Empiric treatment is 458 defined as a fever-driven treatment approach. Patients who would qualify for this approach are 459 patients receiving induction or remission chemotherapy for acute leukaemia or MDS or conditioning 460 chemotherapy for haematopoietic stem cell transplantation. Empiric antifungal treatment is expected 461 to reduce morbidity [181-186] and mortality [187, 188] (Table 29). The duration of empiric antifungal 462 treatment is set by the following rules applied in randomized clinical trials: If the patient is afebrile and 463 has no active infection or infiltrates, then antifungal therapy can be discontinued after recovery of 464 leukocyte counts [188-190]. Today, antifungal stewardship may warrant clinical trials on empiric 465 treatment duration, but no such trial has been conducted so far.

Pre-emptive treatment is a diagnosis driven strategy. In most cases, it is defined by positive GM testing. However, chest CT with pulmonary infiltrates could apply as well. The use of BDG and PCR testing as alternative biomarkers for galactomannan have considerable merit [191, 192], though BDG is not specific for *Aspergillus* disease. In haematological patients, false positive BDG often results from contaminated infusions [193-196]. Very few authors wait for *Aspergillus*-associated suggestive radiological signs including nodule, halo sign, wedge-shaped area of consolidation, or – late in the
course of invasive aspergillosis – the air crescent sign, before starting antifungal treatment. Treatment
choices are as recommended in targeted treatment.

474

475 Adult Patients without Haematological Malignancy

476 **Epidemiology**

477 Approximately 43-80% of the cases of IA appear in patients without a haematological malignancy [52, 478 197-200], although these patients are rarely included in the seminal studies of antifungals [170, 171, 479 173]. The proportion of these patients is even increased when exposed to spore concentrations of >25 480 cfu/m³ in hospital air [201-204]. The non-haematological populations at risk for IA include solid organ 481 transplant recipients (SOT), patients treated with prolonged high dose glucocorticosteroids, or with 482 other immunosuppressants, patients with advanced AIDS or neoplasia, COPD, liver failure, liver 483 cirrhosis, influenza as well as critically ill patients requiring ICU admission [52, 197-199, 205-208]. 484 These patients frequently do not fulfil the EORTC/MSG criteria for invasive aspergillosis [169]. 485 Confirmation of diagnosis may be delayed resulting in high mortality rates. At the same time drug-drug 486 interactions and toxicity can occur more frequently compared to haematological patients [52]. 487 Physicians need to be aware of the specific risk factors, clinical manifestations and management 488 challenges in order to improve outcome. In SOT recipients the average incidence of IA ranges from 0.1 489 to 11.6% [209, 210], with the highest risk in small bowel (11.6%) and lung (8.6%) transplant recipients, 490 followed by patients receiving liver (4.7%), heart (4.0%), pancreas (3.4%), and kidney (1.3%) grafts 491 [209-211]. Half the cases will occur in the first three months after transplantation, in patients with 492 post-surgical risk factors. Late aspergillosis is more common in elderly recipients, and patients with 493 pronounced immunosuppression due to rejection or post-transplant neoplasia or chronically impaired 494 graft function [210, 212]. With the exception of lung transplantation, in which universal prophylaxis is 495 still common, antifungal prophylaxis will target SOT recipients with additional risk factors [211]. Risk 496 factors for early IA in all SOT recipients – Including heart transplants – comprise renal failure requiring 497 replacement therapy, re-intervention, CMV disease, and high environmental exposure to mould 498 spores [211, 213-215]. In liver transplantation, high model for end-stage liver disease (MELD) score, 499 transplantation in fulminant hepatic failure, high intraoperative transfusion needs or re-500 transplantation are considered indications for post-surgical prophylaxis [216-224]. In lung transplant 501 recipients, risk factors include previous respiratory tract colonization with Aspergillus, single lung 502 transplant, CMV disease and acquired hypogammaglobulinaemia [225-227]. In kidney transplantation 503 risk factors include COPD, delayed graft function, bloodstream infection, and acute graft rejection 504 [228] and an >1.25 mg/kg/day average dose of prednisone [229]. Finally, some polymorphisms in 505 defence genes have also been suggested to increase risk in transplant recipients [230, 231].

The incidence of IA in HIV patients has decreased since the advent of new antiretroviral therapy (2.2 cases per 10,000/year), but mortality remains high (38%) [232]. IA typically appears in patients with low CD4 counts and associated conditions such as neutropenia, advanced cirrhosis, liver transplantation or glucocorticosteroid therapy [233-241]. As in other non-haematological populations, EORTC/MSG criteria only detect half of the IA cases diagnosed among HIV-infected patients [232] and in a recent series of autopsies of AIDS patients, only 12% of the patients with IA had been diagnosed ante mortem [242] (Table 30).

IA may affect 0.3% of patients with liver cirrhosis [243]. Both acute liver failure and advanced cirrhosis, mainly alcoholic hepatitis treated with glucocorticosteroids, have been recognized as risk factors for IA [205, 244-246]. A low level of clinical suspicion explains that 53% of the cases of IA in cirrhotic patients are only recognized post-mortem [247] and that liver disease is independently associated with IA-related mortality [199, 248].

IA has also been described in apparently immunocompetent patients in a critical condition as a complication of ARDS, COPD, influenza, pneumonia, burns, severe bacterial infection, surgery, and malnutrition. Incidence is 4-6/1,000 ICU admissions and the mortality is higher than 70% in most series [245, 249-252]. Glucocorticosteroid treatment was the major host factor [253, 254] and as in cirrhotic or HIV positive patients delayed diagnosis is common [255, 256]. COPD patients requiring glucocorticosteroids represent a group with especially high mortality [249, 257, 258]. Risk factors
include admission to ICU, chronic heart failure, and antibiotic treatment and, above all, the cumulative
dose of glucocorticosteroids [257].

526 Pulmonary and CNS aspergillosis predominates in these populations, but disseminated disease, 527 fulminant and atypical forms may occur [203, 214, 225, 251, 259-267]. The sensitivity of most 528 diagnostic methods is lower in non-haematological patients. Isolation of Aspergillus from respiratory 529 cultures has a much lower positive predictive value so over-diagnosis has to be prevented [197, 268-530 272]. Regarding imaging findings, angioinvasive presentation included in the EORTC/MSG criteria is 531 uncommon in this setting [273]. Airway invasive radiological presentation was present in 37% of heart 532 transplant recipients and was associated with delayed diagnosis and poorer prognosis [214, 274]. In 533 COPD and HIV-positive patients, the most common radiological presentation was an alveolar infiltrate 534 [273, 275, 276]. Experience with biomarkers and PCR is still scarce in these populations, but the 535 combination of at least two different methods appears to be the best diagnostic approach [277-285] 536 (Table 31).

537

538 Treatment

539 Despite no comparative studies of antifungal therapy in non-haematological patients voriconazole 540 remains the first option, since it has been related to reduced mortality [216, 286-288] (Table 32). 541 Combination therapy is uncommon, although retrospective data was encouraging in SOT recipients 542 [289]. The risks of drug-drug interactions and toxicity are very important in these populations and TDM 543 is advisable [290-295]. In patients with liver insufficiency, L-AMB is usually the first therapeutic option. 544 Antifungal resistance is not a common problem despite prophylaxis [296, 297], although some cases 545 have been reported [298-300]. Finally, immune reconstitution syndrome may occur after therapy 546 initiation [301].

547 Most lung recipients receive antifungal prophylaxis. Targeted prophylaxis is preferred in the remaining 548 SOT with risk factors [211, 213, 302-305]. However, significant variation in practice has been noted

549 [221, 304, 306, 307]. In order to avoid drug-drug interactions and toxicity, echinocandins or inhaled 550 amphotericin are preferentially used [308-311], although voriconazole has also demonstrated its 551 efficacy and safety in this setting [217, 220, 312-314]. Duration of prophylaxis is adjusted to the 552 presence of risk factors and, with the exception of lung recipients, is usually limited to 3-4 weeks [215] 553 (Table 33).

554

555 Special Considerations in Children

Presenting symptoms, distributions and patterns of diseases and vulnerability to IA are similar between children and adults. However, differences exist in epidemiology and underlying conditions, usefulness of newer diagnostic tools, pharmacology of antifungal agents and evidence from interventional phase III studies. Recommendations for paediatric patients are based on efficacy in phase II and III trials in adults, the availability of paediatric pharmacokinetic data, safety data and supportive efficacy data. In addition, regulatory approval is considered as well. Therapeutic drug monitoring is always recommended when mould-active azoles are used as prophylaxis or treatment.

563 Primary antifungal prophylaxis may be indicated in paediatric patients at 'high risk' for developing 564 invasive fungal diseases, and specifically IA. An incidence rate of IFDs of ≥10% is usually considered as 565 high risk. High-risk populations include children with de novo or recurrent leukaemia (e.g. AML, ALL 566 depending on treatment protocol), bone marrow failure syndromes with profound and persistent 567 neutropenia (e.g. MDS, VSAA), allogeneic HSCT recipients, patients with chronic granulomatous 568 disease and those undergoing lung transplantation. For patients with haematological disorders, the 569 mould-active oral azoles are the first choice to prevent IA in children, although neither itraconazole 570 nor posaconazole are licensed for use in patients <18 years of age. Due to the lack of paediatric data, 571 recommendations for lung and high-risk liver transplant patients correspond to those given for adults 572 [213, 315]. Secondary prophylaxis to prevent recurrence of IA when risk factors are persisting is 573 recommended with an antifungal targeted at the previous Aspergillus species, which caused the first 574 episode (see below and Table 34).

575 Diagnostic procedures used in children are not different from those used in adults but their 576 performance may differ. Suggestive abnormalities (e.g. halo sign, air crescent sign) on CT-chest as 577 described in adults are less common in children in which non-specific masses or infiltrates predominate 578 [316-318]. The GM test on blood and BAL samples has a similar sensitivity and specificity profile 579 compared to adults [319-327]. The BDG test is not specific for *Aspergillus* and is not validated in 580 children. Higher baseline levels are reported in healthy children and therefore the cut-off is yet 581 unknown [328-332].

582 General management principles of IA are consistent with those in adults and include prompt initiation 583 of antifungal therapy, control of predisposing conditions (e.g. reduction or discontinuation of 584 glucocorticosteroids in immunosuppressed, administration of colony-stimulating factors in 585 neutropenic patients), and surgical interventions on a case by case basis using a multidisciplinary 586 approach. Voriconazole is recommended as the first line agent to treat IA in all children except 587 neonates (AIIt). L-AmB is first choice for neonates (AIII) and may replace voriconazole as first line 588 treatment in areas or institutions with a high prevalence of azole-resistant A. fumigatus. Upon 589 diagnosis of invasive pulmonary aspergillosis, thorough evaluation for further sites of infection is 590 required and should include the CNS. The optimal duration of therapy is determined by the resolution 591 of all signs and symptoms and reversal of the underlying deficit in host defences. For salvage therapy 592 and breakthrough infections, a switch to a different class of antifungals is recommended [123, 132, 593 138, 170, 171, 177, 333-341] (Table 35).

If a fever-driven (empiric) strategy is used in at risk paediatric haematological patients, caspofungin or
L-AmB are recommended until resolution of fever and neutropenia [342-344]. Treatment
recommendations for a diagnosis-driven (pre-emptive) strategy correspond to those made for
targeted treatment [185, 186, 345, 346].

598

599 Secondary Prophylaxis

Secondary prophylaxis is a treatment strategy to prevent recurrence of IA during a subsequent risk period of immunosuppression. Patients with a history of IA previously successfully treated with antifungals entering a subsequent risk period of immunosuppression, e.g. allogeneic HCT (early phase), chemotherapy resulting in severe neutropenia (i.e. <500/µL and at least for 7 days), acute GvHD >I° or extensive chronic GvHD, or T-cell suppressing therapy, including steroids, are at risk. Agents for secondary prophylaxis are listed in table 36.

606

607 Treatment of Refractory Disease

608 Refractory IA is defined as progression of disease and should be differentiated from stable disease 609 [349]. Patients with radiological evidence of progression and persisting elevated GM have a very high 610 probability of treatment failure resulting in death. Assessment of response should use composite 611 outcome parameters including clinical, radiological, and mycological criteria. Radiological progression 612 following or closely preceding neutrophil recovery should be carefully evaluated and is not necessarily 613 indicative of failure. Keeping this in mind, assessing response 2 weeks after treatment initiation 614 generally allows predicting the response, especially recognizing oncoming failure [350]. In case of GM 615 negative IA, early assessment of response may be difficult and could require a longer time of therapy. 616 If failure ascertained, look for poor vascular supply (i.e. sinusitis requiring surgical treatment), 617 microbiological confirmation is recommended since identification of the fungus at the species level is 618 pivotal. If a viable organism is recovered, susceptibility testing is recommended, especially regarding 619 azole resistance. On the other hand, azole concentration should be monitored as well (see chapters 620 on resistance and therapeutic drug monitoring within this guideline) [38, 349, 351-359]. The choices 621 of antifungal agents in refractory disease are listed in table 37.

622

623 Chronic Pulmonary Aspergillosis (CPA)

624 CPA is an indolent destructive disease of the lungs usually complicating other pulmonary conditions 625 occurring in non- or mildly immunocompromised patients [360, 361]. Its manifestations include

626 chronic cavitary pulmonary aspergillosis (CCPA), which if left untreated may progress to chronic 627 fibrosing pulmonary aspergillosis (CFPA), Aspergillus nodule and single aspergilloma [11, 362]. 628 Subacute invasive pulmonary aspergillosis (previously chronic necrotizing pulmonary aspergillosis) is 629 also a cavitating destructive lung disease usually found in moderately immunocompromised patients 630 which progresses more rapidly, typically over 1 to 3 months. The diagnosis of CPA requires a 631 combination of characteristics: one or more cavities with or without a fungal ball present or nodules 632 on thoracic imaging, either direct evidence of Aspergillus infection (culture or microscopy from biopsy) 633 or an IgG antibody response to Aspergillus spp. and exclusion of alternative diagnoses (especially 634 mycobacterial infection), all present for at least 3 months [11, 363]. Over 90% of patients have 635 circulating Aspergillus antibody (precipitins) (AII) [364]. A positive culture of A. fumigatus respiratory 636 tract secretion (BAL, bronchoscopy aspiration) is not diagnostic because many different pathologies 637 are attributable to the fungus, and it may be an airway colonizing fungus or a plate contaminant in the 638 laboratory.

639 If a fungal ball is seen, then only a positive test of *Aspergillus* IgG or precipitins confirms pathogenicity.
640 Patients may have CPA and other infections concurrently (see below).

641 The distinctive hallmark of CCPA is new and/or expanding cavities with thick or thin walls in those with 642 chronic lung disease. An intracavitary fungal ball may be present, often with pleural thickening and 643 extensive parenchymal destruction and/or fibrosis. Patients may have CPA and other infections 644 concurrently, especially bacterial including Pseudomonas aeruginosa infection or tuberculosis and 645 non-tuberculous mycobacterial infection. Aspergillus nodules, which may be single or multiple, may 646 mimic malignancy as well as nodules seen in rheumatoid arthritis, coccidioidomycosis, tuberculosis, 647 non-tuberculous mycobacterial infection and - rarely - actinomycosis or rheumatoid arthritis. 648 Typically, Aspergillus nodules appear rounded, some with low attenuation or cavitation within. Some 649 are spiculated, a common feature of carcinoma [362].

650 If technically feasible single aspergilloma should be surgically removed, preferably via video-assisted651 thoracic surgery technique with due consideration to risks as recommended [365]. Long term oral

652 antifungal therapy is strongly recommended in patients with CCPA, partly to reduce general and 653 respiratory symptoms [366, 367], but also to minimise haemoptysis and prevent lung destruction and 654 fibrosis (AII) itraconazole or voriconazole are effective for CCPA (AIII) [11]. Oral posaconazole is a 655 potential alternative treatment (BII) [11]. Six months of therapy is the recommended minimum (AI) 656 [11]. Relapse is common after discontinuation. Intravenous therapy for CPA is useful in patients who 657 fail or are intolerant of triazoles or have triazole resistant A. fumigatus. Prednisolone may be 658 considered for underlying symptom control only if patients are adequately treated with antifungals. 659 Mild and moderate haemoptysis usually responds to tranexamic acid; severe haemoptysis should be 660 arrested with bronchial artery embolization (Table 38).

661

662 Conclusions

This executive summary is a comprehensive guideline covering many aspects of *Aspergillus* diseases.

664 It provides guidance for clinicians on prevention of disease, diagnostic procedures, resistance issues

and treatment of IA as well as chronic pulmonary aspergillosis. The guideline group intends to provide

additional publications supporting the rationale of recommendations given.

Finally, the guideline group provides comprehensive tables explaining various options for specificsituations.

669 Table 1. Strength of recommendation and quality of evidence

Strength of	Definition
Recommendation	
(SoR)	
Grade A	Societies <u>strongly</u> support a recommendation for use
Grade B	Societies moderately support a recommendation for use
Grade C	Societies marginally support a recommendation for use
Grade D	Societies support a recommendation <u>against</u> use
Quality of Evidence	Definition
(QoE)	
Level I	Evidence from at least 1 properly* designed randomized, controlled trial
	(orientated on the primary endpoint of the trial)
Level II	Evidence from at least 1 well-designed clinical trial (incl. secondary
	endpoints), without randomization; from cohort or case-controlled
	analytic studies (preferably from >1 centre); from multiple time series; or
	from dramatic results of uncontrolled experiments
Level III	Evidence from opinions of respected authorities, based on clinical
	experience, descriptive case studies, or reports of expert committees
Added Index	Source of Level II Evidence
r	Meta-analysis or systematic review of RCT
t	Transferred evidence i.e. results from different patients' cohorts, or
	similar immune-status situation
h	Comparator group: historical control
u	Uncontrolled trials

а	For published abstract presented at an international symposium or						
	meeting						
* poor quality of plann	* poor quality of planning, inconsistency of results, indirectness of evidence etc. would lower the						
SoR							

671 Table 2. Recommendations for imaging and bronchoalveolar lavage

Population	Intention	Intervention*	SoR	QoE	Comment	Ref.
Neutropenia, fever or clinical	To detect pulmonary	Chest CT and	Α	II	Within 12-24h after the beginning of fever, dose	[21, 31,
symptom of pneumonia, empiric	infiltrates	thin section			optimization recommended	35, 368]
antibiotics, failing to achieve		multi-				
defervescence, e.g. FUO		detector CT				
		(MDCT)				
Haemoptysis	To identify vessel	Chest angio-	В	II		[24-26]
	occlusion	СТ /				
		pulmonary CT				
		angiography				
Haemoptysis	To identify vessel erosion	Chest angio-	Α	II		[24-26,
		ст /				369, 370]
		pulmonary CT				
		angiography				

	Any	To identify possible	BAL	А	II	[21, 49-
		underlying fungal or				54]
		other infectious disease				
_	Any	To obtain appropriate	CT-guided	А	III	[55, 56]
		specimens for	BAL			
		microscopy, culture and				
		PCR				
L						

⁶⁷² *, Diagnostic tests are interventions; SoR, Strength of recommendation; QoE, Quality of evidence; FUO, fever of unknown origin; CT, computed tomography;

673 BAL, bronchoalveolar lavage; PCR, polymerase chain reaction

Table 3. Microscopic examinations

Popula	Intention	Intervention	SoR	QoE	Comment	Ref.
tion						
Any	To identify fungal	Histological examination	A	111	Histopathology is an essential investigation	[80, 371-
	elements in histological sections and stains	Gomori's methenamine silver stain Periodic acid-Schiff			Inability to definitively distinguish other filamentous fungi GMS: removes cellular background; more sensitive to hyphal elements	373]
					PAS: advantage of counter stain to check cellular detail	
Any	To identify fungal	Fluorescent dyes:	А	11	Not specific to Aspergillus but high sensitivity and the	[374-
	elements in	Calcofluor white [™] , Uvitex			micromorphology may provide info on the fungal class (e.g.	378]
	histological sections	2B, Blancophor™			Aspergillus: typically dichotomous and septate, Mucorales:	
	and stains				pauci-septate and 90° angle branching, yeast: budding)	
					Rapid turnaround time	
					Broad applicability	
					May be applied to frozen sections, paraffin-embedded tissue	

Any	To identify fungal	Immunohistochemistry	В	II	Have the potential to provide genus and species specific data	[374-
	elements in	Monoclonal antibody WF-			Commercially available monoclonal antibodies	378]
	histological sections	AF-1 or EB-A1			WF-AF-1 is specific for A. fumigatus, A. flavus, and A. niger	
	and stains	In situ hybridization			Time consuming and not broadly available	
Any	To identify fungal	Application of fluorescent	Α	11	Essential investigation	[80, 373,
	elements in fresh	dyes Calcofluor white™ or			Not specific for Aspergillus species	379]
	clinical specimens	Uvitex 2B or Blancophor™			High sensitivity	
	(e.g. BAL)				Rapid turn-around time	
					Broad applicability	
					No species identification but the micromorphology may provide	
					info on the fungal class (e.g. Aspergillus: typically dichotomous	
					and septate, Mucorales: pauci-septate and 90° angle branching,	
					yeast: budding)	

676 SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; HE, haematoxylin-eosin; GMS, Gomori's methenamine silver

677 stain; PAS, Periodic acid-Schiff; CNS, central nervous system

Table 4. Sample selection and pre-analytical respiratory sample treatment

Liquefaction using a mucolytic agent, e.g. Pancreatin [®] , Sputolysin [®] , or using sonication and	A	111	Essential investigation High volume sputum culture (entire sample) shown to significantly increase recovery	[81, 380]
Pancreatin [®] , Sputolysin [®] , or using sonication and				
or using sonication and			significantly increase recovery	
1,4-dithiothreitol				
Centrifugation of BALs or	A	- 111	Essential investigation	[81]
bronchial aspirates			Isolation of Aspergillus dependent on volume cultured	
-	Centrifugation of BALs or	Centrifugation of BALs or A	Centrifugation of BALs or A III	Centrifugation of BALs or A III Essential investigation

680 SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction

Table 5. Culture and *Aspergillus* **species identification**

Popula	Intention	Intervention	SoR	QoE	Comment	Ref.
tion						
Any	Primary isolation from deep sites samples (e.g. biopsies, blood, CSF)	Culture on SDA, BHI agar, PDA at 30°C and 37°C for 72 h	A	111	Blood inhibits conidiation; BHI can help to recover some isolates; Isolation of several colonies or isolation of the same fungus from a repeat specimen enhance significance	[81, 381, 382]
	Primary isolation from non-sterile samples, e.g. sputum, respiratory aspirates	Culture on SDA, BHI agar, PDA with gentamicin plus chloramphenicol at 30°C and 37°C for 72 h	A	111	High volume sputum culture (entire sample) shown to significantly increase recovery; Quantitative cultures are not discriminative for infection or colonization	
	Identification of species complex	Macroscopic and microscopic examination from primary cultures	A	II	Colony colour, conidium size, shape and septation. Colour of conidia and conidiophore and conidiogenesis (tease or tape mounts are preferred); Expertise needed for	
	Identification of species complex (and species	Culture on identification media at 25-30ºC, 37ºC	A	II	interpretation	

identification of A.	and 50ºC (2% MEA and			Thermotolerance test (growth at 50 °C for species	
fumigatus specifically)	Czapek-Dox Agar) and			confirmation of A. fumigatus)	
	microscopic examination				
Identification at species	MALDI-TOF MS	В	11	In house databases are often used to improve identification	[383-386]
level	identification			rates	
Identification at species	Sequencing of ITS, beta-	A		Not necessary in organisms with typical growth, but in	[387, 388]
level	tubulin and calmodulin			cases of atypical growth	
To study outbreaks	Microsatellite and CSP	С	II	To study outbreaks (which in general may comprise more	[389-391]
	analysis			than one genotype)	
		В		To study colonisation patterns	[392]

SoR, Strength of recommendation; QoE, Quality of evidence; CSF, cerebrospinal fluid; SDA, Sabouraud dextrose agar; BHI, brain heart infusion; PDA,

potato dextrose agar; MEA, malt extract agar; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectometry

identification; ITS, internal transcribed spacer; CSP, Cell surface protein

Table 6. Galactomannan testing in blood samples

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Patients with prolonged	Prospective	GM in blood*	Α	I	Highest test accuracy requiring 2 consecutive samples with an	[82,
neutropenia or allogeneic stem	screening for IA	Draw samples	С		ODI \geq 0.5 or retesting the same sample	94,
cell transplantation recipients		every 3-4 days			Prospective monitoring should be combined with HRCT and	393-
not on mould-active prophylaxis					clinical evaluation	397]
Patients with prolonged	Prospective	GM in blood*	D		Low prevalence of IA in this setting with consequently low PPV	[398,
neutropenic or allogeneic stem	screening for IA				of blood GM test	399]
cell transplantation recipients on					Prophylaxis may have a negative impact on sensitivity of the	
mould active prophylaxis					test or the low yield may be due to decreased incidence of IA	
Patients with a haematological	To diagnose IA	GM in blood*			Significantly lower sensitivity in non-neutropenic patients	[319,
malignancy						394,
Neutropenic patients			А	П		400,
Non-neutropenic			В	п		401]
patients						

ICU patients	To diagnose IA	GM in blood*	C	11	Better performance in neutropenic than in non-neutropenic patients	[89, 402]
Solid organ recipients	To diagnose IA	GM in blood*	С	II	Low sensitivity, good specificity Most data for lung SOT	[319, 403, 404]
Any other patient	To diagnose IA	GM in blood*	C	II	Piperacillin/tazobactam may no longer be responsible for false positive results according to recent studies Cross reactivity in case of histoplasmosis, fusariosis, talaromycosis (formerly: penicilliosis)False positive results reported due to ingestion of ice-pops, transfusions, antibiotics, Plasmalyt [®] infusion	[401, 405- 412]
Cancer patients	To monitor treatment	GM in blood*	A	II		[85, 359, 413]

685 SoR, Strength of recommendation; QoE, Quality of evidence; *, serum or plasma; GM, galactomannan; IA, invasive aspergillosis; ICU, intensive care unit;

686 ODI, optical density index; PPV, positive predictive value; SOT, solid organ transplantation

Table 7. Galactomannan testing in samples other than blood

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To diagnose	To apply GM test on	A		GM in BAL is a good tool to diagnose, optimal cut-off to positivity	[86, 414-
	pulmonary IA	BAL fluid			0.5 to 1.0	418]
Any	To diagnose cerebral IA	To apply GM test on cerebrospinal fluid	В	II	No validated cut-off	[419, 420]
Any	To detect GM in tissue	To apply GM test on lung biopsies	В	II	Using a cut-off 0.5 resulted in a sensitivity of 90 % and a specificity of 95%; specimens need to be sliced, precondition for doing so is that sufficient material is available; dilution in isotonic saline	[373, 421]

689 SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; GM, galactomannan; IA, invasive aspergillosis

691 Table 8. β-D-glucan assays

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Mixed population: adult ICU,	То	Diagnostic	С	11	5 different assays	[90,
haematological disorders,	diagnose	assay			Overall sensitivity of 77% and specificity of 85%	422]
SOT	IFD				Specificity limits its value in this setting	
		Screening	С	II	Two or more consecutive samples: sensitivity: 65%; specificity: 93%	[90,
		assays			Studies included once to thrice weekly. Varies with assay and cut-off:	422]
					Wako assay sensitivity: 40-97%, specificity: 51-99%	
Adult haematological	То	Diagnostic	С	II	Overall sensitivity: 50-70%, specificity: 91-99%	[193-
malignancy and HSCT	diagnose	assay				195,
	IFD					423-
						428]
ICU – mixed adult	То	Diagnostic	С	II	Overall sensitivity: 78 -85%, specificity: 36-75%, NPV: 85-92%	[429,
immunocompromised	diagnose	assay			Specificity increased at higher cut-off values	430]
patients (haematology, SOT,	IA					

cancer, immunosuppressive						
therapy, liver failure, HIV)						
ICU – mixed adult population:		Screening	С	Ш	Sensitivity: 91%, specificity: 58%, PPV: 25%, NPV: 98%.	[431]
SOT, liver failure,		assays			Positive mean of 5.6 days before positive mould culture	
immunosuppressed					High false positive rate in early ICU admission	
Adult haematological	То	Diagnostic	С	II	Overall sensitivity: 57-76%, specificity: 95-97%	[422,
malignancy and HSCT	diagnose	assay				423,
	IA	Screening	С	II	Overall sensitivity: 46%, specificity: 97%	429]
		assays			Confirmation with GM increases specificity	
					Data suggests BDG is unsuitable for ruling out diagnosis of IA	

692 SoR, Strength of recommendation; QoE, Quality of evidence; HSCT, haematopoietic stem cell transplantation; ICU, intensive care unit; SOT, solid organ

693 transplantation; IFD, invasive fungal disease; PPV, positive predictive value; NPV, negative predictive value; GM, galactomannan; BDG, β-D-glucan test; IA,

694 invasive aspergillosis

695 Table 9. Lateral flow device antigen test for IA

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Haematological malignancy	To diagnose IA	LFD applied on BAL	В	II	Retrospective study. Sensitivity and specificity of BAL LFD	[432]
and solid organ transplant		samples			tests for probable IPA were 100% and 81% (PPV 71%, NPV	
					100%), 5 pts with possible IPA had positive LFD, no proven IA	
Haematopoietic stem cell	To diagnose IA	LFD applied on serum	В	II	Prospective screening in 101 patients undergoing allogeneic	[433]
transplantation		samples			нѕст	
Immunocompromised	To diagnose IA	LFD applied on BAL	В	II	Retrospective study. Sensitivities for LFD, GM, BDG and PCR	[434]
patients		samples			were between 70 and 88%. Combined GM (cut off >1.0 OD)	
					with LFD increased the sensitivity to 94%, while combined GM	
					(cut off >1.0 OD) with PCR resulted in 100% sensitivity	
					(specificity for probable/proven IPA 95-98%).	

696 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; BDG, β-D-glucan test; BAL, bronchoalveolar lavage; GM,

697 galactomannan; HSCT, haematopoietic stem cell transplantation; IFD, invasive fungal diseases; LFD, lateral device flow; NPV, negative predictive value; PCR,

698 polymerase chain reaction; PPV, positive predictive value

700 Table 10. PCR on bronchoalveolar lavage or cerebrospinal fluid

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Patients undergoing	To diagnose IA	BAL PCR	В	II		[435]
allogeneic stem cell						
transplantation						
recipients not on						
mould-active						
prophylaxis						
Patients with	To diagnose IA	BAL PCR	В	11	Methodically different in-house assays, better performance in	[359,
pulmonary infiltrates					patients without antifungal treatment, PCR and galactomannan:	415,
and haematological					increases specificity	434,
malignancies and						436-
prolonged						456]
neutropenia						

ICU patients, mixed	To diagnose IA	BAL PCR	В	II	Commercially available Aspergillus PCR assays with good	[81][41
populations					performance data.	4][454]
						[457][4
						58][45
						9]
Patients with	To diagnose CNS	CSF PCR	В		113 CSF samples from 55 immunocompromised patients	[419,
haematological	aspergillosis or				sensitivity 100%, specificity 93% (retrospective)	460-
malignancies	meningitis					463]

701 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis ; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; ICU,

702 intensive care unit; CNS, central nervous system; CSF, cerebrospinal fluid.

704 Table 11. PCR on whole blood, serum or plasma

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Patients with haematological	To diagnose IA	PCR on blood			Meta-analysis: 16 studies PCR single positive test: Sensitivity: 88%, specificity: 75%; PCR 2 consecutive positive tests: Sensitivity: 75%,	[464]
malignancies		samples			specificity: 87%	
	To diagnose IA	PCR on serum samples	В	II	97% of protocols detected threshold of 10 genomes/ml serum volume >0.5 ml, elution volume <100 μl, sensitivity: 86%; specificity: 94%	[465]
	To diagnose IA	PCR on whole blood samples			First blood PCR assay to be compatible with EAPCRI recommendations, fever driven: Sensitivity: 92%, specificity: 95%, negative PCR result to be used to rule out IA	[466]
Haematopoietic stem cell	To diagnose IA	Prospective screening PCR on	В	II	Combination of serum and whole blood superior	[94- 97]
transplantation		whole blood samples				

To diagnose IA	Prospective	В	П	Addition of GM and PCR monitoring provides greater accuracy, PPV 50-	[98]
	screening PCR on			80%, NPV 80-90%	
	blood samples				
To diagnose IA	PCR and GM in BAL	А	II		[396]

705 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; PCR, polymerase chain reaction; EAPCRI, European Aspergillus PCR

706 Initiative; GM, galactomannan, PPV, positive predictive value; NPV, negative predictive value; BAL, bronchoalveolar lavage

Table 12. Molecular diagnostics on biopsies

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Biopsy with	To detect and	Broad range PCR	Α	11	High sensitivity (> 90 %) and high specificity (99 %); various	[373,
visible	specify a fungus				molecular based techniques available	467]
hyphae						
Biopsy with	To detect and	Broad range PCR	С		Sensitivity (57 %) and specificity (96 %); ability to distinguish	[373,
no visible	specify a fungus				other fungi; performance only in addition to other tests	467]
hyphae						
Biopsy with	To detect and	Broad range PCR on wax	Α	11	TaKaRa DEXPAT kit and QIAamp DNA mini kit detected less	[468,
visible	specify a fungus	embedded specimens			than 10 conidia/sample	469]
hyphae						
Any	To detect and	Fresh tissue samples	В	11	Aspergillus PCR performance analysis yielded	[58]
	specify a fungus				sensitivity/specificity rates of 86% / 100% (79 patients,	
					retrospective study)	

709 SoR, Strength of recommendation; QoE, Quality of evidence; PCR, polymerase chain reaction

710 Table 13. Storage of original samples and isolates

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To prevent loss of	Clinical samples for culture -	A			[98, 381]
	viability of Aspergillus	short-term storage: 4°C to				
	in clinical samples, and	prevent loss of viability and to				
	to reflect the original	reflect the original fungal				
	fungal content	content				
	To prevent	Complete assay soon after	Α	I	GM in serum degrades with short-term and long-term	[80, 371-
	degradation of	delivery to laboratory. Avoid			storage at 4°C; BAL fluid GM ODI remain stable; testing of	373,
	biomarkers, e.g. GM in	short or long-term storage of			pos./neg. serum and BAL fluid pools showed no decline	395]
	serum or BALs or	serum at 4°C			in GM index over 11 months at -20°C	
	bronchial washes					
	Short-term	Repeated sub-culture	Α	I	Viability maintained for several years by frequent sub-	[98, 381]
	maintenance of				culture; Transfer once a month; Maintain at average	
	Aspergillus isolates				ambient room temperature	

Long-term	Water storage/storage under	A	I	Long-term storage means storage periods of 5 years or	
preservation of	mineral oil/silica gel			longer; No further transfers required during this period	
Aspergillus isolates	storage/freeze-drying freezing				
	(-80°C/ceramic beads/liquid				
	nitrogen)				
					ſ

711 SoR, Strength of recommendation; QoE, Quality of evidence; GM, galactomannan; BAL, bronchoalveolar lavage; ODI, optical density index

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	То	Aspergillus-specific antibodies by EIA: Serion	С	II	Antibodies take a mean of 11 days to develop	[470-477]
	diagnose	(Germany), Omega (France), Bio-Rad (France),			after onset of illness; detectable in 29% to	
	IA	Dynamiker (China)			100% of patients during course of acute IA	
		Precipitating antibodies by agar gel double	С	111		[478]
		diffusion (Microgen Ltd. UK) or counter-				
		immuno-electrophoresis				
		Agglutinating antibodies by indirect	С	II	Consider false-negative results due to	[478]
		haemagglutination (EliTech/Fumouze, France)			hypogammaglobulinaemia	
		Specific immunoglobulins to Aspergillus by	С	111		No
		ImmunoCap®				referenc
						found

713 Table 14. Antibody based diagnosis of invasive aspergillosis[11]

714 SoR, Strength of recommendation; QoE, Quality of evidence; EIA, enzyme immunoassay; IA, invasive aspergillosis

715 Table 15. Indications for testing for azole resistance in clinical *Aspergillus* isolates

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
All clinically relevant <i>Aspergillus</i> isolates (in patient groups or regions with known azole resistance)	Identify azole resistance	Reference MIC testing	A	II	In situations where rapid testing is available	[105, 111, 114, 116, 300, 479- 489]
Clinically relevant <i>Aspergillus</i> isolates in patient groups with high prevalence of azole resistance or patients unresponsive to treatment	Identify isolates with intrinsic resistance	Species identification to complex level	A	111	Some species are intrinsically resistant – e.g. <i>A. calidoustus</i> (azole resistant) <i>and A. terreus</i> (AmB resistant)	[103, 490]
Clinically relevant <i>A. fumigatus</i> isolates	Identify azole resistant <i>A. fumigatus</i>	Routine azole agar screening	В	111	Identifies resistant colonies that require MIC-testing	[118, 491]
All isolates –resistance surveillance	Determine the local epidemiology of azole resistance	Periodical reference MIC testing of <i>A. fumigatus</i> complex	A	II	Test at least 100 isolates	[105, 111, 114, 300,

						482-485,
						487-489]
Azole-resistant isolates	and trends in Cyp51A	Cyp51A-gene mutation analysis	A	П	Test resistant isolates from surveillance survey	[107]

716 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, Amphotericin B; MIC, minimum inhibitory concentration

717 Table 16. Azole susceptibility testing: Timing, methods, and number colonies

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
	Confirm or reject azole					
	resistance in clinical A.	Azole agar screening test			MIC testing as soon as the strain is	
	fumigatus isolates when	followed by reference MIC	А	ш	isolated and without waiting for species	[103, 114]
	antifungal treatment is	test where needed			ID	
	considered					
		Reference MIC testing of			Multiple genotypes, i.e. azole-	[115, 492,
4.514	Detect azole-resistant A.	multiple colonies	В	Ш	susceptible and azole-resistant, may be	493]
Any	<i>fumigatus</i> genotypes in a	(up to 5 colonies)			present	495]
					One resistant colony can be identified	
	single culture	Routine azole agar screening	В	ш	among 4 susceptible samples together	[118, 491]
		(up to 5 colonies)			as recently validated.	
	Confirm or reject azole	MIC test using EUCAST			Applicable to all Aspergillus spp.	
	resistance by a validated	method and EUCAST BPs (S, I,	А	ш	Breakpoints established for most	[494-496]
	method	R)			species	

	MIC test using CLSI method and CLSI ECVs (wild- type/non-wild-type)	В	III	Breakpoints not established	[496]
MIC testing of various Aspergillus spp.	Etest®	С	Ш	Confirmation by reference test recommended.	[497-501]

718 SoR, Strength of recommendation; QoE, Quality of evidence; MIC, minimum inhibitory concentration

719 Table 17. Azole MIC testing: Choice of azole compounds

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To determine susceptibility to	MIC (EUCAST/CLSI)	Α	- 111	In general, a sensitive marker for azole	[495, 496,
	itraconazole				resistance in Aspergillus; test itraconazole and	502-506]
					voriconazole as a minimum	
Any	To determine susceptibility to	MIC (EUCAST/CLSI)	A	- 111	Resistance/reduced susceptibility to other	[114, 494,
	voriconazole				azole(s) may accompany that of voriconazole;	496, 504-507]
					isolated voriconazole resistance described	
					related to TR_{46} mutation	
Any	To determine susceptibility to	MIC (EUCAST/CLSI)	В	- 111	Posaconazole resistance without itraconazole	[300, 486,
	posaconazole				resistance not reported so far; current EUCAST	495, 496,
					breakpoint will misclassify approximately 15%	504-509]
					susceptible isolates as I/R	
Any	To determine susceptibility to	MIC (EUCAST/CLSI)	A	111	MIC often similar to voriconazole, but needs	[495, 504,
	isavuconazole				testing separately, if isavuconazole is to be	505, 507,
					used; lower MIC of isavuconazole as compared	510-512]

	to itraconazole and voriconazole for A. lentulus
	and A. udagawae (A. fumigatus complex)
	(CLSI)

720 SoR, Strength of recommendation; QoE, Quality of evidence; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial

721 Susceptibility Testing; CLSI, Clinical & Laboratory Standards Institute

723 Table 18. Amphotericin B susceptibility testing

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Clinically	Confirm or reject AmB	MIC test	С		Acquired resistance to amphotericin B is very rare and	[513-516]
relevant	resistance when				therefore correlation with clinical outcome has not been	
isolate	antifungal treatment is				documented apart from the poorer outcome for high MIC	
	considered				species (A. terreus and A. flavus compared to A. fumigatus).	
Clinically	Interpretation of MIC	MIC test using	В	111	MIC break points proposed for A. fumigatus and A. niger	[495, 517,
relevant	(EUCAST)	EUCAST method and			Epidemiologic cut-offs established for <i>A. flavus, A. fumigatus,</i>	518]
isolate		EUCAST break points			A. niger and A. terreus	
		(S, I, R)			A. terreus is not considered a good target for AmB. A. flavus	
					may be in vitro resistant	
Clinically	Interpretation of MIC	MIC test using CLSI	В	111	ECVs proposed for A. fumigatus, A. flavus, A. nidulans, A.	[519]
relevant	(CLSI)	method and CLSI			niger, A. terreus, A. versicolor. No clinical break points. A.	
isolate		ECVs (wild-type/non-			<i>terreus</i> and <i>flavus</i> , e.g. with MIC below the ECV are not good	
		wild-type)			targets for AmB. No clinical data that <i>A. fumigatus</i> with MIC 2	

		will respond to AmB although classified as wildtype according	
		to CLSI ECVs.	

724 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, amphotericin B; CLSI, Clinical & Laboratory Standards Institute; ECV, epidemiological cut-

725 off value; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration

727 Table 19. Antifungal regimens in intrinsic resistance

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Amphotericin B MIC ≥1	To cure IA	Replace AmB with azole, if azole tested	В	II		[17, 170, 520-
mg/L		susceptible				525]
IA due to A. terreus	To cure IA	Voriconazole	A	11	Avoid AmB	[162, 526,
		Isavuconazole	A			527]
		Posaconazole	В	- 111		
		Itraconazole	В	- 111		
IA due to A. calidoustus	To cure IA	Lipid formulation of AmB	A	II	Avoid azoles	[103, 528]
IA due to A. tubingensis	To cure IA	Other than azole monotherapy	С		Higher azole MIC common, but no data	[501, 529,
(A. niger complex)					on clinical impact	530]
IA due to A. lentulus (A.	To cure IA	Other than azole monotherapy	_			
<i>fumigatus</i> complex)						
IA due to A. alliaceus (A.	To cure IA	Other than AmB monotherapy	С		Avoid AmB	[531]
<i>flavus</i> complex)						

IA due to A. niger	To cure IA	Other than itraconazole and isavuconazole	В		Isavuconazole, posaconazole, and	[501, 512]
complex					voriconazole MIC in general 1 dilution	
					higher compared to A. fumigatus;	
					itraconazole MIC in general 2 steps	
					higher; limited clinical data	
IA due to A. nidulans	To cure IA	Voriconazole	С		AmB MIC elevated, poor clinical	[532, 533]
					responses in chronic granulomatous	
					disease	

728 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, amphotericin B; IA, invasive aspergillosis; MIC, minimum inhibitory concentration

729 Table 20. Optimal therapy in documented azole-resistance

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Isolate with	To cure IA	Voriconazole + echinocandin	A	III	The probability of voriconazole treatment	[534-536]
voriconazole MIC =2		combination therapy or L-AmB			failure may be higher than in voriconazole MIC	
mg/ml		monotherapy for IA (as well as			<2.	
		for CPA)				
Isolate with	To cure IA	L-AmB	A	IIu		[113, 114,
posaconazole MIC						538]
>0.5 mg/ml [537]		AmB lipid complex	С			No reference
						found.
		Voriconazole & anidulafungin	В			[534]
		Posaconazole & caspofungin	С		Posaconazole not licensed for primary	[539]
					treatment	
		Caspofungin or micafungin	С		Patients with contra-indications to AmB &	No reference
					other azoles	found.

730 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, Amphotericin B; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; L-AmB,

731 Liposomal amphotericin B; MIC, minimum inhibitory concentration

732 Table 21. Therapeutic drug monitoring

Examples, comments
Impaired gastrointestinal function; hepatic dysfunction; children, elderly patients, obese patients, critically-ill
patients
Intravenous to oral switch, changing gastrointestinal function, changing hepatic or function, physiological-
instability
Patient receiving medication known to induce cytochrome P450 enzymes especially CYP3A4, antacids,
proton-pump inhibitors (itraconazole capsules, posaconazole suspension), antiretroviral medications.
Patients should have medication records screened using drug interactions screening database before starting
and stopping antifungals (example: www.fungalpharmacology.org, fungal-druginteractions.org, or
http://www.aspergillus.org.uk/content/antifungal-drug-interactions)
Extensive or bulky infection, lesions contiguous with critical structures, CNS infection, multifocal or
disseminated infection
Important issue with longer-term consolidation therapy or secondary prophylaxis in outpatient setting

Suspected breakthrough infection	TDM can establish whether fungal disease progression occurred in the setting of adequate antifungal exposure
Suspected drug toxicity, especially	Exposure-response relationships are described for other toxicities (e.g., hepatotoxicity), the utility of TDM to
neurotoxicity (voriconazole)	prevent their occurrence is less well established

733 CNS, central nervous system; TDM, therapeutic drug monitoring

735 Table 22. Itraconazole therapeutic drug monitoring

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
All patients receiving itraconazoletreatment for IA	Improve efficacy	Measure serum trough level on day 5 of therapy or soon after	A	11	Target itraconazole level >1 mg/L to 4 mg/L by HPLC. Hydroxy-itraconazole metabolite concentrations generally reported separately by HPLC or LC/MS/MS methods, but included in "itraconazole" concentration report by bioassay. Therapeutic range by bioassay may vary by laboratory but typically fall in the range of (3-17 mg/L)	[122, 127] 540-542]
All patients receiving itraconazole for prophylaxis for IA	Improve efficacy	Measure serum trough level on day 5 of therapy or soon after	A	11	Target itraconazole level >0.5 mg/L (HPLC) or > 3 mg/L (bioassay)	[124]
Patients receiving itraconazole	Reduce toxicity	Measure serum trough level on day 5 of therapy or soon after	В	II	Toxicity was associated with itraconazole levels >17.1 mg/L by itraconazole bioassay, which correspond to ~4 mg/L by HPLC	[127]

736 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; HPLC, high performance liquid chromatography; LC, liquid

737 chromatography; MS, mass spectrometry

738 Table 23. Voriconazole therapeutic drug monitoring

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
		Measure plasma trough level	А	II	Target range of 1-5.5 mg/L	[128-131,
All patients		after 2-5 days of therapy or				133, 543-
receiving	Improve efficacy,	soon after				545]
voriconazole	safety and compliance	Repeat plasma trough level	В		Repeat during second week of therapy, additional	[128-131,
treatment for IA	compliance				samples as clinically indicated and outlined in the	133, 543-
					text	545]
All patients	Improve efficacy,	Measure serum trough level	Α	llt	As above; most studies investigated voriconazole	[132, 546,
receiving	safety and	after 2-5 days of therapy or			treatment rather than prophylaxis	547]
voriconazole	compliance of	soon after, and 4 days after				
prophylaxis for IA	prophylaxis	change of dose				
Patients with IA due	Improve efficacy of	Measure serum trough level	А	II	Trough >2 mg/L recommended on the basis of	[131, 548]
to Aspergillus strains	treatment for	after 2 to 5 days of therapy			PK/PD analysis	
of reduced azole	isolates with MIC=2	or soon after and 4 days after				
	mg/ml	change of dose				

susceptibility MIC =2		
mg/ml		

739 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; MIC, minimum inhibitory concentration; PK, pharmacokinetic; PD,

pharmacodynamic

741 Table 24. Posaconazole therapeutic drug monitoring

Population	Intention	Intervention	SoR	QoE	Comments	Ref.
Patients	Improve	Serum trough level on day 5 of therapy or	Α	II	Target level >1 mg/L.	[138]
receiving	efficacy,	soon after			Gastroresistant tablet or intravenous formulation	
posaconazole	compliance				preferred for most patients, consider switch to	
suspension for					tablet or IV, if no therapeutic levels with oral	
treatment of					suspension	
IA					Repeat determination as clinically appropriate	
					Longed half-life gives similar results for random	
					sampling and true trough samples	
Patients	Improve	Serum trough level on day 5 of therapy or	С	II	Target level >0.7 mg/L	[136, 137,
receiving	efficacy,	soon after.			Adequate tissue concentrations may occur despite	549-552]
posaconazole	compliance				serum concentration <0.7 mg/L	
suspension for					Repeat determination as clinically appropriate	
prophylaxis to						
prevent IA						

Patients	Improve	Measure serum trough level on day 5 of	С	III	If treatment failure or toxicity suspected, TDM may	[120,121]
receiving	safety	therapy or soon after			be indicated in patients receiving gastroresistant	
posaconazole					tablet or intravenous formulation	
					Posaconazole exposures between 0.5-3.75 mg/L are	
					well studied and considered safe and effective with	
					all three formulations	
					Posaconazole plasma levels above this exposure	
					range may be associated with toxicity	

742 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; IV, intravenous; TDM, therapeutic drug monitoring; AML, acute

743 myeloid leukaemia; HSCT, haematopoietic stem cell transplantation; GvHD, graft versus host disease

745 Table 25. Isavuconazole therapeutic drug monitoring

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
					Limited data to support routine TDM but may	
					be indicated in the setting of treatment	
					failure, drug interactions, or if toxicity is	
All patients	Improve efficacy				suspected	FDA advisory
receiving	safety and	Measure serum trough level on	с	Ш	The long half-life of isavuconazole (130 hours)	briefing
isavuconazole	compliance	D5 of therapy or soon after			may support use for TDM in some clinical	documents
					situations to confirm drug clearance prior to	
					starting medications metabolized by CYP3A4,	
					especially chemotherapy agents	

746 SoR, Strength of recommendation; QoE, Quality of evidence; TDM, therapeutic drug monitoring; FDA, Food and Drug Administration

747 Table 26. Primary prophylaxis

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Haematological malignancies,		Posaconazole 200 mg tid suspension	A	I	AML/MDS induction only. TDM	[553]
e.g. AML with prolonged and		or 300 mg tablet qd			especially with oral suspension.	
profound neutropenia					Tablets more bioavailable, bridging	
					with posaconazole IV formulation	
					possible	
		L-AmB 12.5 mg biw, nebulized, with	В	I	AML	[554, 555]
	Lower	undetermined dose of fluconazole				
	incidence of IA	ABLC 3 mg/kg 3x/weekly	С	ll _h	No difference to L-AmB regimen	[556]
		Micafungin 50 mg qd	С	llt		[560, 561]
		L-AmB 10 mg/kg q7d	С	IIu		[562]
		L-AmB 50 mg abs q2d	С	IIu		[563]
		L-AmB 15 mg/kg q14d	С	IIu		[564]
		Voriconazole	С	IIt	Not better than fluconazole	[565]

		Itraconazole 400 mg/d, oral solution	D	II	No difference to fluconazole (n=195)	[121, 557-
					and more toxicity	559]
Acute lymphoblastic	Lewer	L-AmB 5 mg/kg biw	D	Ι	L-AmB more toxic than placebo, no	[566]
leukaemia, remission	Lower incidence of IA				significant reduction in IA rate	
induction chemotherapy						
Autologous HSCT or						
treatment of haematological	Lower					No
malignancies besides acute	incidence of IA	Any mould active agent	D	111		reference
leukaemia						found.
Allogeneic HSCT (until		Posaconazole 200 mg tid suspension	В	llt	Neutropenia duration approximately	[553]
neutrophil recovery)		or 300 mg tablet qd			identical, TDM*	
	Lower	L-AmB 12.5 mg biw, nebulized, with	В	llt		[554]
	incidence of IA	fluconazole				
		Voriconazole 200 mg bid	С	I	Not better than fluconazole, TDM	[567, 568]

]	Micafungin 50 mg/d	C	I	But no difference in subgroup	[560]
					analysis for aspergillosis	
		Itraconazole 400 mg/d oral solution	D	I	Toxicity issues; TDM	[554, 559]
Allogeneic HSCT (after	-	Any antifungal agent	D		No study demonstrated outcome	
neutrophil recovery and no					advantage	
GvHD)						
Allogeneic HSCT (with	-	Posaconazole 200 mg tid suspension	A	I	TDM	[569]
moderate to severe GvHD		or 300 mg tablet qd				
and/or intensified immuno-		Voriconazole 200 mg bid	С	II	Not better than fluconazole; TDM	[567, 568]
suppression)		Itraconazole 400 mg/d, oral solution	С	II	Toxicity issues; TDM	[559]
		Micafungin 50 mg/d	С		Only few patients with GVHD	[560]
Allogeneic HSCT (until		Posaconazole 200 mg tid suspension	В	IIt	Neutropenia duration approximately	[553]
neutrophil recovery)	To reduce IA	or 300 mg tablet qd			identical. TDM	
Allogeneic HSCT (after	attributable	Any other antifungal	D	111	No study demonstrated outcome	
neutrophil recovery, without	mortality				advantage	
GvHD)						

Posaconazole 200 mg tid suspension	A	11	Mainly IFD-attributable mortality,	[569]
or 300 mg tablet qd			ТДМ	

748 SoR, Strength of recommendation; QoE, Quality of evidence; qd, once daily; bid, twice daily; tid, thrice daily; AML, acute myeloid leukaemia; MDS,

749 myelodysplastic syndrome; TDM, therapeutic drug monitoring; ABLC, amphotericin B lipid complex; L-AmB, Liposomal amphotericin B; HSCT,

750 haematopoietic stem cell transplantation; GvHD, graft versus host disease; IFD, invasive fungal disease

752 Table 27. Targeted therapy of pulmonary disease – First line

Population	Intention	Intervention	SoR	QoE ¹	QoE ²	QoE ³	Comment	Ref.
 ¹ Neutropenia (non- allo HSCT recipients) 		Isavuconazole 200 mg iv tid day 1-2, then 200 mg qd oral	A	I	IIt	IIt	D III, if mould active azole prophylaxis less adverse effects than voriconazole	[173, 512, 633, 634]
² Allo-HSCT (during	To increase response and	Voriconazole 2x 6 mg/kg IV (oral 400 mg bid) on day 1, then 2x 4 mg/kg IV (oral 200 to 300 mg bid)	A	I	llt	IIt	C III for start with oral; D III, if prior mould active azole prophylaxis; TDM	[170, 172, 512, 635]
neutropenia)	survival rate	L-AmB 3 mg/kg	В	II	IIt	llt		[171]
 ³ Allo-HSCT (w/o neutropenia) 		Combination of voriconazole 6/4 mg/kg bid (after one week oral possible (300 mg bid)) + anidulafungin 200/100 mg	С	I	II _{t,}	II _{t,}	No significant difference compared to voriconazole, in GM positive (subgroup) better survival; TDM	[172, 635]
or other non-		Caspofungin 70 mg qd day 1, followed by 50 mg qd (if body weight <80kg)	С	=	II	=		[618-620]

neutropenic							D III for start with oral,	
patients		Itraconazole 200 mg q12h iv on day 1, then 200 mg/qd	с	111	ll _{t,a}	II _{t,a}	TDM D III, if mould active azole prophylaxis	[512, 542]
		AmB lipid complex (ABLC) 5 mg/kg	С	- 111				[636]
		Micafungin 100 mg	С	- 111				[637-639]
		AmB colloidal dispersion (ABCD) 4-6 mg/kg	D	I	llt	IIt		[142]
		Conventional AmB 1-1.5 mg/kg	D	I	llt	llt		[170]
		Other combinations	D				Efficacy unproven	[640]
Life-	Bridging until	Arterial embolization, emergency surgical	В	- 111				[641]
threatening	neutrophil	intervention						
haemoptysis	recovery							

753 SoR, Strength of recommendation; QoE, Quality of evidence; allo-HSCT, allogeneic haematopoietic stem cell transplantation; bid, twice daily; tid, thrice

daily, qd, once daily; IA, invasive aspergillosis; IV, intravenous; TDM, therapeutic drug monitoring; GM, galactomannan

755 Table 28. Targeted therapy of extrapulmonary disease – First line

Population	Intention	Intervention	SoR	QoE	Comment	Ref
		Surgical debridement, if surgically possible	A	IIu		[642 <i>,</i> 643]
Suspected or proven IA of	To increase	Voriconazole	A	llu	N=5/5 N=81, 48 proven cases, 33 probable cases, TDM recommended targeting trough concentration of 2-5.5 mg/L	[170]
the central nervous	response and	Posaconazole	D		8 patients documented in studies (5 failures)	[644]
system	survival rate	Itraconazole	D			
,		Lipid formulations of AmB	В	111	Case collections, animal data	[645- 647]
		cAmB	D	I	Renal toxicity	[189, 648- 650]
		Echinocandins	D	111	Insufficient tissue penetration	[646]

Patients with clinical		Surgery	А		Need to be considered on an individual basis and decision	
suspicion of or proven		Local antifungal therapy	с	111		
invasive sinus aspergillosis	_					
Patients with invasive		Voriconazole	А	ll _t	N=8/7, TDM recommended	[170,
	To cure					651]
sinus aspergillosis (all					Active against mucormycosis as well since mixed	
levels of certainty:		L-AmB	А	IIt		[171]
suspected through					infections occur or cannot be differentiated	
nroven)		Posaconazole, itraconazole,	6		Not well specified in studies, TDM recommended for	[652,
proven)		echinocandins	С	111	posaconazole and itraconazole	653]

756 SoR, Strength of recommendation; QoE, Quality of evidence; TDM, therapeutic drug monitoring; AmB, Amphotericin B, cAmB, conventional amphotericin B;

757 L-AmB, liposomal amphotericin B

759 Table 29. Fever-driven ("empiric") approach

Population	Intention	Intervention	SoR	QoE	Comment	Ref
		Caspofungin 70 mg qd day 1,			Caspofungin was associated with a significantly	
		followed by 50 mg qd (if body	А	I	higher rate of survival than L-AmB (subgroup	[188]
		weight <80kg)			analysis).	
Chemotherapy for					Less toxicity in comparison to cAmB but more renal	[188,
haematological malignancies or HSCT,		L-AmB 3 mg/kg	В	I	toxicity compared to echinocandin	189]
neutropenia $<500/\mu$ L ≥ 96	Reduction in the incidence of IA	Voriconazole 6 mg/kg bid IV			Failed the 10% non-inferiority cut-off when compared with L-AmB, but first-line for aspergillosis.	
h, fever (>38°C), and	and/or related	(oral 400 mg bid) on day 1,	В	П	Activity of azoles empirical therapy for persistent	[190]
parenteral broad spectrum antibacterial	mortality	then 4 mg/kg bid IV (oral 200 to 300 mg bid)			fever may be limited in patients receiving	
therapy \geq 96 h (some					prophylaxis with an agent of the same class. TDM*	
centres consider 48h)					Activity of azoles empirical therapy for persistent	
		Itraconazole 200 mg qd iv	С	II	fever may be limited in patients receiving prophylaxis with an agent of the same class. TDM*	[666]
		ABLC 5 mg/kg qd	С		Infusion-related toxicity (fever, chills, hypoxia)	[667]

ABCD 4 mg/kg	С	I	Same as above	[668]
				[189,
				342,
		I	Poor tolerance due to extreme toxicity	649,
cAmB 0.5-1 mg/kg qd	D			650,
				666,
				668]
Micafungin 100 mg qd	В	II		[669]
Fluconazole	D	llr	No activity against Aspergillus	[670]

760 SoR, Strength of recommendation; QoE, Quality of evidence; L-AmB, liposomal amphotericin B; cAmB, conventional amphotericin B; IV, intravenous; TDM,

therapeutic drug monitoring; ABLC, amphotericin B lipid complex; ABCD, amphotericin B colloidal dispersion

Table 30. Non-haematological patients at high risk

Population	Intention	Intervention	SoR	QoE	Ref.
SOT lung with pre-transplantation colonization and Aspergillus in intraoperative	To identify patients	Consider	В		[210, 226, 692]
culture OR CMV disease OR higher donor age OR prolonged ischaemia time OR	with high risk of IA	prophylaxis			[215, 693-695]
receiving daclizumab OR bronchial anastomotic ischemia OR bronchial stent OR					
single lung SOT					
SOT lung with repeated acute and chronic rejection	-		В	IIt	[696, 697]
SOT heart with re-operation, CMV infection, haemodialysis, other episode of IA	To identify patients	Consider	A	II _h	[204]
in the program within 2 months	with high risk of IA	prophylaxis			
SOT heart with airborne Aspergillus spores in ICU	-		A	II	[203, 204]
SOT heart with sirolimus OR tacrolimus OR hypogammaglobulinemia			В	ll _h	[212, 698]
SOT liver with one of the following characteristics: requirement for dialysis OR	To identify patients	Consider	В	ll _h	[210, 211, 217,
retransplantation OR fulminant hepatic failure OR MELD score >30	with high risk of IA	prophylaxis			224, 308, 311,
					607, 699-702]

SOT liver with one of the following characteristics: ICU admission or			C		
corticosteroid requirement previous 2-4 weeks to transplant OR >15 units of					
packed red blood cells during transplant surgery OR reoperation involving the					
intraabdominal cavity OR choledochojejunostomy					
SOT kidney with one of the following characteristics: Pre-transplant COPD OR	To identify patients	Consider	А	ll _h	[228]
delayed graft function OR post-transplant blood stream infection OR acute graft	with high risk of IA	prophylaxis			
rejection					
COPD with one of the following characteristics: high (systemic) cumulative	To identify patients	Consider	А	llt	[232, 257, 703,
glucocorticosteroid dose OR refractory to antibiotic therapy OR admission to the	with high risk of IA	prophylaxis			704]
intensive-care unit					
HIV with CD4 count <100 cells/μl	To identify patients	Consider	А	ll _h	[232]
	with high risk of IA	prophylaxis			
ICU patients with either COPD OR requiring glucocorticosteroids therapy	To identify patients	Consider	А	ll _h	[257, 703, 704]
ICU patients with either acute liver failure OR burns OR severe bacterial	with high risk of IA	prophylaxis	В		
infection OR malnutrition					

with high risk of IA To identify patients	prophylaxis Consider			705, 706]
To identify patients	Consider			
		В	ll _h	[244, 707]
with high risk of IA	prophylaxis			
To identify patients	Consider	A	ll _h	[708, 709]
with high risk of IA	prophylaxis	В		[706]
To identify	Consider	С		No reference
populations at high	prophylaxis			found.
risk of IA				
T F	To identify patients with high risk of IA To identify populations at high	To identify patientsConsiderwith high risk of IAprophylaxisTo identifyConsiderpopulations at highprophylaxis	To identify patientsConsiderAwith high risk of IAprophylaxisBTo identifyConsiderCpopulations at highprophylaxis	To identify patientsConsiderAIIhwith high risk of IAprophylaxisBIIITo identifyConsiderCIIIpopulations at highprophylaxisIII

763 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; CMV, cytomegalovirus; ICU, intensive care unit; COPD, chronic

764 obstructive pulmonary disease; BAL, bronchoalveolar lavage

Table 31. Diagnosis-driven ("pre-emptive") approach in non-haematological patients

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
COPD	To diagnose IA	Respiratory culture	A	IIu	Isolation of <i>Aspergillus</i> in culture from admitted patients with COPD	[257, 281,
					represents IA in at least 22% of patients	282, 710]
COPD	To diagnose IA	GM BAL	В	IIu	Sensitivity/specificity of BAL GM >1.0 cut-off is 67% / 96%, at GM	[281]
					>0.5 cut-off is 89% / 88%	
Underlying	To diagnose IA	Lateral flow device BAL	С	11	Sensitivity / specificity 77% / 92%	[285]
respiratory					(Not commercially available at the time of writing)	
disease						
ніv	To diagnose IA	Direct microscopy	A	ll _h	50% positive	[232]
ніv	To diagnose IA	GM BAL	В	IIu	53% positive	[232]
ніv	To diagnose IA	GM serum	В	IIu	34% positive	[232]
нιν	To diagnose IA	Histology	A	IIu	75% positive	[232]
ICU	To diagnose IA	BDG serum	В	IIu	Autopsy study, non-haematological immunocompromised critically	[429]

					ill patients with lower respiratory tract infection. Using 140 pg/ml		
					cut-off, sensitivity/specificity 100% / 70%		
ICU	To diagnose IA	BDG serum	В	IIu	BDG appeared a mean of 6.5 days before Aspergillus was grown	[711]	
ICU	To diagnose IA	Respiratory culture	В	IIu		[89, 713]	712,
ICU	To diagnose IA	GM BAL	С	IIu	Using cut-off ODI 0.5 sensitivity/specificity 88-90% / 87-100%	[89, 713]	712,
ICU	To diagnose IA	SeptiFast®	С	ll _h	Sensitivity/specificity 66% / 98%, PPV 93%, NPV 88%	[714,	715]
Non haematological	To diagnose IA	Culture	A	ll _h	Very low PPV of <i>Aspergillus</i> spp. culture from respiratory samples	[197]	
Non haematological	To diagnose IA	Culture	A	II _h	Sensitivity of BAL higher for non-neutropenic patients	[52]	
Non- haematological	To diagnose IA	GM serum	С	II	Using cut-off of 0.5 ng/ml sensitivity/specificity 60% / 89%	[710]	

Non-	To diagnose IA	MycAssay Aspergillus®	С	II	Sensitivity, specificity, PPV, and NPV of first sample/any sample were	[278]
haematological					87%/93%, 87%/82%, 34%/34%, 92%/100%	
SOT, any	To diagnose IA	Respiratory culture	D	II	Low sensitivity and specificity	[87, 282]
SOT, any	To diagnose IA	GM BAL	В	II	Using cut-off ODI 1.0 sensitivity/specificity 100% / 91%	[716]
SOT, any	To diagnose IA	High-resolution chest computed tomography	A	111	Bilateral bronchial wall thickening and centrilobular opacities, tree- in-bud pattern (65%), ground-glass opacities and/or bilateral areas of consolidation (23%)	[214, 717]
SOT, any	To diagnose IA	Lateral flow device BAL	С	II	N=11 SOT	[284, 434, 718]
SOT Heart	To diagnose IA	Respiratory culture	A	II _h	Overall positive predictive value (PPV) 60-70%, PPV 88-100% with respiratory specimens other than sputum; recovery of <i>A. fumigatus</i> PPV 78-91%	[271]
SOT Heart	To diagnose IA	High-resolution computed tomography	A	ll _h	Provided significant additional information in 41%; positive with a normal chest X-ray in 18%	[274]

		of the thorax				
SOT Lung	To diagnose IA	BDG serum	С	IIu	Sensitivity/specificity 64%, 9%, PPV 14%, NPV 50%	[719]
SOT Lung	To diagnose IA	GM BAL	В	II	Using cut-off ODI 1.5 sensitivity/specificity 100% / 90%	[87, 88 720, 721]
SOT Lung	To diagnose IA	PCR of respiratory samples	В	II		[88]

767 SoR, Strength of recommendation; QoE, Quality of evidence; COPD, chronic obstructive pulmonary disease; BDG, ß-D-glucan; IA, invasive aspergillosis; ICU,

768 intensive care unit; SOT, solid organ transplantation; PPV, positive predictive value; GM, galactomannan; ODI, optical density index; NPV, negative predictive

769 value; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction

770 Table 32. Treatment in non-haematological patients

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
HIV	To treat IA	Voriconazole	A		Consider drug-drug interactions with antiretroviral drugs.	[722]
SOT Heart	To treat IA	Itraconazole	С	111	6 patients cured with itraconazole 200-400 mg/d Erratic absorption and interaction with calcineurin inhibitors and other agents	[723]
SOT, any	To treat IA	Voriconazole	A	111	e.g. Herbrecht study 11 SOT; voriconazole increases the levels of anti- calcineurin immunesuppressors, TDM; monitor liver function tests especially in liver transplant recipients.	[170, 214, 287, 333, 607-609, 673, 724- 726]
SOT, any	To treat IA	L-AmB	A	II		[678, 727, 728]
SOT, any	To treat IA	Voriconazole &	В	II	40 SOT voriconazole & caspofungin (n=40) vs amphotericin B (n=47).	[289]

		caspofungin			Survival benefit in pts with A. fumigatus or renal insufficiency	
SOT, if	To treat IA	Caspofungin	В	111	Complete response 83%; response 7/9 monotherapy and 7/10	[621, 622,
voriconazole					combination	686, 729]
contraindicated						

771 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; SOT, solid organ transplantation; L-AmB, Liposomal amphotericin B; SOT,

solid organ transplantation; TDM, therapeutic drug monitoring

Table 33. Prophylaxis in non-haematological patients

Population	Intervention	Intention	SoR	QoE	Comment	Refer	ence
SOT Lung	Universal* prophylaxis	To prevent IA	A	I	Invasive fungal infection appeared at a median of 35 days	[304 <i>,</i> 730]	315,
	Targeted* prophylaxis	To prevent IA	С	111		[315, 731]	694,
	Inhaled cAmB	To prevent IA	В	II _h	25 mg/day for 4 days, followed by 25 mg/week for 7 weeks. More adverse events in inhaled deoxycholate vs lipid-based Breakthrough IA in 7-10%	[732,	733]
	Inhaled lipid-based AmB	To prevent IA	A	Ι	More adverse events with inhaled deoxycholate vs lipid-based but similar efficacy; various possible protocols: 50mg/day for 4 days, then 50mg/week for 7 weeks; 50mg/day for 2 weeks, then once weekly for 10 weeks; 25mg thrice weekly between day 1 and day 60 post SOT and once weekly between day 60 and day 180	[724, 735]	732-

	Voriconazole	To prevent IA	Α		Voriconazole 2x200 mg/d more hepatotoxic than itraconazole 2x200	[303,	304,
					mg/d. Usual duration of prophylaxis 3-6 months; monitor liver and	315,	731,
					skin toxicity	736]	
	Voriconazole pre- emptive, if colonized	To prevent IA	В	IIu	Breakthrough IA <2% at 6 months	[731]	
	Voriconazole for three months	To prevent IA	С	11	No effect of voriconazole on the incidence of IA (45% vs 49%)	[303]	
SOT Heart	Universal* prophylaxis with itraconazole or inhaled AmB	To prevent IA	С	I		[214, 738]	737,
	Universal* prophylaxis with itraconazole or inhaled AmB	To prevent IA	C	II	IA rates 5% without prophylaxis, 1.5% with itraconazole 2x200 mg, 0% with inhaled AmB	[214 <i>,</i> 738]	737,
	Targeted* prophylaxis with echinocandins	To prevent IA	A	IIt	Prophylaxis in 10% of patients, IA rate reduced from 9% to 2%, attributable mortality from 6% to 2%; duration dependant of risk	[215]	

					factors persistence		
SOT Liver	Targeted* prophylaxis	To prevent IA	В		IA rate reduced, mortality unaffected	[607, 7	739-
	with lipid AmB					741]	
	Targeted* prophylaxis	To prevent IA	А	I	Standard dosed echinocandins reduced IA rate; duration of	[217, 3	308,
	with echinocandins				prophylaxis usually 21 days post SOT	311, 742	<u>?]</u>

775 SoR, Strength of recommendation; QoE, Quality of evidence; * targeted prophylaxis = only if additional risk factors; universal prophylaxis = to all patients in

population; IA, invasive aspergillosis; SOT, solid organ transplantation; AmB, Amphotericin B; cAmB, conventional amphotericin B deoxycholate

778 Table 34. Prophylaxis in children at high risk

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Allogeneic HSCT, pre-		Itraconazole	A/B*	IIt	TDM recommended; Approved indication; not approved EU < 18 years	[122, 559, 570-579]
Allogeneic HSCT, post- engraftment phase, GvHD and augmented immunosuppression;	Prevention of IA	Posaconazole	A	IIt	TDM recommended; only supportive paediatric data for ≥ 13 years of age	[136, 137, 338, 553, 569, 580- 586]
High-risk patients with de novo or recurrent leukaemia, bone marrow failure syndromes with		Voriconazole	A	IIt	Not approved for <2 years; Inference from efficacy from HSCT trials and supportive studies; TDM recommended	[130, 131, 135, 546, 567, 568, 587-593]
prolonged and profound neutropenia		Liposomal amphotericin B	В	_t / *	Not approved for prophylaxis; Optimal dose of alternate administration unknown; Alternative if triazoles are not tolerated / contraindicated	[563 <i>,</i> 594- 599]

		Micafungin	В	_t / *	No definite evidence (trend only) for prophylactic efficacy against <i>Aspergillus</i> spp. Alternative if triazoles are not tolerated or contraindicated	[560, 600- 604]
Chronic granulomatous	Prevention of	Itraconazole	A	II	Approved indication; not approved in the EU for < 18 years; TDM recommended	[122, 575- 578, 605, 606]
disease (CGD) patients	IA	Posaconazole	A	111	Not EU approved for children < 18 years; TDM recommended; PK and safety data for children ≥ 4 years	[136, 137, 582-585]

⁷⁷⁹ * SoR = B for allogeneic HSCT post-engraftment phase, GvHD (graft versus host disease) and augmented immunosuppression

780 * QoE = III for allogeneic HSCT post-engraftment phase, GvHD and augmented immunosuppression

781 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; TDM, therapeutic drug monitoring; HSCT, haematopoietic stem cell

782 transplantation

Table 35. Treatment in children

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Any paediatric	Treatment	Voriconazole 18 mg/kg/d iv day 1,	Α	llt	Not approved in patients <2 yrs; TDM	[130, 131,
population other than	proven/probable IA	followed by 16 mg/kg/d iv or 18			recommended.	135, 170,
neonates		mg/kg/d po in 2 divided dosages				333, 546,
		(up to 14 years and < 50 kg); if				589-592,
		>15 yrs or >12 yrs and >50 kg use				607-613]
		adult dosing recommendations				
Any paediatric	Treatment	L-AmB 3 mg/kg/d	В	llt	Comparison between 2 dosages of L-AmB, no	[171, 597,
population other than	proven/probable IA				comparison to voriconazole	599, 614-
neonates						617]
Any paediatric	Treatment	Caspofungin 70 mg/m ² day 1,	С	llt	Study prematurely stopped due to low accrual	[616, 618-
population other than	proven/probable IA	followed by 50 mg/m ² /d (max. 70				628]
neonates		mg/d)				
Neonates	Treatment	L-AmB 3 mg/kg/d	Α	III		[629-632]
	proven/probable IA					

785 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; TDM, therapeutic drug monitoring; L-AmB, liposomal amphotericin B

Table 36. Secondary prophylaxis

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Previous IA and	To reduce risk of	Secondary prophylaxis with an Aspergillus	A		Results compared to historical data, mostly in	[654-
undergoing allogeneic	IA recurrence	active antifungal proven to be effective in			allogeneic HSCT setting	659]
HSCT or entering risk		the actual patient				
period with non-		Voriconazole	A	II _h	IA: 31/45 pts, 1 year cumulative incidence of IFD	[654]
resectable foci of					6.7±3.6%, TDM	
Aspergillus disease		Caspofungin 70 mg day 1, followed by 50	В	ll _h		[658]
		mg/d IV until stable engraftment, followed				
		by 400 mg itraconazole suspension PO				
		L-AmB followed by voriconazole	С		Fungal infection related mortality 28% despite	[657,
					lipid-based AmB	660]
Previous IA and with	To reduce risk of	Surgical resection following by secondary	В	111	Timing and methods of surgery important.	[661-
resectable foci of	IA recurrence	prophylaxis			Concomitant administration of appropriate	665]
Aspergillus disease					antifungal compound justified.	

before entering risk			Indication for surgical intervention by appropriate	
period			specialist. Interdisciplinary consensus needed.	

787 SoR, Strength of recommendation; QoE, Quality of evidence; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis, IFD, invasive fungal

788 disease; TDM, therapeutic drug monitoring, PO, per os; L-AmB, liposomal amphotericin B

Table 37. Antifungal drugs in refractory disease

Population	Intention	Intervention	SoR	QoE	Comment	Ref
		Switch to another drug class	A	111		
		Any combination	С	111	No prospective study demonstrated superiority of combination therapy	[671]
					over monotherapy	
	Achieve complete or	Voriconazole	A	II		[333, 672- 674]
Haematological patients with	partial response, or	L-AmB 3-5 mg/kg	В	11	Majority voted for BII others for AII	[598, 675,
refractory IA	stable disease, improve survival					676] [636, 676-
		ABLC 5 mg/kg	C	II		678]
		ABCD			No longer commercially available	[679, 680]
		Caspofungin 70 mg qd day 1, followed by 50	В		Very few data in case of	[335, 674,
		mg qd (if body weight <80kg)			voriconazole/posaconazole failure	681-687]
		Micafungin 75-200 mg qd	С	Ш		[638, 688]

Posaconazole 200 mg qid or 400 bid suspension or 300 mg tablet bid day 1, followed by 300 mg qd	В	11		[138, 336, 689, 690]
Itraconazole	D		In case of refractoriness to voriconazole	
Itraconazole oral forms	C	II	Poor bioavailability	[126]
Itraconazole IV formulation			Commercially not available everywhere	[542, 691]

790 SoR, Strength of recommendation; QoE, Quality of evidence; L-AmB, Liposomal amphotericin B; ABLC, amphotericin B lipid complex; ABCD, amphotericin B

colloidal dispersion; IV, intravenous; TDM, therapeutic drug monitoring; qd, once daily; bid, twice daily; qid, four times daily

Table 38. Chronic pulmonary aspergillosis

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Cavitary or nodular	Diagnosis or exclusion of CPA	Direct microscopy for	A	llt	Positive microscopy is a strong indicator of	[743]
pulmonary infiltrate in non-		hyphae			infection, not studied in CPA, but in ABPA	
immuno-compromised		Histology	A		In CPA histology distinguishes between	[744]
patients					CNPA and CCPA	
		Fungal culture (respiratory	A	- 111	Bacterial culture plates are less sensitive	[269]
		secretion)			than fungal culture plates	
Cavitary or nodular	Diagnosis or exclusion of CPA	Aspergillus IgG antibodies	A	11	IgG and precipitins test standardization	[364]
pulmonary infiltrate in non-					incomplete	
immuno-compromised						
patients						
CPA patients with progressive	Control of infection	Itraconazole: Start 200 mg	A		No data to indicate which agent is	[364,
disease		bid, adjust with TDM			preferable	745]


Voriconazole Start 150-200			Voriconazole preferred for CNPA and	[366,
mg bid, adjust with TDM			patients with fungal balls to minimize risk	746,
			of resistance	747]
Posaconazole	В	II	Higher rate of adverse events, if some	[748]
400 mg bid (oral suspension)			adverse events with itraconazole and	
300 mg qd (delayed release			voriconazole	
tablets)				

794 SoR, Strength of recommendation; QoE, Quality of evidence; CPA, chronic pulmonary aspergillosis; ABPA, allergic bronchopulmonary aspergillosis; SAIA,

subacute invasive aspergillosis; CNPA, chronic necrotising pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; qd, once daily; bid, twice

796 daily; TDM, therapeutic drug monitoring

798 Figure 1. Management during neutropenia



800 References

802	1	Arendrup MC, Boekhout T, Akova M, et al. Escmid and ecmm joint clinical guidelines for the
803		diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014; 20
804		Suppl 3: 76-98.
805	2	Chowdhary A, Meis JF, Guarro J, et al. Escmid and ecmm joint clinical guidelines for the
806		diagnosis and management of systemic phaeohyphomycosis: Diseases caused by black fungi.
807		<i>Clin Microbiol Infect</i> . 2014; 20 Suppl 3 : 47-75.
808	3	Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. Escmid and ecmm joint clinical guidelines for
809		the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014; 20 Suppl
810		3 : 5-26.
811	4	Cornely OA, Bassetti M, Calandra T, et al. Escmid* guideline for the diagnosis and
812		management of candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect.
813		2012; 18 Suppl 7 : 19-37.
814	5	Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. Escmid* guideline for the diagnosis and
815		management of candida diseases 2012: Diagnostic procedures. Clin Microbiol Infect. 2012; 18
816		Suppl 7: 9-18.
817	6	Hope WW, Castagnola E, Groll AH, et al. Escmid* guideline for the diagnosis and
818		management of candida diseases 2012: Prevention and management of invasive infections in
819		neonates and children caused by candida spp. Clin Microbiol Infect. 2012; 18 Suppl 7: 38-52.
820	7	Lortholary O, Petrikkos G, Akova M, et al. Escmid* guideline for the diagnosis and
821		management of candida diseases 2012: Patients with hiv infection or aids. Clin Microbiol
822		Infect. 2012; 18 Suppl 7 : 68-77.
823	0	Terterane AM Disbardson M Deilides E et al Esemid and some joint guidelines on
025	8	Tortorano AM, Richardson M, Roilides E, et al. Escmid and ecmm joint guidelines on
824	8	diagnosis and management of hyalohyphomycosis: Fusarium spp., scedosporium spp. And

826	9	Ullmann AJ, Akova M, Herbrecht R, et al. Escmid* guideline for the diagnosis and
827		management of candida diseases 2012: Adults with haematological malignancies and after
828		haematopoietic stem cell transplantation (hct). Clin Microbiol Infect. 2012; 18 Suppl 7 : 53-67.
829	10	Ullmann AJ, Cornely OA, Donnelly JP, et al. Escmid* guideline for the diagnosis and
830		management of candida diseases 2012: Developing european guidelines in clinical
831		microbiology and infectious diseases. Clin Microbiol Infect. 2012; 18 Suppl 7 : 1-8.
832	11	Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis:
833		Rationale and clinical guidelines for diagnosis and management. <i>Eur Respir J</i> . 2016; 47 : 45-68.
834	12	Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European society of clinical
835		microbiology and infectious diseases (escmid) fungal infection study group (efisg) and
836		european confederation of medical mycology (ecmm) 2013 joint guidelines on diagnosis and
837		management of rare and emerging fungal diseases. Clin Microbiol Infect. 2014; 20 Suppl 3: 1-
838		4.
839	13	Marchiori E, Irion KL. Commentary on: "Analysis of initial and follow-up ct findings in patients
840		with invasive pulmonary aspergillosis after solid organ transplantation". Clin Radiol. 2012; 67:
841		1153-1154.
842	14	Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary
843		aspergillosis should depend on both the underlying condition and the leukocyte count of
844		patients with hematologic malignancies. <i>Blood</i> . 2012; 119 : 1831-1837; quiz 1956.
845	15	Lim C, Seo JB, Park SY, et al. Analysis of initial and follow-up ct findings in patients with
846		invasive pulmonary aspergillosis after solid organ transplantation. Clin Radiol. 2012; 67:
847		1179-1186.
848	16	Wingard JR. New approaches to invasive fungal infections in acute leukemia and
849		hematopoietic stem cell transplant patients. Best practice & research Clinical haematology.
850		2007; 20 : 99-107.
851	17	Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary
852		aspergillosis: Clinical significance of the halo sign. <i>Clin Infect Dis</i> . 2007; 44 : 373-379.
853	18	Greene R. The radiological spectrum of pulmonary aspergillosis. Medical mycology. 2005; 43
854		Suppl 1: S147-154.

- Heussel CP, Kauczor HU, Heussel G, Fischer B, Mildenberger P, Thelen M. Early detection of
 pneumonia in febrile neutropenic patients: Use of thin-section ct. *AJR American journal of roentgenology*. 1997; **169**: 1347-1353.
- Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in
 bone marrow and blood stem-cell transplant recipients: Use of high-resolution computed
 tomography. J Clin Oncol. 1999; 17: 796-805.
- 21 Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary
 aspergillosis in neutropenic patients using early thoracic computed tomographic scan and
 surgery. J Clin Oncol. 1997; 15: 139-147.
- Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery
 in the management of invasive pulmonary aspergillosis in neutropenic patients. *Clin Microbiol Infect*. 2001; **7 Suppl 2**: 54-61.
- 23 Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary
 23 zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. *Clin Infect Dis*.
 2005; **41**: 60-66.
- Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for
 diagnosis of invasive mold diseases in patients with hematological malignancies. *Clin Infect Dis.* 2012; **54**: 610-616.
- Stanzani M, Sassi C, Lewis RE, et al. High resolution computed tomography angiography
 improves the radiographic diagnosis of invasive mold disease in patients with hematological
 malignancies. *Clin Infect Dis.* 2015; **60**: 1603-1610.
- Sonnet S, Buitrago-Tellez CH, Tamm M, Christen S, Steinbrich W. Direct detection of
 angioinvasive pulmonary aspergillosis in immunosuppressed patients: Preliminary results
 with high-resolution 16-mdct angiography. *AJR American journal of roentgenology*. 2005; **184**: 746-751.
- Sodhi KS, Khandelwal N, Saxena AK, et al. Rapid lung mri in children with pulmonary
 infections: Time to change our diagnostic algorithms. *J Magn Reson Imaging*. 2016; 43: 11961206.

- Maschmeyer G, Carratala J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung
 infiltrates in febrile neutropenic patients (allogeneic sct excluded): Updated guidelines of the
 infectious diseases working party (agiho) of the german society of hematology and medical
 oncology (dgho). Ann Oncol. 2015; 26: 21-33.
- Rieger C, Herzog P, Eibel R, Fiegl M, Ostermann H. Pulmonary mri--a new approach for the
 evaluation of febrile neutropenic patients with malignancies. *Support Care Cancer*. 2008; 16:
 599-606.
- Araz O, Karaman A, Ucar EY, Bilen Y, Durur Subasi I. Dce-mri findings of invasive aspergillosis
 in patient with acute myeloid leukemia. *Clin Respir J.* 2014; 8: 248-250.
- Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G, Herbst EW, Langer M. Invasive
 pulmonary aspergillosis. Mri, ct, and plain radiographic findings and their contribution for
 early diagnosis. *Chest*. 1994; **106**: 1156-1161.
- Yan C, Tan X, Wei Q, et al. Lung mri of invasive fungal infection at 3 tesla: Evaluation of five
 different pulse sequences and comparison with multidetector computed tomography (mdct). *Eur Radiol.* 2015; **25**: 550-557.
- Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography
 with [18f]fluorodeoxyglucose for invasive fungal infections. *Clin Microbiol Infect*. 2011; 17:
 409-417.
- 901 34 Camus V, Edet-Sanson A, Bubenheim M, et al. (1)(8)f-fdg-pet/ct imaging in patients with
 902 febrile neutropenia and haematological malignancies. *Anticancer research*. 2015; **35**: 2999903 3005.
- 90435Desoubeaux G, Bailly E, Chandenier J. Diagnosis of invasive pulmonary aspergillosis: Updates905and recommendations. *Med Mal Infect*. 2014; **44**: 89-101.
- Bruno C, Minniti S, Vassanelli A, Pozzi-Mucelli R. Comparison of ct features of aspergillus and
 bacterial pneumonia in severely neutropenic patients. *Journal of thoracic imaging*. 2007; 22:
 160-165.
- 90937Nucci M, Nouer SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive910aspergillosis without prespecified radiologic findings: Proposal for inclusion of a new

- 911 category of aspergillosis and implications for studying novel therapies. *Clin Infect Dis.* 2010;
 912 **51**: 1273-1280.
- Sa Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of
 invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in
 patients with neutropenia. *J Clin Oncol.* 2001; **19**: 253-259.
- 40 Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerhouni EA, Siegelman SS. Invasive pulmonary
 aspergillosis in acute leukemia. The contribution of ct to early diagnosis and aggressive
 management. *Chest.* 1987; **92**: 95-99.
- Franquet T, Gimenez A, Hidalgo A. Imaging of opportunistic fungal infections in
 immunocompromised patient. *Eur J Radiol.* 2004; **51**: 130-138.
- 42 Horger M, Hebart H, Einsele H, et al. Initial ct manifestations of invasive pulmonary
 aspergillosis in 45 non-hiv immunocompromised patients: Association with patient outcome? *Eur J Radiol.* 2005; **55**: 437-444.
- Althoff Souza C, Muller NL, Marchiori E, Escuissato DL, Franquet T. Pulmonary invasive
 aspergillosis and candidiasis in immunocompromised patients: A comparative study of the
 high-resolution ct findings. *Journal of thoracic imaging*. 2006; **21**: 184-189.
- Horger M, Einsele H, Schumacher U, et al. Invasive pulmonary aspergillosis: Frequency and
 meaning of the "hypodense sign" on unenhanced ct. *The British journal of radiology*. 2005; **78**: 697-703.
- Marchiori E, Godoy MC, Zanetti G, Hochhegger B, Rodrigues RS. The reversed halo sign.
 Another ct finding useful for distinguish invasive pulmonary aspergillosis and pulmonary
 lymphoma. *Eur J Radiol*. 2011; **79**: e96-97.
- 46 Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis
 after allogeneic hematopoietic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*.
 2005; **11**: 506-511.

940	47	Logan PM, Primack SL, Miller RR, Muller NL. Invasive aspergillosis of the airways:
941		Radiographic, ct, and pathologic findings. <i>Radiology</i> . 1994; 193 : 383-388.
942	48	Liss B, Vehreschild JJ, Bangard C, et al. Our 2015 approach to invasive pulmonary
943		aspergillosis. <i>Mycoses</i> . 2015; 58 : 375-382.
944	49	Azoulay E, Mokart D, Lambert J, et al. Diagnostic strategy for hematology and oncology
945		patients with acute respiratory failure: Randomized controlled trial. Am J Respir Crit Care
946		<i>Med</i> . 2010; 182 : 1038-1046.
947	50	Hummel M, Rudert S, Hof H, Hehlmann R, Buchheidt D. Diagnostic yield of bronchoscopy
948		with bronchoalveolar lavage in febrile patients with hematologic malignancies and
949		pulmonary infiltrates. Ann Hematol. 2008; 87: 291-297.
950	51	Boersma WG, Erjavec Z, van der Werf TS, de Vries-Hosper HG, Gouw AS, Manson WL.
951		Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with
952		hematologic malignancies: Bal versus psb and pbal. Respiratory medicine. 2007; 101: 317-
953		325.
954	52	Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and
955		biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-
956		year survey. <i>Clin Infect Dis</i> . 2006; 43 : 577-584.
957	53	Jain P, Sandur S, Meli Y, Arroliga AC, Stoller JK, Mehta AC. Role of flexible bronchoscopy in
958		immunocompromised patients with lung infiltrates. Chest. 2004; 125: 712-722.
959	54	Peikert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible
960		bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Mayo Clinic
961		proceedings. 2005; 80 : 1414-1420.
962	55	Ramila E, Sureda A, Martino R, et al. Bronchoscopy guided by high-resolution computed
963		tomography for the diagnosis of pulmonary infections in patients with hematologic
964		malignancies and normal plain chest x-ray. <i>Haematologica</i> . 2000; 85: 961-966.
965	56	Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S.
966		Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid
967		and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J
968		Haematol. 2003; 121 : 448-457.

969 57 de Bazelaire C, Coffin A, Cohen-Zarade S, et al. Ct-guided biopsies in lung infections in
970 patients with haematological malignancies. *Diagnostic and interventional imaging*. 2013; 94:
971 202-215.

872 58 Reinwald M, Spiess B, Heinz WJ, et al. Aspergillus pcr-based investigation of fresh tissue and
973 effusion samples in patients with suspected invasive aspergillosis enhances diagnostic
974 capabilities. *Journal of clinical microbiology*. 2013; **51**: 4178-4185.

975 59 Gupta S, Sultenfuss M, Romaguera JE, et al. Ct-guided percutaneous lung biopsies in patients
976 with haematologic malignancies and undiagnosed pulmonary lesions. *Hematol Oncol.* 2010;
977 28: 75-81.

978 60 Shi JM, Cai Z, Huang H, et al. Role of ct-guided percutaneous lung biopsy in diagnosis of
979 pulmonary fungal infection in patients with hematologic diseases. *International journal of*980 *hematology*. 2009; **89**: 624-627.

41 Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided
42 percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised
45 patients. *Clin Infect Dis.* 2007; 45: e101-104.

Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture,
and polymerase chain reaction assays to detect invasive mold infections from biopsy
specimens. *Clin Infect Dis*. 2007; **44**: 1078-1083.

63 Carrafiello G, Lagana D, Nosari AM, et al. Utility of computed tomography (ct) and of fine
988 needle aspiration biopsy (fnab) in early diagnosis of fungal pulmonary infections. Study of
989 infections from filamentous fungi in haematologically immunodeficient patients. *La*990 *Radiologia medica*. 2006; **111**: 33-41.

991 64 Nosari A, Anghilieri M, Carrafiello G, et al. Utility of percutaneous lung biopsy for diagnosing
992 filamentous fungal infections in hematologic malignancies. *Haematologica*. 2003; 88: 1405993 1409.

Manhire A, Charig M, Clelland C, et al. Guidelines for radiologically guided lung biopsy. *Thorax.* 2003; **58**: 920-936.

99666Georgiadou SP, Sampsonas FL, Rice D, Granger JM, Swisher S, Kontoyiannis DP. Open-lung997biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe

and reveals noncancerous, noninfectious entities as the most common diagnoses. *Eur J Clin Microbiol Infect Dis*. 2013; **32**: 101-105.
 Armenian SH, Hoffman JA, Butturini AM, Kapoor N, Mascarenhas L. Invasive diagnostic

- 1001procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant1002recipients. *Pediatr Transplant*. 2007; **11**: 736-742.
- 100368Zihlif M, Khanchandani G, Ahmed HP, Soubani AO. Surgical lung biopsy in patients with1004hematological malignancy or hematopoietic stem cell transplantation and unexplained1005pulmonary infiltrates: Improved outcome with specific diagnosis. Am J Hematol. 2005; 78:100694-99.
- Wingard JR, Hiemenz JW, Jantz MA. How i manage pulmonary nodular lesions and nodular
 infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell
 transplantation. *Blood*. 2012; **120**: 1791-1800.
- 1010 70 Choi YR, An JY, Kim MK, et al. The diagnostic efficacy and safety of endobronchial ultrasound1011 guided transbronchial needle aspiration as an initial diagnostic tool. *Korean J Intern Med*.
 1012 2013; 28: 660-667.
- 1013 71 Casal RF, Adachi R, Jimenez CA, Sarkiss M, Morice RC, Eapen GA. Diagnosis of invasive
 1014 aspergillus tracheobronchitis facilitated by endobronchial ultrasound-guided transbronchial
 1015 needle aspiration: A case report. *Journal of medical case reports*. 2009; **3**: 9290.
- 1016 72 Aragaki-Nakahodo A, Benzaquen S, Kirschner M. Coinfection by nocardia beijingensis and
 1017 nocardia arthritidis in an immunocompromised patient diagnosed by endobronchial
 1018 ultrasound guided transbronchial needle aspiration (ebus-tbna). *Respir Med Case Rep.* 2014;
 1019 12: 22-23.

Thery A, Espitalier F, Cassagnau E, Durand N, Malard O. Clinical features and outcome of
 sphenoid sinus aspergillosis: A retrospective series of 15 cases. *European annals of otorhinolaryngology, head and neck diseases*. 2012; **129**: 179-184.

1023 74 Miyamoto Y, Sakamoto Y, Ohuchi M, et al. Orbital apex syndrome caused by invasive
1024 aspergillosis as an adverse effect of systemic chemotherapy for metastatic colorectal cancer:
1025 A case report. *Anticancer research*. 2016; **36**: 821-823.

1026	75	Yuan L, Prayson RA. Optic nerve aspergillosis. Journal of clinical neuroscience : official journal
1027		of the Neurosurgical Society of Australasia. 2015; 22 : 1191-1193.
1028	76	Marzolf G, Sabou M, Lannes B, et al. Magnetic resonance imaging of cerebral aspergillosis:
1029		Imaging and pathological correlations. <i>PLoS One</i> . 2016; 11 : e0152475.
1030	77	Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in
1031		immunocompromised patients: Ct and mr imaging findings. AJR American journal of
1032		roentgenology. 1994; 162 : 155-159.
1033	78	DeLone DR, Goldstein RA, Petermann G, et al. Disseminated aspergillosis involving the brain:
1034		Distribution and imaging characteristics. AJNR American journal of neuroradiology. 1999; 20:
1035		1597-1604.
1036	79	Guermazi A, Gluckman E, Tabti B, Miaux Y. Invasive central nervous system aspergillosis in
1037		bone marrow transplantation recipients: An overview. Eur Radiol. 2003; 13: 377-388.
1038	80	Rüchel R, Schaffrinski M. Versatile fluorescent staining of fungi in clinical specimens by using
1039		the optical brightener blankophor. Journal of clinical microbiology. 1999; 37: 2694-2696.
1040	81	Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD. Volume
1041		dependency for culture of fungi from respiratory secretions and increased sensitivity of
1042		aspergillus quantitative pcr. <i>Mycoses</i> . 2014; 57 : 69-78.
1043	82	Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the aspergillus
1044		double-sandwich enzyme immunoassay. Clin Infect Dis. 2007; 44: 1329-1336.
1045	83	Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of
1046		invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin
1047		Infect Dis. 2014; 59 : 1696-1702.
1048	84	Teering S, Verreth A, Peeters A, et al. Prognostic value of serum galactomannan in mixed icu
1049		patients: A retrospective observational study. Anaesthesiol Intensive Ther. 2014; 46: 145-154.
1050	85	Nouér SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. Earlier response
1051		assessment in invasive aspergillosis based on the kinetics of serum aspergillus
1052		galactomannan: Proposal for a new definition. <i>Clin Infect Dis</i> . 2011; 53 : 671-676.

- 105386D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar1054lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and1055clinical validity. Journal of clinical microbiology. 2012; 50: 1258-1263.
- 1056 87 Pasqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of invasive aspergillosis in lung
 1057 transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid.
 1058 Transplantation. 2010; 90: 306-311.
- 105988Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an aspergillus real-time polymerase1060chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the1061diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. *Clin Infect Dis.*10622011; **52**: 1218-1226.

1063 89 Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid:
1064 A tool for diagnosing aspergillosis in intensive care unit patients. *Am J Respir Crit Care Med*.
1065 2008; **177**: 27-34.

1066 90 Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas
1067 ME. ß-d-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. *Clin*1068 *Infect Dis.* 2011; **52**: 750-770.

Prattes J, Lackner M, Eigl S, et al. Diagnostic accuracy of the aspergillus -specific
bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. *Mycoses*.
2015; **58**: 461-469.

- Boch T, Reinwald M, Postina P, et al. Identification of invasive fungal diseases in
 immunocompromised patients by combining an aspergillus specific pcr with a multifungal
 DNA-microarray from primary clinical samples. *Mycoses*. 2015; **58**: 735-745.
- 107593Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological1076patients by combined use of galactomannan, 1,3-beta-d-glucan, aspergillus pcr, multifungal1077DNA-microarray, and aspergillus azole resistance pcrs in blood and bronchoalveolar lavage1078samples: Results of a prospective multicentre study. Clin Microbiol Infect. 2016.
- 107994Springer J, Morton CO, Perry M, et al. Multicenter comparison of serum and whole-blood1080specimens for detection of aspergillus DNA in high-risk hematological patients. Journal of1081clinical microbiology. 2013; 51: 1445-1450.

- Springer J, White PL, Hamilton S, et al. Comparison of performance characteristics of
 aspergillus pcr in testing a range of blood-based samples in accordance with international
 methodological recommendations. *Journal of clinical microbiology*. 2016; 54: 705-711.
- 1085 96 White PL, Wiederhold NP, Loeffler J, et al. Comparison of nonculture blood-based tests for
 1086 diagnosing invasive aspergillosis in an animal model. *Journal of clinical microbiology*. 2016;
 1087 54: 960-966.
- White PL, Barnes RA, Springer J, et al. Clinical performance of aspergillus pcr for testing
 serum and plasma: A study by the european aspergillus pcr initiative. *Journal of clinical microbiology*. 2015; **53**: 2832-2837.
- 1091 98 Rogers TR, Morton CO, Springer J, et al. Combined real-time pcr and galactomannan
 1092 surveillance improves diagnosis of invasive aspergillosis in high risk patients with
 1093 haematological malignancies. *Br J Haematol*. 2013; **161**: 517-524.
- 109499Aguado JM, Vazquez L, Fernandez-Ruiz M, et al. Serum galactomannan versus a combination1095of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early1096therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled1097trial. Clin Infect Dis. 2015; 60: 405-414.
- 1098 100 Vermeulen E, Lagrou K, Verweij PE. Azole resistance in aspergillus fumigatus: A growing
 1099 public health concern. *Curr Opin Infect Dis.* 2013; 26: 493-500.
- 101 Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant aspergillus fumigatus
 1101 strains due to agricultural azole use creates an increasing threat to human health. *PLoS*1102 *pathogens*. 2013; **9**: e1003633.
- 102 Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive aspergillosis and azole
 1104 resistance in patients with acute leukaemia: The sepia study. *International journal of*1105 *antimicrobial agents*. 2017; **49**: 218-223.
- 103 Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to
 1107 antifungal agents. *Medical mycology*. 2011; 49 Suppl 1: S82-89.
- 1108104Anderson JB. Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness. Nat1109Rev Microbiol. 2005; 3: 547-556.

1110 105 van der Linden JW, Arendrup MC, Warris A, et al. Prospective multicenter international 1111 surveillance of azole resistance in aspergillus fumigatus. Emerg Infect Dis. 2015; 21: 1041-1112 1044. 1113 106 Chowdhary A, Sharma C, van den Boom M, et al. Multi-azole-resistant aspergillus fumigatus 1114 in the environment in tanzania. J Antimicrob Chemother. 2014; 69: 2979-2983. 1115 107 Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus: 1116 Can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016; 62: 362-1117 368. 1118 108 Ozmerdiven GE, Ak S, Ener B, et al. First determination of azole resistance in aspergillus 1119 fumigatus strains carrying the tr34/I98h mutations in turkey. J Infect Chemother. 2015; 21: 1120 581-586. 1121 109 Astvad KM, Jensen RH, Hassan TM, et al. First detection of tr46/y121f/t289a and tr34/l98h 1122 alterations in aspergillus fumigatus isolates from azole-naive patients in denmark despite 1123 negative findings in the environment. Antimicrob Agents Chemother. 2014; 58: 5096-5101. 1124 110 Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in aspergillus 1125 fumigatus: A side-effect of environmental fungicide use? Lancet Infect Dis. 2009; 9: 789-795. 1126 111 Stensvold CR, Nistrup Jørgensen L, M CA. Azole-resistant invasive aspergillosis: Relationship 1127 to agriculture. Curr Fungal Infect Rep. 2012; 6: 178-191. 1128 112 Bowyer P, Denning DW. Environmental fungicides and triazole resistance in aspergillus. Pest 1129 Manag Sci. 2014; 70: 173-178. 1130 113 van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in 1131 aspergillus fumigatus, the netherlands, 2007-2009. Emerg Infect Dis. 2011; 17: 1846-1854. 1132 114 van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly 1133 resistant aspergillus fumigatus and recovery of genetically related resistant isolates from 1134 domiciles. Clin Infect Dis. 2013; 57: 513-520. 1135 115 Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in 1136 aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009; 15: 1068-1137 1076.

1138 116 Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms 1139 in aspergillus fumigatus during azole therapy: A case study and review of the literature. 1140 Antimicrob Agents Chemother. 2012; 56: 10-16. 1141 117 Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of itraconazole-1142 resistant and -susceptible strains of aspergillus fumigatus in routine cultures. J Antimicrob 1143 Chemother. 2015; 70: 412-415. 1144 118 Arendrup MC, Verweij PE, Mouton JW, Lagrou K, Meletiadis J. Multicentre validation of 4-1145 well azole agar plates as a screening method for detection of clinically relevant azole-1146 resistant aspergillus fumigatus. J Antimicrob Chemother. 2017; 72: 3325-3333. 1147 Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and 119 1148 emerging indications. Antimicrob Agents Chemother. 2009; 53: 24-34. 1149 120 Tricot G, Joosten E, Boogaerts MA, Vande-Pitte J, Cauwenbergh G. Ketoconazole vs. 1150 Itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary 1151 results of two nonrandomized studies. Rev Infect Diseases. 9: S94-S95. 1152 121 Morgenstern GR, Prentice AG, Grant Prentice H, et al. A randomized controlled trial of 1153 itraconazole versus fluconazole for the prevention of fungal infections in patients with 1154 haematological malignancies. Br J Haematol. 1999; 105: 901-911. 1155 Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf I. Itraconazole 122 1156 trough concentrations in antifungal prophylaxis with six different dosing regimens using 1157 hydroxypropyl-ß-cyclodextrin oral solution or coated-pellet capsules. *Mycoses*. 1999; 42: 1158 591-600. 1159 123 Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in 1160 neutropenic patients after prophylaxis with itraconazole. *Mycoses*. 1999; **42**: 443-451. 1161 124 Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal 1162 infections in neutropenic patients treated for hematologic malignancies: Evidence from a 1163 meta-analysis of 3,597 patients. J Clin Oncol. 2003; 21: 4615-4626. 1164 125 Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal 1165 prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. 1166 Mycoses. 1989; **32 Suppl 1**: 103-108.

- 1167126Denning DW, Lee JY, Hostetler JS, et al. Niaid mycoses study group multicenter trial of oral1168itraconazole therapy for invasive aspergillosis. Am J Med. 1994; 97: 135-144.
- 1169127Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of1170itraconazole: Implications for therapeutic drug monitoring. *Clin Infect Dis.* 2009; **49**: 928-930.
- 1171128Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous1172voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based
- analysis of adult patients with invasive fungal infections. *Clin Infect Dis.* 2012; **55**: 381-390.
- 1174 129 Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug
 1175 monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin* 1176 *Infect Dis.* 2008; **46**: 201-211.
- 1177 130 Park WB, Kim N-H, Kim K-H, et al. The effect of therapeutic drug monitoring on safety and
 1178 efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. *Clin Infect*1179 *Dis.* 2012; **55**: 1080-1087.
- 1180 131 Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole
 and its relationship to plasma concentrations in patients. *Antimicrob Agents Chemother*.
 1182 2011; 55: 4782-4788.
- 1183 132 Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic
 1184 hematopoietic stem cell transplantation in patients on prophylactic voriconazole. *Bone*1185 *Marrow Transplant.* 2007; 40: 451-456.
- 1186 133 Dolton MJ, Ray JE, Chen SCA, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole
 1187 pharmacokinetics and therapeutic drug monitoring. *Antimicrob Agents Chemother*. 2012; 56:
 1188 4793-4799.
- 1189134Neely M, Margol A, Fu X, et al. Achieving target voriconazole concentrations more accurately1190in children and adolescents. Antimicrob Agents Chemother. 2015; 59: 3090-3097.
- 1191 135 Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of
 voriconazole in children, adolescents and adults. *Antimicrob Agents Chemother*. 2012; 56:
 3032-3042.

- 1194 136 Jang SH, Colangelo PM, Gobburu JVS. Exposure--response of posaconazole used for 1195 prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on 1196 drug concentrations in plasma. Clinical Pharmacology & Therapeutics. 2010; 88: 115-119. 1197 137 Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of 1198 posaconazole as prophylaxis against invasive fungal infections. *Clinical pharmacology and* 1199 therapeutics. 2011; 89: 351-352. 1200 138 Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in 1201 patients who are refractory to or intolerant of conventional therapy: An externally controlled 1202 trial. Clin Infect Dis. 2007; 44: 2-12. 1203 139 European Medicine A. Assessment report: Noxafil. 2014. 1204 140 Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the 1205 phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of 1206 invasive fungal disease Journal of Antimicrobial Chemotherapy. 2017. 1207 141 Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a 1208 posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob 1209 Chemother. 2016; 71: 1747. 1210 142 Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of 1211 amphotericin b colloidal dispersion versus amphotericin b for treatment of invasive 1212 aspergillosis in immunocompromised patients. Clin Infect Dis. 2002; 35: 359-366. 1213 143 Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin b plus flucytosine in 194 1214 patients with cryptococcal meningitis. Am J Med. 1987; 83: 236-242. 1215 144 Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15 1216 years experience from the uk. J Antimicrob Chemother. 2007; 59: 791-793. 1217 145 Walsh TJ, Dixon DM. Nosocomial aspergillosis: Environmental microbiology, hospital 1218 epidemiology, diagnosis and treatment. European journal of epidemiology. 1989; 5: 131-142.
- 1219146Goodley JM, Clayton YM, Hay RJ. Environmental sampling for aspergilli during building1220construction on a hospital site. *The Journal of hospital infection*. 1994; **26**: 27-35.

- 1221 147 Perraud M, Piens MA, Nicoloyannis N, Girard P, Sepetjan M, Garin JP. Invasive nosocomial
 1222 pulmonary aspergillosis: Risk factors and hospital building works. *Epidemiol Infect*. 1987; 99:
 1223 407-412.
- 1224 148 Opal SM, Asp AA, Cannady PB, Jr., Morse PL, Burton LJ, Hammer PG, 2nd. Efficacy of infection
 1225 control measures during a nosocomial outbreak of disseminated aspergillosis associated with
 1226 hospital construction. *The Journal of infectious diseases*. 1986; **153**: 634-637.
- 1227 149 Weems JJ, Jr., Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: An
 1228 independent risk factor for invasive aspergillosis and zygomycosis in patients with
 1229 hematologic malignancy. *Infect Control.* 1987; 8: 71-75.
- 1230 150 Meheust D, Le Cann P, Reboux G, Millon L, Gangneux JP. Indoor fungal contamination: Health
 1231 risks and measurement methods in hospitals, homes and workplaces. *Crit Rev Microbiol*.
 1232 2014; 40: 248-260.
- 1233 151 Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial aspergillus
 1234 infections. Unique risk of bone marrow transplant recipients. *The American journal of*1235 *medicine*. 1987; 83: 709-718.
- 1236 152 Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow
 1237 isolation. *The Journal of hospital infection*. 1989; **14**: 89-94.
- 1238153Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an1239outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant1240unit. Infect Control Hosp Epidemiol. 2000; **21**: 18-23.
- 1241 154 Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL, Jr. Efficacy of high 1242 efficiency particulate air filtration in preventing aspergillosis in immunocompromised
 1243 patients with hematologic malignancies. *Infect Control Hosp Epidemiol*. 2002; 23: 525-531.
- 1244 155 Maschmeyer G, Neuburger S, Fritz L, et al. A prospective, randomised study on the use of
 1245 well-fitting masks for prevention of invasive aspergillosis in high-risk patients. *Ann Oncol.*1246 2009; **20**: 1560-1564.
- 1247156Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic aspergillus species recovered from a1248hospital water system: A 3-year prospective study. Clin Infect Dis. 2002; 34: 780-789.

- 1249 157 Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial
 1250 infections: A plea for action. *Archives of internal medicine*. 2002; **162**: 1483-1492.
 1251 158 Anaissie EJ, Stratton SL, Dignani MC, et al. Cleaning patient shower facilities: A novel
- 1252approach to reducing patient exposure to aerosolized aspergillus species and other1253opportunistic molds. Clin Infect Dis. 2002; **35**: E86-88.
- 1254159Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including aspergillus species) in1255hospital water distribution systems: A 3-year prospective study and clinical implications for1256patients with hematologic malignancies. *Blood*. 2003; **101**: 2542-2546.
- 1257 160 Lee LD, Hachem RY, Berkheiser M, Hackett B, Jiang Y, Raad, II. Hospital environment and
 1258 invasive aspergillosis in patients with hematologic malignancy. *Am J Infect Control*. 2012; 40:
 1259 247-249.
- 1260161Mahieu LM, De Dooy JJ, Van Laer FA, Jansens H, leven MM. A prospective study on factors1261influencing aspergillus spore load in the air during renovation works in a neonatal intensive1262care unit. The Journal of hospital infection. 2000; 45: 191-197 [Record as supplied by1263publisher].
- 1264 162 Rüping MJ, Gerlach S, Fischer G, et al. Environmental and clinical epidemiology of aspergillus
 1265 terreus: Data from a prospective surveillance study. *The Journal of hospital infection*. 2011;
 1266 **78**: 226-230.
- 1267 163 Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic
 1268 malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (19891269 2003). *Haematologica*. 2006; **91**: 986-989.
- 1270164Sinko J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem1271cell transplant recipients: An autopsy-driven survey. *Transpl Infect Dis.* 2008; **10**: 106-109.
- 1272 165 Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of
 1273 invasive fungal infections in patients with haematological malignancies: A 20-year autopsy
 1274 study. *Mycoses*. 2013; **56**: 638-645.
- 1275 166 Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould
 1276 infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis.* 2002; **34**: 909-917.

- 1277 167 Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a
 1278 large cohort of patients undergoing bone marrow transplantation. *The Journal of infectious*1279 *diseases*. 1997; **175**: 1459-1466.
- 168 Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection
 in adult hematopoietic stem cell transplant recipients: Analysis of multicenter prospective
 antifungal therapy (path) alliance registry. *Clin Infect Dis.* 2009; **48**: 265-273.
- 1283 169 De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from 1284 the european organization for research and treatment of cancer/invasive fungal infections 1285 cooperative group and the national institute of allergy and infectious diseases mycoses study 1286 group (eortc/msg) consensus group. *Clin Infect Dis.* 2008; **46**: 1813-1821.
- 1287170Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin b for1288primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408-415.
- 1289 171 Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin b as initial therapy for 1290 invasive mold infection: A randomized trial comparing a high-loading dose regimen with 1291 standard dosing (ambiload trial). *Clin Infect Dis.* 2007; **44**: 1289-1297.
- 1292 172 Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive
 1293 aspergillosis: A randomized trial. *Annals of internal medicine*. 2015; **162**: 81-89.
- 1294 173 Maertens JA, Raad, II, Marr KA, et al. Isavuconazole versus voriconazole for primary
 1295 treatment of invasive mould disease caused by aspergillus and other filamentous fungi
 1296 (secure): A phase 3, randomised-controlled, non-inferiority trial. *Lancet*. 2016; **387**: 760-769.
- 1297 174 Ofran Y, Avivi I, Oliven A, et al. Granulocyte transfusions for neutropenic patients with life threatening infections: A single centre experience in 47 patients, who received 348
 granulocyte transfusions. *Vox Sang.* 2007; **93**: 363-369.
- 1300 175 Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon gamma1b immune
 1301 enhancement in 20 patients with hematologic malignancies and systemic opportunistic
 1302 infections treated with donor granulocyte transfusions. *Cancer*. 2006; **106**: 2664-2671.
- 1303 176 Sachs UJ, Reiter A, Walter T, Bein G, Woessmann W. Safety and efficacy of therapeutic early
 1304 onset granulocyte transfusions in pediatric patients with neutropenia and severe infections.
 1305 Transfusion. 2006; 46: 1909-1914.

Dignani MC, Rex JH, Chan KW, et al. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. *Cancer*. 2005; : 199-204. Lee JJ, Chung IJ, Park MR, et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia. 2001; 15: 203-207. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia. 1997; 11: 1621-1630. Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2009: CD005341. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. The American journal of medicine. 1982; 72: 101-111. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore). 1982; 61: 153-165. Empiric antifungal therapy in febrile granulocytopenic patients. Eortc international antimicrobial therapy cooperative group. The American journal of medicine. 1989; 86: 668-672. Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer. 2008; 44: 2192-2203. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial. *Clin Infect Dis.* 2009; : 1042-1051. Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: A prospective feasibility study. J Clin Oncol. 2010; 28: 667-674.

- 1334 187 Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus pre-emptive
 1335 therapy in the management of fungal infections: The hema e-chart project. *Haematologica*.
 1336 2011; **96**: 1366-1370.
- 1337 188 Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin b for
 1338 empirical antifungal therapy in patients with persistent fever and neutropenia. *N Engl J Med*.
 1339 2004; **351**: 1391-1402.
- 1340 189 Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin b for empirical therapy in
 1341 patients with persistent fever and neutropenia. National institute of allergy and infectious
 1342 diseases mycoses study group. *N Engl J Med.* 1999; **340**: 764-771.
- 1343 190 Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin b
 1344 for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J*1345 *Med.* 2002; **346**: 225-234.
- 1346 191 White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time pcr, galactomannan
 1347 enzyme-linked immunosorbent assay (elisa), and a novel lateral-flow device for diagnosis of
 1348 invasive aspergillosis. *Journal of clinical microbiology*. 2013; **51**: 1510-1516.
- 1349 192 White PL, Wingard JR, Bretagne S, et al. Aspergillus polymerase chain reaction: Systematic
 1350 review of evidence for clinical use in comparison with antigen testing. *Clin Infect Dis.* 2015;
 1351 61: 1293-1303.
- 1352 193 Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-d-glucan
 1353 contamination of common antimicrobials-authors' response. *J Antimicrob Chemother*. 2016;
 1354 **71**: 2997-2999.
- 1355 194 Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-d-glucan
 1356 contamination of common antimicrobials. *J Antimicrob Chemother*. 2016; **71**: 913-915.
- 1357195Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-ß-d-glucan concentrations in1358blood products predict false positive post-transfusion results. *Mycoses*. 2016; **59**: 39-42.
- Hammarstrom H, Kondori N, Friman V, Wenneras C. How to interpret serum levels of betaglucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients:
 Optimal cut-off levels and confounding factors. *Eur J Clin Microbiol Infect Dis.* 2015; **34**: 917925.

- 1363197Bouza E, Guinea J, Pelaez T, Perez-Molina J, Alcala L, Munoz P. Workload due to aspergillus1364fumigatus and significance of the organism in the microbiology laboratory of a general1365hospital. Journal of clinical microbiology. 2005; 43: 2075-2079.
- 1366198Montagna MT, Lovero G, Coretti C, et al. Simiff study: Italian fungal registry of mold1367infections in hematological and non-hematological patients. *Infection*. 2014; **42**: 141-151.
- 1368199Garcia-Vidal C, Peghin M, Cervera C, et al. Causes of death in a contemporary cohort of1369patients with invasive aspergillosis. *PLoS One*. 2015; **10**: e0120370.
- 1370 200 Vena A, Munoz P, Pelaez T, Guinea J, Valerio M, Bouza E. Non-construction related
 1371 aspergillus outbreak in non-haematological patients related to high concentrations of
 1372 airborne spores in non-hepa filtered areas. *ID week, San Diego, Ca.* 2015; Octuber 7-11.
- 1373201Ruiz-Camps I, Aguado JM, Almirante B, et al. [recommendations of the spanish society of1374infectious diseases and clinical microbiology (seimc) on the prevention of invasive fungal1375infection due to filamentous fungi]. Enferm Infecc Microbiol Clin. 2010; 28: 172 e171-1721376e121.
- Guinea J, Pelaez T, Alcala L, Bouza E. Outdoor environmental levels of aspergillus spp. Conidia
 over a wide geographical area. *Medical mycology*. 2006; **44**: 349-356.
- Pelaez T, Munoz P, Guinea J, et al. Outbreak of invasive aspergillosis after major heart
 surgery caused by spores in the air of the intensive care unit. *Clin Infect Dis*. 2012; **54**: e2431.
- 1382204Munoz P, Guinea J, Pelaez T, Duran C, Blanco JL, Bouza E. Nosocomial invasive aspergillosis in1383a heart transplant patient acquired during a break in the hepa air filtration system. Transpl1384Infect Dis. 2004; 6: 50-54.
- 1385205Tang HJ, Liu WL, Chang TC, et al. Multiple brain abscesses due to aspergillus fumigatus in a1386patient with liver cirrhosis: A case report. *Medicine (Baltimore)*. 2016; **95**: e2813.
- 1387206Pilmis B, Puel A, Lortholary O, Lanternier F. New clinical phenotypes of fungal infections in1388special hosts. *Clin Microbiol Infect*. 2016.
- 1389207Falcone M, Concia E, Iori I, et al. Identification and management of invasive mycoses in1390internal medicine: A road-map for physicians. Intern Emerg Med. 2014; 9: 501-511.

1391	208	Peghin M, Ruiz-Camps I, Garcia-Vidal C, et al. Unusual forms of subacute invasive pulmonary
1392		aspergillosis in patients with solid tumors. <i>J Infect</i> . 2014; 69 : 387-395.
1393	209	Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant
1394		recipients: Results of the transplant-associated infection surveillance network (transnet). Clin
1395		Infect Dis. 2010; 50 : 1101-1111.
1396	210	Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ
1397		transplant recipients: A case-control study. <i>Clin Infect Dis</i> . 2005; 41 : 52-59.
1398	211	Singh N, Husain S, Practice ASTIDCo. Aspergillosis in solid organ transplantation. Am J
1399		Transplant. 2013; 13 Suppl 4 : 228-241.
1400	212	Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant
1401		recipients in the current era. <i>Medical mycology</i> . 2006; 44 : 445-449.
1402	213	Gavalda J, Meije Y, Fortun J, et al. Invasive fungal infections in solid organ transplant
1403		recipients. Clin Microbiol Infect. 2014; 20 Suppl 7: 27-48.
1404	214	Munoz P, Ceron I, Valerio M, et al. Invasive aspergillosis among heart transplant recipients: A
1405		24-year perspective. J Heart Lung Transplant. 2014; 33: 278-288.
1406	215	Munoz P, Valerio M, Palomo J, et al. Targeted antifungal prophylaxis in heart transplant
1407		recipients. Transplantation. 2013; 96: 664-669.
1408	216	Barchiesi F, Mazzocato S, Mazzanti S, et al. Invasive aspergillosis in liver transplant recipients:
1409		Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. Liver Transpl.
1410		2015; 21 : 204-212.
1411	217	Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin
1412		versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant
1413		recipients. Am J Transplant. 2014; 14 : 2758-2764.
1414	218	Lichtenstern C, Hochreiter M, Zehnter VD, et al. Pretransplant model for end stage liver
1415		disease score predicts posttransplant incidence of fungal infections after liver
1416		transplantation. <i>Mycoses</i> . 2013; 56 : 350-357.

- 1417 219 Ohkubo T, Sugawara Y, Takayama T, Kokudo N, Makuuchi M. The risk factors of fungal
 1418 infection in living-donor liver transplantations. *J Hepatobiliary Pancreat Sci.* 2012; 19: 3821419 388.
- San-Juan R, Aguado JM, Lumbreras C, et al. Universal prophylaxis with fluconazole for the
 prevention of early invasive fungal infection in low-risk liver transplant recipients. *Transplantation*. 2011; **92**: 346-350.
- Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver
 transplant recipients. *Am J Transplant*. 2008; 8: 426-431.
- 1425222Osawa M, Ito Y, Hirai T, et al. Risk factors for invasive aspergillosis in living donor liver1426transplant recipients. *Liver Transpl.* 2007; **13**: 566-570.
- 1427223Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant1428recipients: A multi-center prospective observational study. Am J Transplant. 2006; 6: 386-1429391.
- 1430224Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver1431transplant recipients. *Liver Transpl.* 2002; 8: 1065-1070.
- Singh N, Husain S. Aspergillus infections after lung transplantation: Clinical differences in
 type of transplant and implications for management. *J Heart Lung Transplant*. 2003; 22: 258266.
- Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk
 factor for bronchiolitis obliterans syndrome. *Am J Transplant*. 2009; **9**: 1903-1911.
- 1437 227 Geltner C, Lass-Florl C. Invasive pulmonary aspergillosis in organ transplants--focus on lung
 1438 transplants. *Respir Investig*. 2016; 54: 76-84.
- 1439228Lopez-Medrano F, Silva JT, Fernandez-Ruiz M, et al. Risk factors associated with early invasive1440pulmonary aspergillosis in kidney transplant recipients: Results from a multinational matched1441case-control study. Am J Transplant. 2016; 16: 2148-2157.
- Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH, Jr. Invasive
 aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. *The Journal of infectious diseases*. 1983; **148**: 230-238.

- 1445 230 Wojtowicz A, Gresnigt MS, Lecompte T, et al. II1b and defb1 polymorphisms increase
 1446 susceptibility to invasive mold infection after solid-organ transplantation. *The Journal of*1447 *infectious diseases*. 2015; **211**: 1646-1657.
- 1448231Wojtowicz A, Lecompte TD, Bibert S, et al. Ptx3 polymorphisms and invasive mold infections1449after solid organ transplant. *Clin Infect Dis.* 2015; **61**: 619-622.
- 1450232Denis B, Guiguet M, de Castro N, et al. Relevance of eortc criteria for the diagnosis of1451invasive aspergillosis in hiv-infected patients, and survival trends over a 20-year period in1452france. Clin Infect Dis. 2015; 61: 1273-1280.
- 1453 233 Libanore M, Prini E, Mazzetti M, et al. Invasive aspergillosis in italian aids patients. *Infection*.
 1454 2002; **30**: 341-345.
- 1455 234 Moreno A, Perez-Elias M, Casado J, et al. Role of antiretroviral therapy in long-term survival
 1456 of patients with aids-related pulmonary aspergillosis. *Eur J Clin Microbiol Infect Dis.* 2000; 19:
 1457 688-693.
- 1458 235 Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system
 1459 aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and
 1460 review. *Medicine (Baltimore)*. 2000; **79**: 269-280.
- 1461236Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the1462literature. Clin Infect Dis. 2001; **32**: 358-366.
- 1463237Gastaca M, Aguero F, Rimola A, et al. Liver retransplantation in hiv-infected patients: A1464prospective cohort study. *Am J Transplant*. 2012; **12**: 2465-2476.
- 1465 238 Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human
 1466 immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: A fipse/gesida
 1467 prospective cohort study. *Liver Transpl.* 2012; **18**: 70-81.
- Woitas RP, Rockstroh JK, Theisen A, Leutner C, Sauerbruch T, Spengler U. Changing role of
 invasive aspergillosis in aids--a case control study. *J Infect*. 1998; **37**: 116-122.
- Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired
 immunodeficiency syndrome: Report of 33 cases. French cooperative study group on
 aspergillosis in aids. *The American journal of medicine*. 1993; **95**: 177-187.

Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991; 324: 654-662. Antinori S, Nebuloni M, Magni C, et al. Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with aids: A retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol. 2009; 132: 221-227. Chen J, Yang Q, Huang J, Li L. Clinical findings in 19 cases of invasive pulmonary aspergillosis with liver cirrhosis. Multidiscip Respir Med. 2014; 9: 1. Jeurissen S, Vogelaers D, Sermijn E, et al. Invasive aspergillosis in patients with cirrhosis, a case report and review of the last 10 years. Acta Clin Belg. 2013; 68: 368-375. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive aspergillosis in critically ill patients: Analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004; : 251-257. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol. 2007; 41: 403-411. Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. *Medical mycology*. 2011; **49**: 406-413. Russo A, Giuliano S, Vena A, et al. Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: Does galactomannan have a role? Diagn Microbiol Infect Dis. 2014; 80: 83-86. Delsuc C, Cottereau A, Frealle E, et al. Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: A matched cohort study. Crit Care. 2015; 19: 421. Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the intensive care unit: A multicentre, prospective, observational study in italy (2006-2008). Mycoses. 2012; 55: 73-79. Jensen J, Guinea J, Torres-Narbona M, Munoz P, Pelaez T, Bouza E. Post-surgical invasive aspergillosis: An uncommon and under-appreciated entity. J Infect. 2010; 60: 162-167.

- Vehreschild JJ, Brockelmann PJ, Bangard C, et al. Pandemic 2009 influenza a(h1n1) virus
 infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. *Epidemiol Infect.* 2012; **140**: 1848-1852.
- 1503 253 Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of aspergillus spp. From
 1504 the respiratory tract in critically ill patients: Risk factors, clinical presentation and outcome.
 1505 *Crit Care*. 2005; **9**: R191-199.
- 1506254Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in1507critically ill patients. *Curr Opin Infect Dis.* 2014; **27**: 174-183.
- 1508255Bassetti M, Righi E, De Pascale G, et al. How to manage aspergillosis in non-neutropenic1509intensive care unit patients. *Crit Care*. 2014; **18**: 458.
- 1510256Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A. Invasive aspergillosis in the1511intensive care unit. Ann N Y Acad Sci. 2012; 1272: 31-39.
- 1512 257 Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillosis in patients with chronic
 1513 obstructive pulmonary disease: Incidence, risk factors, and outcome. *Clin Microbiol Infect*.
 1514 2010; **16**: 870-877.
- 1515258Tutar N, Metan G, Koc AN, et al. Invasive pulmonary aspergillosis in patients with chronic1516obstructive pulmonary disease. *Multidiscip Respir Med.* 2013; 8: 59.
- Giannella M, Munoz P, Guinea J, Escribano P, Rodriguez-Creixems M, Bouza E. Growth of
 aspergillus in blood cultures: Proof of invasive aspergillosis in patients with chronic
 obstructive pulmonary disease? *Mycoses*. 2013; 56: 488-490.
- 1520 260 Eworo A, Munoz P, Yanez JF, et al. [cardiac invasive aspergillosis in a heart transplant
 1521 recipient]. *Rev Iberoam Micol.* 2011; 28: 134-138.
- 1522 261 El-Sayed Ahmed MM, Almanfi A, Aftab M, Singh SK, Mallidi HR, Frazier OH. Aspergillus
 1523 mediastinitis after orthotopic heart transplantation: A case report. *Tex Heart Inst J.* 2015; 42:
 1524 468-470.
- Wiltberger G, Schmelzle M, Schubert S, et al. Invasive cardiac aspergillosis after orthotopic
 liver transplantation. *Z Gastroenterol*. 2014; **52**: 813-817.

1527 263 Spapen H, Spapen J, Taccone FS, et al. Cerebral aspergillosis in adult critically ill patients: A 1528 descriptive report of 10 patients from the aspicu cohort. Int J Antimicrob Agents. 2014; 43: 1529 165-169. 1530 264 Sole A, Ussetti P. [mold infections in lung transplants]. Rev Iberoam Micol. 2014; 31: 229-236. 1531 265 Fortun J, Meije Y, Fresco G, Moreno S. [aspergillosis. Clinical forms and treatment]. Enferm 1532 Infecc Microbiol Clin. 2012; 30: 201-208. 1533 266 Singh N, Sun HY. Iron overload and unique susceptibility of liver transplant recipients to 1534 disseminated disease due to opportunistic pathogens. *Liver Transpl.* 2008; **14**: 1249-1255. 1535 267 Shields RK, Nguyen MH, Shullo MA, et al. Invasive aspergillosis among heart transplant 1536 recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction 1537 syndrome. Scand J Infect Dis. 2012; 44: 982-986. 1538 268 Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of aspergillus species: A 1539 hospital-based survey of aspergillosis. Clin Infect Dis. 2001; 33: 1824-1833. 1540 269 Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive 1541 pulmonary aspergillosis. The American journal of medicine. 1996; 100: 171-178. 1542 270 Escribano P, Marcos-Zambrano LJ, Pelaez T, et al. Sputum and bronchial secretion samples 1543 are equally useful as bronchoalveolar lavage samples for the diagnosis of invasive pulmonary 1544 aspergillosis in selected patients. *Medical mycology*. 2015; 53: 235-240. 1545 271 Munoz P, Alcala L, Sanchez Conde M, et al. The isolation of aspergillus fumigatus from 1546 respiratory tract specimens in heart transplant recipients is highly predictive of invasive 1547 aspergillosis. Transplantation. 2003; 75: 326-329. 1548 272 Barton RC, Hobson RP, McLoughlin H, Morris A, Datta B. Assessment of the significance of 1549 respiratory culture of aspergillus in the non-neutropenic patient. A critique of published 1550 diagnostic criteria. Eur J Clin Microbiol Infect Dis. 2013; 32: 923-928. 1551 273 Zaspel U, Denning DW, Lemke AJ, et al. Diagnosis of ipa in hiv: The role of the chest x-ray and 1552 radiologist. Eur Radiol. 2004; 14: 2030-2037.

1553 274 Munoz P, Vena A, Ceron I, et al. Invasive pulmonary aspergillosis in heart transplant
1554 recipients: Two radiologic patterns with a different prognosis. *J Heart Lung Transplant*. 2014;
1555 33: 1034-1040.

- 1556275Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive1557pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012; 186: 56-64.
- 1558276Bulpa P, Dive A. Diagnosis of invasive bronchial-pulmonary aspergillosis in patients with1559chronic obstructive respiratory diseases. Crit Care. 2011; 15: 420; author reply 420.
- 1560277Singh N, Winston DJ, Limaye AP, et al. Performance characteristics of galactomannan and1561beta-d-glucan in high-risk liver transplant recipients. *Transplantation*. 2015; **99**: 2543-2550.
- 1562278Guinea J, Padilla C, Escribano P, et al. Evaluation of mycassay aspergillus for diagnosis of1563invasive pulmonary aspergillosis in patients without hematological cancer. *PLoS One*. 2013; 8:1564e61545.
- Zarrinfar H, Makimura K, Satoh K, Khodadadi H, Mirhendi H. Incidence of pulmonary
 aspergillosis and correlation of conventional diagnostic methods with nested pcr and realtime pcr assay using bal fluid in intensive care unit patients. *J Clin Lab Anal*. 2013; 27: 181185.
- 1569 280 Chong GL, van de Sande WW, Dingemans GJ, et al. Validation of a new aspergillus real-time
 1570 pcr assay for direct detection of aspergillus and azole resistance of aspergillus fumigatus on
 1571 bronchoalveolar lavage fluid. *Journal of clinical microbiology*. 2015; **53**: 868-874.
- 1572 281 Fortun J, Martin-Davila P, Gomez Garcia de la Pedrosa E, et al. Galactomannan in
 1573 bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological
 1574 patients. J Infect. 2016; 72: 738-744.

1575 282 Fortun J, Martin-Davila P, Alvarez ME, et al. False-positive results of aspergillus
1576 galactomannan antigenemia in liver transplant recipients. *Transplantation*. 2009; 87: 2561577 260.

1578 283 Cai X, Ni W, Wei C, Cui J. Diagnostic value of the serum galactomannan and (1, 3)-beta-d1579 glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients. *Intern Med*.
1580 2014; **53**: 2433-2437.

- 1581 284 Eigl S, Prattes J, Lackner M, et al. Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in icu patients. *Crit Care*. 2015; **19**: 178.
 1583 285 Prattes J, Flick H, Pruller F, et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. *Am J Respir Crit Care Med*. 2014; **190**: 922-929.
 1585 286 Lopez-Medrano F, Fernandez-Ruiz M, Silva JT, et al. Clinical presentation and determinants of
- 1586mortality of invasive pulmonary aspergillosis in kidney transplant recipients: A multinational1587cohort study. Am J Transplant. 2016.
- 1588287Cherian T, Giakoustidis A, Yokoyama S, et al. Treatment of refractory cerebral aspergillosis in1589a liver transplant recipient with voriconazole: Case report and review of the literature. *Exp*1590*Clin Transplant*. 2012; **10**: 482-486.
- Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo M. Us hospital database analysis of
 invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. J *Med Econ.* 2011; 14: 227-237.
- Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary
 therapy for invasive aspergillosis in solid organ transplant recipients: A prospective,
 multicenter, observational study. *Transplantation*. 2006; **81**: 320-326.
- Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole
 hepatotoxicity at 12 weeks in lung transplant recipients. *Am J Transplant*. 2012; **12**: 19291935.
- 1600291Shoham S, Ostrander D, Marr K. Posaconazole liquid suspension in solid organ transplant1601recipients previously treated with voriconazole. *Transpl Infect Dis*. 2015; **17**: 493-496.
- Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole
 plasma concentrations in intensive care unit patients and patients with hematological
 malignancies. *Antimicrob Agents Chemother*. 2013; 57: 3262-3267.
- 1605 293 Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous
 1606 voriconazole formulated with sulfobutylether beta-cyclodextrin in haematological patients
 1607 with renal impairment. *Mycoses*. 2016.

- Guinea J, Escribano P, Marcos-Zambrano LJ, et al. Therapeutic drug monitoring of
 voriconazole helps to decrease the percentage of patients with off-target trough serum
 levels. *Medical mycology*. 2016; 54: 353-360.
- 1611 295 Vanstraelen K, Wauters J, Vercammen I, et al. Impact of hypoalbuminemia on voriconazole
 1612 pharmacokinetics in critically ill adult patients. *Antimicrob Agents Chemother*. 2014; 58:
 1613 6782-6789.
- Shalhoub S, Luong ML, Howard SJ, et al. Rate of cyp51a mutation in aspergillus fumigatus
 among lung transplant recipients with targeted prophylaxis. *J Antimicrob Chemother*. 2015;
 1616
 70: 1064-1067.
- 1617 297 Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J. Is azole resistance in aspergillus fumigatus
 1618 a problem in spain? *Antimicrob Agents Chemother*. 2013; 57: 2815-2820.
- 1619 298 Fuhren J, Voskuil WS, Boel CH, et al. High prevalence of azole resistance in aspergillus
 1620 fumigatus isolates from high-risk patients. *J Antimicrob Chemother*. 2015; **70**: 2894-2898.
- 1621299Egli A, Fuller J, Humar A, et al. Emergence of aspergillus calidoustus infection in the era of1622posttransplantation azole prophylaxis. *Transplantation*. 2012; **94**: 403-410.
- 1623300Kuipers S, Bruggemann RJ, de Sevaux RG, et al. Failure of posaconazole therapy in a renal1624transplant patient with invasive aspergillosis due to aspergillus fumigatus with attenuated1625susceptibility to posaconazole. Antimicrob Agents Chemother. 2011; 55: 3564-3566.
- 1626301Singh N, Suarez JF, Avery R, et al. Immune reconstitution syndrome-like entity in lung1627transplant recipients with invasive aspergillosis. *Transpl Immunol.* 2013; **29**: 109-113.
- Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients?
 Curr Opin Infect Dis. 2013; **26**: 317-325.
- 1630303Tofte N, Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M. Use of prophylactic1631voriconazole for three months after lung transplantation does not reduce infection with
- aspergillus: A retrospective study of 147 patients. *Scand J Infect Dis*. 2012; **44**: 835-841.
- 1633304Bhaskaran A, Mumtaz K, Husain S. Anti-aspergillus prophylaxis in lung transplantation: A1634systematic review and meta-analysis. Curr Infect Dis Rep. 2013; 15: 514-525.

- 1635 305 Koo S, Kubiak DW, Issa NC, et al. A targeted peritransplant antifungal strategy for the
 1636 prevention of invasive fungal disease after lung transplantation: A sequential cohort analysis.
 1637 Transplantation. 2012; 94: 281-286.
- Munoz P, Rojas L, Cervera C, et al. Poor compliance with antifungal drug use guidelines by
 transplant physicians: A framework for educational guidelines and an international
 consensus on patient safety. *Clin Transplant*. 2012; **26**: 87-96.
- 1641 307 He SY, Makhzoumi ZH, Singer JP, Chin-Hong PV, Arron ST. Practice variation in aspergillus
 1642 prophylaxis and treatment among lung transplant centers: A national survey. *Transpl Infect*1643 *Dis*. 2015; **17**: 14-20.
- 1644308Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of1645invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015; 60: 997-16461006.
- 1647 309 Peghin M, Monforte V, Martin-Gomez MT, et al. 10 years of prophylaxis with nebulized
 1648 liposomal amphotericin b and the changing epidemiology of aspergillus spp. Infection in lung
 1649 transplantation. *Transpl Int*. 2016; **29**: 51-62.
- 1650 310 Patel TS, Eschenauer GA, Stuckey LJ, Carver PL. Antifungal prophylaxis in lung transplant
 1651 recipients. *Transplantation*. 2016.
- 1652 311 Fortun J, Muriel A, Martin-Davila P, et al. Caspofungin versus fluconazole as prophylaxis of
 1653 invasive fungal infection in high-risk liver transplantation recipients: A propensity score
 1654 analysis. *Liver Transpl.* 2016; **22**: 427-435.
- 1655312Kato K, Nagao M, Nakano S, et al. Itraconazole prophylaxis for invasive aspergillus infection in1656lung transplantation. *Transpl Infect Dis.* 2014; **16**: 340-343.
- 1657 313 Balogh J, Gordon Burroughs S, Boktour M, et al. Efficacy and cost-effectiveness of
 1658 voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant
 1659 recipients. *Liver Transpl.* 2016; 22: 163-170.
- 1660 314 Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant
 1661 recipients. *Liver Transpl.* 2012; **18**: 680-685.
- 1662315Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal1663prophylaxis strategies in lung transplantation. *Transpl Infect Dis.* 2006; 8: 213-218.

1664	316	Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. Ct of invasive pulmonary
1665		aspergillosis in children with cancer. Pediatr Radiol. 1993; 23: 177-180.
1666	317	Archibald S, Park J, Geyer JR, Hawkins DS. Computed tomography in the evaluation of febrile
1667		neutropenic pediatric oncology patients. <i>Pediatr Infect Dis J</i> . 2001; 20 : 5-10.
1668	318	Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: A multicenter
1669		retrospective analysis of 139 contemporary cases. <i>Pediatrics</i> . 2008; 121 : e1286-1294.
1670	319	Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay:
1671		A meta-analysis. Clin Infect Dis. 2006; 42: 1417-1727.
1672	320	Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and
1673		monitoring of invasive fungal infections in pediatric patients with cancer and hematologic
1674		disorders. <i>Pediatric blood & cancer</i> . 2007; 48 : 28-34.
1675	321	Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective aspergillus galactomannan
1676		antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J.
1677		2007; 26 : 558-564.
1678	322	Hayden R, Pounds S, Knapp K, et al. Galactomannan antigenemia in pediatric oncology
1679		patients with invasive aspergillosis. <i>Pediatr Infect Dis J</i> . 2008; 27 : 815-819.
1680	323	Castagnola E, Furfaro E, Caviglia I, et al. Performance of the galactomannan antigen
1681		detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing
1682		haemopoietic stem cell transplantation. Clin Microbiol Infect. 2010; 16: 1197-1203.
1683	324	Fisher BT, Zaoutis TE, Park JR, et al. Galactomannan antigen testing for diagnosis of invasive
1684		aspergillosis in pediatric hematology patients. <i>J Pediatric Infect Dis Soc</i> . 2012; 1: 103-111.
1685	325	Choi SH, Kang ES, Eo H, et al. Aspergillus galactomannan antigen assay and invasive
1686		aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients.
1687		Pediatric blood & cancer. 2013; 60 : 316-322.
1688	326	Jha AK, Bansal D, Chakrabarti A, Shivaprakash MR, Trehan A, Marwaha RK. Serum
1689		galactomannan assay for the diagnosis of invasive aspergillosis in children with
1690		haematological malignancies. <i>Mycoses</i> . 2013; 56 : 442-448.

- 1691 327 Dinand V, Anjan M, Oberoi JK, et al. Threshold of galactomannan antigenemia positivity for
 1692 early diagnosis of invasive aspergillosis in neutropenic children. *J Microbiol Immunol Infect*.
 1693 2016; 49: 66-73.
- Smith PB, Benjamin DK, Jr., Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ.
 Quantification of 1,3-beta-d-glucan levels in children: Preliminary data for diagnostic use of
 the beta-glucan assay in a pediatric setting. *Clin Vaccine Immunol*. 2007; 14: 924-925.
- 1697 329 Zhao L, Tang JY, Wang Y, et al. [value of plasma beta-glucan in early diagnosis of invasive
 1698 fungal infection in children]. *Zhongguo Dang Dai Er Ke Za Zhi*. 2009; **11**: 905-908.
- 1699330Mularoni A, Furfaro E, Faraci M, et al. High levels of beta-d-glucan in immunocompromised1700children with proven invasive fungal disease. *Clin Vaccine Immunol.* 2010; **17**: 882-883.
- Badiee P, Alborzi A, Karimi M, et al. Diagnostic potential of nested pcr, galactomannan eia,
 and beta-d-glucan for invasive aspergillosis in pediatric patients. *J Infect Dev Ctries*. 2012; 6:
 352-357.
- Koltze A, Rath P, Schoning S, et al. Beta-d-glucan screening for detection of invasive fungal
 disease in children undergoing allogeneic hematopoietic stem cell transplantation. *Journal of clinical microbiology*. 2015; **53**: 2605-2610.
- 1707333Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment1708of acute invasive aspergillosis. Clin Infect Dis. 2002; 34: 563-571.
- Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis,
 scedosporiosis and other invasive fungal infections in children. *Pediatr Infect Dis J.* 2002; 21:
 240-248.
- Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of
 invasive aspergillosis in patients refractory to or intolerant of conventional antifungal
 therapy. *Clin Infect Dis.* 2004; **39**: 1563-1571.
- 1715 336 Raad, II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive
 1716 aspergillosis in patients with hematologic malignancies: Posaconazole compared with high1717 dose lipid formulations of amphotericin b alone or in combination with caspofungin.
 1718 Leukemia. 2008; 22: 496-503.

- 1719 337 Cornely OA, Maertens J, Bresnik M, Ullmann AJ, Ebrahimi R, Herbrecht R. Treatment
 1720 outcome of invasive mould disease after sequential exposure to azoles and liposomal
 1721 amphotericin b. *J Antimicrob Chemother*. 2010; 65: 114-117.
- Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections
 associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem
 cell transplantation recipients. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2011; **17**: 507-515.
- 1726339De la Serna J, Jarque I, Lopez-Jimenez J, et al. Treatment of invasive fungal infections in high1727risk hematological patients. The outcome with liposomal amphotericin b is not negatively1728affected by prior administration of mold-active azoles. *Rev Esp Quimioter*. 2013; **26**: 64-69.
- Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal
 breakthrough infections, fungal colonization and emergence of resistant strains in high-risk
 patients receiving antifungal prophylaxis with posaconazole: Real-life data from a singlecentre institutional retrospective observational study. *J Antimicrob Chemother*. 2012; 67:
 2268-2273.
- 1734 341 Lehrnbecher T, Kalkum M, Champer J, Tramsen L, Schmidt S, Klingebiel T. Immunotherapy in
 1735 invasive fungal infection--focus on invasive aspergillosis. *Current pharmaceutical design*.
 1736 2013; 19: 3689-3712.
- 1737 342 Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus
 1738 conventional amphotericin b for the treatment of pyrexia of unknown origin in neutropenic
 1739 patients. *Br J Haematol.* 1997; **98**: 711-718.
- Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of
 caspofungin versus liposomal amphotericin b for empiric antifungal therapy in pediatric
 patients with persistent fever and neutropenia. *Pediatr Infect Dis J.* 2010; **29**: 415-420.
- 1743 344 Caselli D, Paolicchi O. Empiric antibiotic therapy in a child with cancer and suspected
 1744 septicemia. *Pediatr Rep.* 2012; **4**: e2.
- 1745 345 Tan BH, Low JG, Chlebicka NL, et al. Galactomannan-guided preemptive vs. Empirical
 1746 antifungals in the persistently febrile neutropenic patient: A prospective randomized study.
 1747 Int J Infect Dis. 2011; 15: e350-356.

1748 346 Castagnola E, Bagnasco F, Amoroso L, et al. Role of management strategies in reducing 1749 mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem 1750 cell transplant: A single center 30-year experience. Pediatr Infect Dis J. 2014; 33: 233-237. 1751 347 Borjesson J, Latifi A, Friman O, Beckman MO, Oldner A, Labruto F. Accuracy of low-dose chest 1752 ct in intensive care patients. Emerg Radiol. 2011; 18: 17-21. 1753 348 Yamamura J, Tornquist K, Buchert R, et al. Simulated low-dose computed tomography in 1754 oncological patients: A feasibility study. Journal of computer assisted tomography. 2010; 34: 1755 302-308. 1756 349 Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes 1757 in clinical trials of invasive fungal diseases: Mycoses study group and european organization 1758 for research and treatment of cancer consensus criteria. Clin Infect Dis. 2008; 47: 674-683. 1759 350 Vehreschild JJ, Heussel CP, Groll AH, et al. Serial assessment of pulmonary lesion volume by 1760 computed tomography allows survival prediction in invasive pulmonary aspergillosis. Eur 1761 Radiol. 2017. 1762 351 Nouer SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. Earlier response 1763 assessment in invasive aspergillosis based on the kinetics of serum aspergillus 1764 galactomannan: Proposal for a new definition. Clin Infect Dis. 2011; 53: 671-676. 1765 352 Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis. 2008; 46: 1426-1766 1433. 1767 353 Bennett JE. Salvage therapy for aspergillosis. Clin Infect Dis. 2005; 41 Suppl 6: S387-388. 1768 354 Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological 1769 markers to predict the outcome of invasive pulmonary aspergillosis in hematological 1770 patients. Journal of clinical microbiology. 2012; 50: 823-830. 1771 355 Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for 1772 outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 1773 2009; **115**: 355-362. 1774 356 Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant 1775 recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis. 1776 2002; **34**: 939-943.

- Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in
 cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle,
 description, and clinical and research implications. *Cancer*. 2007; **110**: 112-120.
- Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues
 related to the design and interpretation of clinical trials of salvage therapy for invasive mold
 infection. *Clin Infect Dis.* 2006; **43**: 1449-1455.
- Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological
 markers to predict the outcome of invasive pulmonary aspergillosis in hematological
 patients. *Journal of clinical microbiology*. 2012; **50**: 823-830.
- Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including
 simple aspergilloma. *Eur Respir J.* 2011; **37**: 865-872.
- Salzer HJ, Cornely OA. Awareness of predictors of mortality may help improve outcome in
 chronic pulmonary aspergillosis. *Eur Respir J.* 2017; 49.
- Muldoon EG, Sharman A, Page I, Bishop P, Denning DW. Aspergillus nodules; another
 presentation of chronic pulmonary aspergillosis. *BMC Pulm Med*. 2016; 16: 123.
- Salzer HJ, Heyckendorf J, Kalsdorf B, Rolling T, Lange C. Characterization of patients with
 chronic pulmonary aspergillosis according to the new escmid/ers/ecmm and idsa guidelines. *Mycoses.* 2017; **60**: 136-142.
- 1795364Dumollard C, Bailly S, Perriot S, et al. Prospective evaluation of a new aspergillus igg enzyme1796immunoassay kit for diagnosis of chronic and allergic pulmonary aspergillosis. Journal of1797clinical microbiology. 2016; 54: 1236-1242.
- Farid S, Mohamed S, Devbhandari M, et al. Results of surgery for chronic pulmonary
 aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence--a
 national centre's experience. *J Cardiothorac Surg.* 2013; **8**: 180.
- 1801 366 Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: A
 1802 prospective multicenter trial. *Eur J Clin Microbiol Infect Dis*. 2012; **31**: 3231-3239.
- 1803 367 Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW. Long-term antifungal
 1804 treatment improves health status in patients with chronic pulmonary aspergillosis: A
 1805 longitudinal analysis. *Clin Infect Dis.* 2013; **57**: 828-835.

- 1806 368 Pasmans HL, Loosveld OJ, Schouten HC, Thunnissen F, van Engelshoven JM. Invasive
 1807 aspergillosis in immunocompromised patients: Findings on plain film and (hr)ct. *Eur J Radiol*.
 1808 1992; **14**: 37-40.
- 1809 369 Heussel CP, Kauczor HU, Heussel G, Mildenberger P, Dueber C. Aneurysms complicating
 1810 inflammatory diseases in immunocompromised hosts: Value of contrast-enhanced ct.
 1811 *European radiology*. 1997; **7**: 316-319.
- 1812 370 Didier M, Guedin P, Staub F, et al. Pulmonary arterial mycotic pseudoaneurysms in a patient
 1813 with invasive pulmonary aspergillosis. Successful occlusion by coils. *American journal of*1814 respiratory and critical care medicine. 2014; **190**: 112-113.
- 1815 371 Denning DW, Kibbler CC, Barnes RA, British Society for Medical M. British society for medical
 1816 mycology proposed standards of care for patients with invasive fungal infections. *Lancet* 1817 *Infect Dis.* 2003; **3**: 230-240.
- 1818 372 Vyzantiadis TA, Johnson EM, Kibbler CC. From the patient to the clinical mycology laboratory:
 1819 How can we optimise microscopy and culture methods for mould identification? *J Clin*1820 *Pathol.* 2012; 65: 475-483.
- 1821 373 Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided
 1822 percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised
 1823 patients. *Clin Infect Dis.* 2007; **45**: e101-e104.
- 1824374Choi JK, Mauger J, McGowan KL. Immunohistochemical detection of aspergillus species in1825pediatric tissue samples. Am J Clin Pathol. 2004; 121: 18-25.
- 1826 375 Kaufman L, Standard PG, Jalbert M, Kraft DE. Immunohistologic identification of aspergillus
 1827 spp. And other hyaline fungi by using polyclonal fluorescent antibodies. *Journal of clinical* 1828 *microbiology*. 1997; **35**: 2206-2209.
- 1829 376 Verweij PE, Smedts F, Poot T, Bult P, Hoogkamp-Korstanje JA, Meis JF. Immunoperoxidase
 1830 staining for identification of aspergillus species in routinely processed tissue sections. *J Clin*1831 *Pathol.* 1996; **49**: 798-801.
- 1832 377 Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of
 1833 aspergillus, fusarium, and pseudallescheria species in tissue section. *Diagn Mol Pathol*.
 1834 2003; 12: 21-26.

1835 378 Sundaram C, Umabala P, Laxmi V, et al. Pathology of fungal infections of the central nervous 1836 system: 17 years' experience from southern india. *Histopathology*. 2006; **49**: 396-405. 1837 379 Chander J, Chakrabarti A, Sharma A, Saini JS, Panigarhi D. Evaluation of calcofluor staining in 1838 the diagnosis of fungal corneal ulcer. Mycoses. 1993; 36: 243-245. 1839 380 Baxter CG, Jones AM, Webb K, Denning DW. Homogenisation of cystic fibrosis sputum by 1840 sonication--an essential step for aspergillus pcr. J Microbiol Methods. 2011; 85: 75-81. 1841 381 Cuenca-Estrella M, Bassetti M, Lass-Flîrl C, R†cil Z, Richardson M, Rogers TR. Detection and 1842 investigation of invasive mould disease. J Antimicrob Chemother. 2011; 66: i15-i24. 1843 382 Richardson M, Ellis M. Clinical and laboratory diagnosis. Hosp Med. 2000; 61: 610-614. 1844 383 Alanio A, Beretti JL, Dauphin B, et al. Matrix-assisted laser desorption ionization time-of-flight 1845 mass spectrometry for fast and accurate identification of clinically relevant aspergillus 1846 species. Clin Microbiol Infect. 2011; 17: 750-755. 1847 384 Bille E, Dauphin B, Leto J, et al. Maldi-tof ms andromas strategy for the routine identification 1848 of bacteria, mycobacteria, yeasts, aspergillus spp. And positive blood cultures. Clin Microbiol 1849 Infect. 2012; 18: 1117-1125. 1850 385 De Carolis E, Vella A, Florio AR, et al. Use of matrix-assisted laser desorption ionization-time 1851 of flight mass spectrometry for caspofungin susceptibility testing of candida and aspergillus 1852 species. Journal of clinical microbiology. 2012; 50: 2479-2483. 1853 386 Lau AF, Drake SK, Calhoun LB, Henderson CM, Zelazny AM. Development of a clinically 1854 comprehensive database and a simple procedure for identification of molds from solid media 1855 by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Journal of 1856 clinical microbiology. 2013; 51: 828-834. 1857 Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of aspergillus, 387 1858 fusarium, and mucorales species in the clinical mycology laboratory: Where are we and 1859 where should we go from here? Journal of clinical microbiology. 2009; 47: 877-884. 1860 388 Samson RA, Hong S, Peterson SW, Frisvad JC, Varga J. Polyphasic taxonomy of aspergillus 1861 section fumigati and its teleomorph neosartorya. Stud Mycol. 2007; 59: 147-203.

- 1862 389 Caramalho R, Gusm∆o L, Lackner M, Amorim A, Araujo R. Snapafu: A novel single nucleotide
 1863 polymorphism multiplex assay for aspergillus fumigatus direct detection, identification and
 1864 genotyping in clinical specimens. *PLoS One*. 2013; 8: e75968.
- 1865 390 Hurst SF, Kidd SE, Morrissey CO, et al. Interlaboratory reproducibility of a single-locus
 1866 sequence-based method for strain typing of aspergillus fumigatus *Journal of clinical*1867 *microbiology*. 2009; **47**: 1562-1564.
- 1868 391 Guinea J, García de Viedma D, Peláez T, et al. Molecular epidemiology of aspergillus
 1869 fumigatus : An in-depth genotypic analysis of isolates involved in an outbreak of invasive
 1870 aspergillosis. *Journal of clinical microbiology*. 2011; 49: 3498-3503.
- 1871 392 Rougeron A, Giraud S, Razafimandimby B, Meis JF, Bouchara JP, Klaassen CH. Different
 1872 colonization patterns of aspergillus terreus in patients with cystic fibrosis. *Clin Microbiol* 1873 *Infect*. 2014; **20**: 327-333.
- Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of
 circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic
 stem cell transplant recipients. *The Journal of infectious diseases*. 2002; **186**: 1297-1306.
- 1877 394 Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive
 1878 aspergillosis in immunocompromised patients. *The Cochraen Collaboration*. 2008; 4:
 1879 CD007394.
- 1880 395 Furfaro E, Mikulska M, Miletich F, Viscoli C. Galactomannan: Testing the same sample twice?
 1881 *Transpl Infect Dis.* 2012; **14**: E38-E39.
- 1882 396 Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and pcr versus culture and histology
 1883 for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology
 1884 patients: A randomised controlled trial. *Lancet Infect Dis.* 2013; **13**: 519-528.
- Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating
 galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged
 neutropenic patients and stem cell transplantation recipients: A prospective validation. *Blood.* 2001; **97**: 1604-1610.

- 1889 398 Hoenigl M, Seeber K, Koidl C, et al. Sensitivity of galactomannan enzyme immunoassay for
 1890 diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical
 1891 therapy. *Mycoses*. 2013; 56: 471-476.
- 1892399Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the1893aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005; 40: 1762-1769.
- 1894 400 Cordonnier C, Botterel F, Ben Amor R, et al. Correlation between galactomannan antigen
 1895 levels in serum and neutrophil counts in haematological patients with invasive aspergillosis.
 1896 *Clin Microbiol Infect*. 2009; **15**: 81-86.
- Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal
 infection: A prospective feasibility study. *Clin Infect Dis.* 2005; **41**: 1242-1250.
- 1900402Guinea J, Jensen J, Peláez T, et al. Value of a single galactomannan determination (platelia)1901for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation1902of aspergillus spp. *Medical mycology*. 2008; **46**: 575-579.
- 1903403Husain S, Kwak EJ, Obman A, et al. Prospective assessment of platelia aspergillus1904galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant1905recipients. Am J Transplant. 2004; 4: 796-802.
- 1906404Tabarsi P, Soraghi A, Marjani M, et al. Comparison of serum and bronchoalveolar lavage1907galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. *Exp*1908*Clin Transplant.* 2012; **10**: 278-281.
- Guigue N, Menotti J, Ribaud P. False positive galactomannan test after ice-pop ingestion. *N Engl J Med.* 2013; 369: 97-98.
- 1911406Petraitiene R, Petraitis V, Witt JR, 3rd, et al. Galactomannan antigenemia after infusion of1912gluconate-containing plasma-lyte. Journal of clinical microbiology. 2011; 49: 4330-4332.
- Martin-Rabadan P, Gijon P, Alonso Fernandez R, Ballesteros M, Anguita J, Bouza E. Falsepositive aspergillus antigenemia due to blood product conditioning fluids. *Clin Infect Dis*.
 2012; **55**: e22-27.

- Mikulska M, Furfaro E, Del Bono V, et al. Piperacillin/tazobactam (tazocintm) seems to be no
 longer responsible for false-positive results of the galactomannan assay. *J Antimicrob Chemother*. 2012; 67: 1746-1748.
- 1919409Vergidis P, Walker RC, Kaul DR, et al. False-positive aspergillus galactomannan assay in solid1920organ transplant recipients with histoplasmosis. *Transpl Infect Dis.* 2012; **14**: 213-217.
- 1921410Huang YT, Hung CC, Liao CH, Sun HY, Chang SC, Chen YC. Detection of circulating1922galactomannan in serum samples for diagnosis of penicillium marneffei infection and1923cryptococcosis among patients infected with human immunodeficiency virus. Journal of1924clinical microbiology. 2007; 45: 2858-2862.
- 1925411Nucci M, Carlesse F, Cappellano P, et al. Earlier diagnosis of invasive fusariosis with1926aspergillus serum galactomannan testing. *PLoS One*. 2014; **9**: e87784.
- 1927412King ST, Stover KR. Considering confounders of the galactomannan index: The role of1928piperacillin-tazobactam. *Clin Infect Dis.* 2014; **58**: 751-752.
- 1929413Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of1930outcome of invasive aspergillosis. Journal of clinical microbiology. 2012; 50: 2330-2336.
- 1931414Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an aspergillus real-time polymerase1932chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the1933diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis.19342011; 52: 1218-1226.
- 1935415Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with1936hematological malignancies: A multicenter prospective evaluation of an aspergillus pcr1937assay and a galactomannan elisa in bronchoalveolar lavage sample. *Eur J Haematol.* 2012; 89:1938120-127.
- Heng SC, Morrissey O, Chen SC, et al. Utility of bronchoalveolar lavage fluid galactomannan
 alone or in combination with pcr for the diagnosis of invasive aspergillosis in adult
 hematology patients: A systematic review and meta-analysis. *Crit Rev Microbiol*. 2015; **41**:
 124-134.

- 1943 417 Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting
 1944 galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. *PLoS*1945 *One*. 2012; **7**: e43347.
- 1946 418 Fisher CE, Stevens AM, Leisenring W, Pergam SA, Boeckh M, Hohl TM. The serum
 1947 galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with
 1948 invasive aspergillosis. *Clin Infect Dis.* 2013; 57: 1001-1004.
- Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: Diagnosis by
 non-culture-based microbiological methods and management. *Journal of clinical microbiology*. 1999; **37**: 1186-1189.
- 1952 420 Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the
 1953 cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis.
 1954 *Journal of clinical microbiology*. 2002; **40**: 1496-1499.
- 1955421Klont RR, Mennink-Kersten MA, Verweij PE. Utility of aspergillus antigen detection in1956specimens other than serum specimens. Clin Infect Dis. 2004; **39**: 1467-1474.
- 1957422Lu Y, Chen YQ, Guo YL, Qin SM, Wu C, Wang K. Diagnosis of invasive fungal disease using1958serum (1-3)-ß-d-glucan: A bivariate meta-analysis. Intern Med. 2011; 50: 2783-2791.
- Lamoth F, Cruciani M, Mengoli C, et al. ß-glucan antigenemia assay for the diagnosis of
 invasive fungal infections in patients with hematological malignancies: A systematic review
 and meta-analysis of cohort studies from the third european conference on infections in
 leukemia (ecil-3). *Clin Infect Dis.* 2012; **54**: 633-643.
- 1963 424 Senn L, Robinson JO, Schmidt S, et al. 1,3-beta-d-glucan antigenemia for early diagnosis of
 1964 invasive fungal infections in neutropenic patients with acute leukemia. *Clin Infect Dis.* 2008;
 1965 46: 878-885.
- Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-dglucan concentrations in patients with persistent neutropenic fever. *J Med Microbiol*. 2008;
 57: 287-295.
- 1969426Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of1970real-time pcr, double-sandwich enzyme-linked immunosorbent assay for galactomannan,

- 1971and a (1-->3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with1972hematological disorders. Journal of clinical microbiology. 2004; 42: 2733-2741.
- 1973 427 Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal
 1974 infections: Validation, cutoff development, and performance in patients with acute
 1975 myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis.* 2004; **39**: 199-205.
- 1976 428 Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-1977 >3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis*.
 1978 2005; **41**: 654-659.
- 1979 429 De Vlieger G, Lagrou K, Maertens J, Verbeken E, Meersseman W, Van Wijngaerden E. Beta-d1980 glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised
 1981 critically ill patients with symptoms of respiratory infection: An autopsy-based study. *Journal*1982 of clinical microbiology. 2011; 49: 3783-3787.
- 1983 430 Del Bono V, Delfino E, Furfaro E, et al. Clinical performance of the (1,3)-beta-d-glucan assay
 1984 in early diagnosis of nosocomial candida bloodstream infections. *Clin Vaccine Immunol.* 2011;
 1985 18: 2113-2117.
- 1986431Acosta J, Catalan M, del Palacio-Pérez-Medel A, et al. Prospective study in critically ill non-1987neutropenic patients: Diagnostic potential of (1,3)-ß-d-glucan assay and circulating1988galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis.19892012; **31**: 721-731.
- Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for
 invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ
 transplant patients. *J Infect.* 2012; 65: 588-591.
- 1993433Held J, Schmidt T, Thornton CR, Kotter E, Bertz H. Comparison of a novel aspergillus lateral-1994flow device and the platelia© galactomannan assay for the diagnosis of invasive aspergillosis1995following haematopoietic stem cell transplantation. Infection. 2013; **41**: 1163-1169.
- Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-d-glucan,
 aspergillus lateral-flow device, conventional culture, and pcr tests with bronchoalveolar
 lavage fluid for diagnosis of invasive pulmonary aspergillosis. *Journal of clinical microbiology*.
 2014; **52**: 2039-2045.

2000 435 Einsele H, Quabeck K, Müller KD, et al. Prediction of invasive pulmonary aspergillosis from
2001 colonisation of lower respiratory tract before marrow transplantation. *Lancet*. 1998; **352**:
2002 1443.

2003 436 Tang CM, Holden DW, Aufauvre-Brown A, Cohen J. The detection of aspergillus spp. By the
2004 polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid. *Am Rev Respir*2005 *Dis.* 1993; **148**: 1313-1317.

Verweij PE, Latge JP, Rijs AJ, et al. Comparison of antigen detection and pcr assay using
 bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients
 receiving treatment for hematological malignancies. *Journal of clinical microbiology*. 1995;
 33: 3150-3153.

2010 438 Bretagne S, Costa JM, Marmorat-Khuong A, et al. Detection of aspergillus species DNA in
2011 bronchoalveolar lavage samples by competitive pcr. *Journal of clinical microbiology*. 1995;
2012 33: 1164-1168.

2013 439 Jones ME, Fox AJ, Barnes AJ, et al. Pcr-elisa for the early diagnosis of invasive pulmonary
2014 aspergillus infection in neutropenic patients. *J Clin Pathol.* 1998; **51**: 652-656.

Skladny H, Buchheidt D, Baust C, et al. Specific detection of aspergillus species in blood and
 bronchoalveolar lavage samples of immunocompromised patients by two-step pcr. *Journal of clinical microbiology*. 1999; **37**: 3865-3871.

2018 441 Buchheidt D, Baust C, Skladny H, et al. Detection of aspergillus species in blood and
2019 bronchoalveolar lavage samples from immunocompromised patients by means of 2-step
2020 polymerase chain reaction: Clinical results. *Clin Infect Dis.* 2001; **33**: 428-435.

442 Hayette MP, Vaira D, Susin F, et al. Detection of aspergillus species DNA by pcr in
bronchoalveolar lavage fluid. *Journal of clinical microbiology*. 2001; **39**: 2338-2340.

443 Melchers WJ, Verweij PE, van den Hurk P, et al. General primer-mediated pcr for detection of
aspergillus species. *Journal of clinical microbiology*. 1994; **32**: 1710-1717.

2025444Buchheidt D, Baust C, Skladny H, Baldus M, Bräuninger S, Hehlmann R. Clinical evaluation of a2026polymerase chain reaction assay to detect aspergillus species in bronchoalveolar lavage2027samples of neutropenic patients. *Br J Haematol.* 2002; **116**: 803-811.

- 2028 445 Raad I, Hanna H, Huaringa A, Sumoza D, Hachem R, Albitar M. Diagnosis of invasive
 2029 pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in
 2030 bal. *Chest.* 2002; **121**: 1171-1176.
- 2031 446 Spiess B, Buchheidt D, Baust C, et al. Development of a lightcycler pcr assay for detection and
 2032 quantification of aspergillus fumigatus DNA in clinical samples from neutropenic patients.
 2033 Journal of clinical microbiology. 2003; 41: 1811-1818.
- 447 Meltiadis J, Melchers WJ, Meis JF, van den Hurk P, Jannes G, Verweij PE. Evaluation of a
 polymerase chain reaction reverse hybridization line probe assay for the detection and
 identification of medically important fungi in bronchoalveolar lavage fluids. *Medical mycology*. 2003; **41**: 65-74.
- 2038 448 Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time pcr, conventional pcr,
 and galactomannan antigen detection by enzyme-linked immunosorbent assay using
 bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive
 pulmonary aspergillosis. *Journal of clinical microbiology*. 2003; **41**: 3922-3925.
- 2042 449 Rantakokko-Jalava K, Laaksonen S, Issakainen J, et al. Semiquantitative detection by real-time
 2043 pcr of aspergillus fumigatus in bronchoalveolar lavage fluids and tissue biopsy specimens
 2044 from patients with invasive aspergillosis. *Journal of clinical microbiology*. 2003; **41**: 43042045 4311.
- 2046 450 Lass-Flörl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal
 2047 therapy by pcr analysis of blood samples. *Journal of clinical microbiology*. 2004; 42: 41542048 4157.
- Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus
 galactomannan enzyme immunoassay and quantitative pcr for diagnosis of invasive
 aspergillosis with bronchoalveolar lavage fluid. *Journal of clinical microbiology*. 2004; 42:
 5517-5522.
- 2053 452 Khot PD, Ko DL, Hackman RC, Fredricks DN. Development and optimization of quantitative
 2054 pcr for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. *BMC Infect*2055 *Dis.* 2008; **8**: 73.

- 2056 453 Fréalle E, Decrucq K, Botterel F, et al. Diagnosis of invasive aspergillosis using
- bronchoalveolar lavage in haematology patients: Influence of bronchoalveolar lavage human
 DNA content on real-time pcr performance. *Eur J Clin Microbiol Infect Dis*. 2009; **28**: 223-232.
- 2059454Torelli R, Sanguinetti M, Moody A, et al. Diagnosis of invasive aspergillosis by a commercial2060real-time pcr assay for aspergillus DNA in bronchoalveolar lavage fluid samples from high-2061risk patients compared to a galactomannan enzyme immunoassay. Journal of clinical2062microbiology. 2011; 49: 4273-4278.
- 2063 455 Buess M, Cathomas G, Halter J, et al. Aspergillus- pcr in bronchoalveolar lavage for detection
 2064 of invasive pulmonary aspergillosis in immunocompromised patients. *BMC Infect Dis.* 2012;
 2065 12: 237.

2066 456 Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the
2067 diagnostic performance of pcr for diagnosing invasive aspergillosis in bronchoalveolar lavage
2068 samples of patients with haematological malignancies. *J Antimicrob Chemother*. 2012; 67:
2069 2260-2267.

- 2070 457 Orsi CF, Gennari W, Venturelli C, et al. Performance of 2 commercial real-time polymerase
 2071 chain reaction assays for the detection of aspergillus and pneumocystis DNA in
 2072 bronchoalveolar lavage fluid samples from critical care patients. *Diagn Microbiol Infect Dis*.
 2073 2012; **73**: 138-143.
- Guinea J, Padilla C, Escribano P, et al. Evaluation of mycassayt aspergillus for diagnosis of
 invasive pulmonary aspergillosis in patients without hematological cancer. *PLoS One*. 2013; 8:
 e61545.
- 2077459Steinmann J, Buer J, Rath PM, Paul A, Saner F. Invasive aspergillosis in two liver transplant2078recipients: Diagnosis by septifast. *Transpl Infect Dis.* 2009; **11**: 175-178.
- 2079460Komatsu H, Fujisawa T, Inui A, et al. Molecular diagnosis of cerebral aspergillosis by sequence2080analysis with panfungal polymerase chain reaction. J Pediatr Hematol Oncol. 2004; 26: 40-44.
- 461 Kami M, Shirouzu I, Mitani K, et al. Early diagnosis of central nervous system aspergillosis
 with combination use of cerebral diffusion-weighted echo-planar magnetic resonance image
 and polymerase chain reaction of cerebrospinal fluid. *Intern Med.* 1999; **38**: 45-48.

- 462 Hummel M, Spiess B, Kentouche K, et al. Detection of aspergillus DNA in cerebrospinal fluid
 from patients with cerebral aspergillosis by a nested pcr assay. *Journal of clinical microbiology*. 2006; 44: 3989-3993.
- 2087463Badiee P, Alborzi A. Assessment of a real-time pcr method to detect human non-cryptococcal2088fungal meningitis. Arch Iran Med. 2011; 14: 381-384.
- 2089464Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnely JP. Use of pcr for diagnosis of invasive2090aspergillosis: Systematic review and meta-analysis. Lancet Infect Dis. 2009; **9**: 89-96.
- White PL, Mengoli C, Bretagne S, et al. Evaluation of aspergillus pcr protocols for testing
 serum specimens. *Journal of clinical microbiology*. 2011; **49**: 3842-3848.
- White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a
 whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in
 hematology patients in a routine clinical setting. *Clin Infect Dis.* 2006; **42**: 479-486.
- 2096 467 Lass-Flörl C, Mutschlechner W, Aigner M, et al. Utility of pcr in diagnosis of invasive fungal
 2097 infections: Real-life data from a multicenter study. *Journal of clinical microbiology*. 2013; 51:
 2098 863-868.
- 2099 468 Paterson PJ, Seaton S, McLaughlin J, Kibbler CC. Development of molecular methods for the
 2100 identification of aspergillus and emerging moulds in paraffin wax embedded tissue sections.
 2101 *Mol Pathol.* 2003; 56: 368-370.
- 2102 469 Paterson PJ, Seaton S, McHugh TD, et al. Validation and clinical application of molecular
 2103 methods for the identification of molds in tissue. *Clin Infect Dis.* 2006; **42**: 51-56.
- von Eiff M, Roos N, Schulten R, Hesse M, ZÅhlsdorf M, van de Loo J. Pulmonary aspergillosis:
 Early diagnosis improves survival. *Respiration*. 1995; **62**: 341-347.
- 2106 471 Kappe R, Rimek D. Antibody detection in patients with invasive aspergillosis. *Mycoses*. 2004;
 2107 47: 59.
- 2108 472 Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and
 2109 biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 62110 year survey. *Clin Infect Dis.* 2006; **43**: 577-584.

- Weig M, Frosch M, Tintelnot K, et al. Use of recombinant mitogillin for improved
 serodiagnosis of aspergillus fumigatus -associated diseases. *Journal of clinical microbiology*.
 2001; **39**: 1721-1730.
- 2114 474 Du C, Wingard JR, Cheng S, Nguyen MH, Clancy C. Serum igg responses against aspergillus
 2115 proteins before hematopoietic stem cell transplantation or chemotherapy identify patients
 2116 who develop invasive aspergillosis. *Biology of blood and marrow transplantation : journal of*2117 *the American Society for Blood and Marrow Transplantation*. 2012; **18**: 1927-1934.
- Holmberg K, Berdischewsky M, Young LS. Serologic immunodiagnosis of of invasive
 aspergillosis. *The Journal of infectious diseases*. 1980; 141: 656-664.
- 476 Manso E, Montillo M, De Sio G, D'Amico S, Discepoli G, Leoni P. Value of antigen and
 antibody detection in the serological diagnosis of invasive aspergillosis in patients with
 hematological malignancies. *Eur J Clin Microbiol Infect Dis.* 1994; 13: 756-760.
- Mishra SK, Falkenberg S, Masihi KN. Efficacy of enzyme-linked immunosorbent assay in
 serodiagnosis of aspergillosis. *Journal of clinical microbiology*. 1983; 17: 708-710.
- Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one antigen
 test for the diagnosis of invasive aspergillosis. *Mycoses*. 1996; **39**: 13-23.
- Fraczek MG, Bromley M, Buied A, et al. The cdr1b efflux transporter is associated with noncyp51a-mediated itraconazole resistance in aspergillus fumigatus. *J Antimicrob Chemother*.
 2013; **68**: 1486-1496.
- 2130 480 Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in aspergillus fumigatus:
 2131 2008 and 2009. *J Antimicrob Chemother*. 2010; 65: 2116-2118.

Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in
aspergillus fumigatus during azole therapy associated with change in virulence. *PLoS ONE*.
2010; 5: e10080.

- 2135 482 van der Linden JW, Jansen RR, Bresters D, et al. Azole-resistant central nervous system
 2136 aspergillosis. *Clin Infect Dis.* 2009; **48**: 1111-1113.
- 2137483Badali H, Vaezi A, Haghani I, et al. Environmental study of azole-resistant aspergillus2138fumigatus with tr34/l98h mutations in the cyp51a gene in iran. *Mycoses*. 2013; **56**: 659-663.

- 2139 484 Chowdhary A, Kathuria S, Xu J, et al. Clonal expansion and emergence of environmental
 2140 multiple-triazole-resistant aspergillus fumigatus strains carrying the tr(3)(4)/I98h mutations
 2141 in the cyp51a gene in india. *PLoS ONE*. 2012; **7**: e52871.
- 2142 485 Mortensen KL, Mellado E, Lass-Florl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC.
- 2143 Environmental study of azole-resistant aspergillus fumigatus and other aspergilli in austria, 2144 denmark, and spain. *Antimicrob Agents Chemother*. 2010; **54**: 4545-4549.
- Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW. Breakpoints for antifungal agents:
 An update from eucast focussing on echinocandins against candida spp. And triazoles against
 aspergillus spp. *Drug Resist Updat*. 2013; **16**: 81-95.
- 2148487Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant aspergillus fumigatus due2149to tr46/y121f/t289a mutation emerging in belgium, july 2012. *Euro Surveill*. 2012; **17**.
- 2150 488 Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple2151 triazole-resistant aspergillus fumigatus strains carrying the tr/l98h mutations in the cyp51a
 2152 gene in india. J Antimicrob Chemother. 2012; 67: 362-366.
- 2153 489 Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. First reported case of azole2154 resistant aspergillus fumigatus due to the tr/l98h mutation in germany. *Antimicrob Agents*2155 *Chemother*. 2012; **56**: 6060-6061.
- 490 Balajee SA, Baddley JW, Peterson SW, et al. Aspergillus alabamensis, a new clinically relevant
 2157 species in the section terrei. *Eukaryot Cell*. 2009; 8: 713-722.
- 491 Buil JB, van der Lee HAL, Rijs A, et al. Single-center evaluation of an agar-based screening for
 azole resistance in aspergillus fumigatus by using vipcheck. *Antimicrob Agents Chemother*.
 2160 2017; **61**.
- van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE. Aspergillosis--and a
 misleading sensitivity result. *Lancet*. 2007; **370**: 102.
- 493 Howard SJ, Pasqualotto AC, Anderson MJ, et al. Major variations in aspergillus fumigatus
 arising within aspergillomas in chronic pulmonary aspergillosis. *Mycoses*. 2013; 56: 434-441.
- 494 Hope WW, Cuenca-Estrella M, Lass-Florl C, Arendrup MC, European Committee on
 Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility T. Eucast
 technical note on voriconazole and aspergillus spp. *Clin Microbiol Infect*. 2013; 19: E278-280.

Arendrup MC, Meletiadis J, Mouton JW, et al. Eucast technical note on isavuconazole
breakpoints for aspergillus, itraconazole breakpoints for candida and updates for the
antifungal susceptibility testing method documents. *Clin Microbiol Infect*. 2016; 22: 571
e571-574.

2172 496 Rex JH, Clinical, Institute LS. *Reference method for broth dilution antifungal susceptibility*2173 *testing of filamentous fungi: Approved standard*: Clinical and Laboratory Standards Institute,
2174 2008.

2175 497 Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant aspergillus
2176 fumigatus in adults with cystic fibrosis exposed to itraconazole. *Antimicrob Agents*2177 *Chemother*. 2012; **56**: 869-874.

498 Araujo R, Espinel-Ingroff A. Comparison of assessment of oxygen consumption, etest, and clsi
 m38-a2 broth microdilution methods for evaluation of the susceptibility of aspergillus
 fumigatus to posaconazole. *Antimicrob Agents Chemother*. 2009; 53: 4921-4923.

499 Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of
posaconazole, voriconazole, itraconazole, and amphotericin b against *aspergillus* and *rhizopus*, and synergy testing for *rhizopus*. *Medical mycology*. 2008; 46: 567-573.

2184500Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of2185isavuconazole (bal4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete,2186candida, aspergillus, fusarium, and scedosporium species. Antimicrob Agents Chemother.21872008; 52: 1396-1400.

2188501Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance2189in the aspergillus niger complex. Antimicrob Agents Chemother. 2011; 55: 4802-4809.

2190 502 Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between
2191 in-vitro susceptibility testing to itraconazole and in-vivo outcome of aspergillus fumigatus
2192 infection. J Antimicrob Chemother. 1997; 40: 401-414.

2193503Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in aspergillus2194fumigatus. Antimicrob Agents Chemother. 1997; 41: 1364-1368.

2195504Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. In vitro activity of2196isavuconazole against 208 aspergillus flavus isolates in comparison with 7 other antifungal

- agents: Assessment according to the methodology of the european committee on
 antimicrobial susceptibility testing. *Diagn Microbiol Infect Dis*. 2011; **71**: 370-377.
- 2199 505 Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole
 2200 antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected
 2201 from 2010 to 2011: Application of new clsi clinical breakpoints and epidemiological cutoff
 2202 values for characterization of geographic and temporal trends of antifungal resistance.
 2203 *Journal of clinical microbiology*. 2013; **51**: 2571-2581.
- Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in aspergillus
 fumigatus and spread of a single resistance mechanism. *PLoS Med.* 2008; 5: e219.
- 2206 507 Perkhofer S, Lechner V, Lass-Florl C, European Committee on Antimicrobial Susceptibility T.
 2207 In vitro activity of isavuconazole against aspergillus species and zygomycetes according to
 2208 the methodology of the european committee on antimicrobial susceptibility testing.
 2209 Antimicrob Agents Chemother. 2009; 53: 1645-1647.
- Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D. Multiple-azole resistant aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease
 successfully treated with long-term oral posaconazole and surgery. *Medical mycology*. 2009;
 47: 217-220.
- Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole
 against three clinical aspergillus fumigatus isolates with mutations in the cyp51a gene.
 Antimicrob Agents Chemother. 2010; 54: 860-865.
- 2217510Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole mic2218distributions and epidemiological cutoff values for aspergillus spp. For the clsi m38-a2 broth2219microdilution method. Antimicrob Agents Chemother. 2013; 57: 3823-3828.
- Howard SJ, Lass-Florl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of
 isavuconazole susceptibility of aspergillus and candida species by the eucast method.
 Antimicrob Agents Chemother. 2013; 57: 5426-5431.
- 2223512Gregson L, Goodwin J, Johnson A, et al. In vitro susceptibility of aspergillus fumigatus to2224isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole. Antimicrob2225Agents Chemother. 2013; 57: 5778-5780.

- Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in
 patients with cancer and invasive aspergillosis: Difficulties in establishing correlation
 between in vitro susceptibility data and the outcome of initial amphotericin b therapy. *Pharmacotherapy*. 2005; **25**: 1174-1180.
- Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility
 testing of aspergillus flavus: Inoculum dependence with itraconazole and lack of correlation
 between susceptibility to amphotericin b in vitro and outcome in vivo. *Antimicrob Agents Chemother*. 2001; 45: 1456-1462.
- 2234515Barchiesi F, Spreghini E, Sanguinetti M, et al. Effects of amphotericin b on aspergillus flavus2235clinical isolates with variable susceptibilities to the polyene in an experimental model of2236systemic aspergillosis. J Antimicrob Chemother. 2013; 68: 2587-2591.
- Hadrich I, Makni F, Neji S, et al. Amphotericin b in vitro resistance is associated with fatal
 aspergillus flavus infection. *Medical mycology*. 2012; **50**: 829-834.
- Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW, European Committee on
 Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility T. Eucast
 technical note on aspergillus and amphotericin b, itraconazole, and posaconazole. *Clin Microbiol Infect.* 2012; 18: E248-250.
- 2243 518 European committee on antimicrobial susceptibility testing. <u>http://www.eucast.org</u>
- Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type mic distributions and
 epidemiological cutoff values for the triazoles and six aspergillus spp. For the clsi broth
 microdilution method (m38-a2 document). *Journal of clinical microbiology*. 2010; 48: 32513257.
- 2248520Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable2249mortality in invasive aspergillosis. Clin Infect Dis. 2008; 47: 1176-1184.
- 2250 521 Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following
 hematopoietic cell transplantation: Outcomes and prognostic factors associated with
 mortality. *Clin Infect Dis.* 2007; **44**: 531-540.
- 2253522Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid2254leukemia: A seifem-2008 registry study. *Haematologica*. 2010; **95**: 644-650.

- 2255523Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant2256patients with invasive aspergillosis. Clin Infect Dis. 2010; 50: 1559-1567.
- 2257524Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in2258france: The saif network (2005-2007). Clin Microbiol Infect. 2011; 17: 1882-1889.
- Perkhofer S, Lass-Florl C, Hell M, et al. The nationwide austrian aspergillus registry: A
 prospective data collection on epidemiology, therapy and outcome of invasive mould
 infections in immunocompromised and/or immunosuppressed patients. *Int J Antimicrob Agents*. 2010; **36**: 531-536.
- Lass-Florl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In
 vitro activities of various antifungal drugs against aspergillus terreus: Global assessment
 using the methodology of the european committee on antimicrobial susceptibility testing.
 Antimicrob Agents Chemother. 2009; 53: 794-795.
- Kathuria S, Sharma C, Singh PK, et al. Molecular epidemiology and in-vitro antifungal
 susceptibility of aspergillus terreus species complex isolates in delhi, india: Evidence of
 genetic diversity by amplified fragment length polymorphism and microsatellite typing. *PLoS One*. 2015; **10**: e0118997.
- Alastruey-Izquierdo A, Cuesta I, Houbraken J, Cuenca-Estrella M, Monzon A, Rodriguez Tudela JL. In vitro activity of nine antifungal agents against clinical isolates of aspergillus
 calidoustus. *Medical mycology*. 2010; **48**: 97-102.
- Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL.
 Aspergillus section fumigati: Antifungal susceptibility patterns and sequence-based
 identification. *Antimicrob Agents Chemother*. 2008; **52**: 1244-1251.
- Datta K, Rhee P, Byrnes E, 3rd, et al. Isavuconazole activity against aspergillus lentulus,
 neosartorya udagawae, and cryptococcus gattii, emerging fungal pathogens with reduced
 azole susceptibility. *Journal of clinical microbiology*. 2013; **51**: 3090-3093.
- 531 Howard SJ. Multi-resistant aspergillosis due to cryptic species. *Mycopathologia*. 2014; **178**:
 435-439.
- 2282532Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous disease: Insights2283into pathogenesis and management. Curr Opin Infect Dis. 2012; 25: 658-669.

- Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans
 infection in chronic granulomatous disease. *Medicine (Baltimore)*. 1998; **77**: 345-354.
- Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. Efficacy and
 pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive
 aspergillosis. J Antimicrob Chemother. 2013; 68: 385-393.
- Seyedmousavi S, Mouton JW, Melchers WJ, Bruggemann RJ, Verweij PE. The role of azoles in
 the management of azole-resistant aspergillosis: From the bench to the bedside. *Drug Resist Updat*. 2014; **17**: 37-50.
- 2292 536 Newton PJ, Harris C, Morris J, Denning DW. Impact of liposomal amphotericin b therapy on
 2293 chronic pulmonary aspergillosis. *J Infect*. 2016.
- Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in aspergillus: Proposed
 nomenclature and breakpoints. *Drug Resist Updat*. 2009; **12**: 141-147.
- Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. Pharmacodynamics and doseresponse relationships of liposomal amphotericin b against different azole-resistant
 aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. *Antimicrob Agents Chemother*. 2013; 57: 1866-1871.
- Lepak AJ, Marchillo K, VanHecker J, Andes DR. Impact of in vivo triazole and echinocandin
 combination therapy for invasive pulmonary aspergillosis: Enhanced efficacy against cyp51
 mutant isolates. *Antimicrob Agents Chemother*. 2013; 57: 5438-5447.
- 2303 540 Denning DW. Treatment of invasive aspergillosis. *J Infect*. 1994; **28 Suppl 1**: 25-33.
- 2304541Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with2305itraconazole. The American journal of medicine. 1989; 86: 791-800.
- 2306 542 Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole
 2307 in the treatment of invasive pulmonary aspergillosis in patients with hematologic
 2308 malignancies, chronic granulomatous disease, or aids. *Clin Infect Dis.* 2001; **33**: e83-90.
- Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: Clinical
 application of therapeutic drug monitoring in korean patients. *Int J Infect Dis.* 2011; **15**: e753758.

- Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is
 important to ensure successful antifungal therapy and to avoid hepatic damage in patients
 with hematological disorders. *International journal of hematology*. 2009; **89**: 592-599.
- Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. *Antimicrob Agents Chemother*. 2006; **50**: 1570-1572.
- 2317 546 Pieper S, Kolve H, Gumbinger HG, Goletz G, Wurthwein G, Groll AH. Monitoring of
 voriconazole plasma concentrations in immunocompromised paediatric patients. J
 2319 Antimicrob Chemother. 2012; 67: 2717-2724.
- Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole
 therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: Factors
 impacting levels of and associations between serum troughs, efficacy, and toxicity. *Antimicrob Agents Chemother*. 2012; 56: 2371-2377.
- Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J. Susceptibility breakpoints
 and target values for therapeutic drug monitoring of voriconazole and aspergillus fumigatus
 in an in vitro pharmacokinetic/pharmacodynamic model. *J Antimicrob Chemother*. 2014; 69:
 1611-1619.
- 2328 549 Conte JE, Jr., Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary
 pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy
 subjects. Antimicrob Agents Chemother. 2009; 53: 703-707.
- 2331 550 Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Sheppard DC. Pharmacokinetics of
 2332 posaconazole within epithelial cells and fungi: Insights into potential mechanisms of action
 2333 during treatment and prophylaxis. *The Journal of infectious diseases*. 2013; **208**: 1717-1728.
- 2334 551 Campoli P, Al Abdallah Q, Robitaille R, et al. Concentration of antifungal agents within host
 cell membranes: A new paradigm governing the efficacy of prophylaxis. *Antimicrob Agents Chemother*. 2011; **55**: 5732-5739.
- 2337 552 Blennow O, Eliasson E, Pettersson T, et al. Posaconazole concentrations in human tissues
 after allogeneic stem cell transplantation. *Antimicrob Agents Chemother*. 2014; 58: 49414943.

- 2340553Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. Fluconazole or itraconazole2341prophylaxis in patients with neutropenia. N Engl J Med. 2007; **356**: 348-359.
- Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin b for the
 prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized,
 placebo-controlled trial. *Clin Infect Dis.* 2008; **46**: 1401-1408.
- Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal
 amphotericin-b and impact on pulmonary function: Data from a randomized placebocontrolled trial. *Pulm Pharmacol Ther.* 2008; **21**: 855-859.
- Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin b lipid complex as prophylaxis of
 invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic
 syndrome undergoing induction chemotherapy. *Cancer*. 2004; **100**: 581-589.
- 2351 557 Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs
 2352 fluconazole for the prevention of fungal infections in patients with acute leukemia and
 2353 hematopoietic stem cell transplant recipients. *Bone Marrow Transplant*. 2006; **38**: 127-134.
- 2354558Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing2355itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal2356infections in patients with haematological malignancy and profound neutropenia. J2357Antimicrob Chemother. 2006; 57: 317-325.
- 2358 559 Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of
 fungal infections in patients receiving allogeneic stem cell transplants. *Blood*. 2004; **103**:
 1527-1533.
- van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for
 prophylaxis against invasive fungal infections during neutropenia in patients undergoing
 hematopoietic stem cell transplantation. *Clin Infect Dis.* 2004; **39**: 1407-1416.
- 2364 561 Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis
 2365 against invasive fungal infections in hematopoietic stem cell transplant recipients. *J Infect*.
 2366 2016; **73**: 496-505.

- 2367 562 Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal
 2368 amphotericin b for prophylaxis of invasive fungal infection in immunocompromised patients:
 2369 Prophysome study. *Int J Antimicrob Agents*. 2008; **31**: 135-141.
- 2370 563 Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin b in the prevention
 2371 of invasive fungal infections in patients with prolonged neutropenia: Results from a
 2372 randomized, single-center trial. *Ann Oncol.* 2006; **17**: 1306-1312.
- Annino L, Chierichini A, Anaclerico B, et al. Prospective phase ii single-center study of the
 safety of a single very high dose of liposomal amphotericin b for antifungal prophylaxis in
 patients with acute myeloid leukemia. *Antimicrob Agents Chemother*. 2013; 57: 2596-2602.
- 2376 565 Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus
 2377 voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell
 2378 transplantation. *Blood*. 2010; **116**: 5111-5118.
- 2379 566 Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin
 2380 b versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. *J Antimicrob*2381 *Chemother*. 2017; **72**: 2359-2367.
- 2382 567 Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus
 voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell
 transplantation. *Blood*. 2010; **116**: 5111-5118.
- Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal
 prophylaxis following allogeneic haematopoietic stem-cell transplantation. *Br J Haematol*.
 2011; **155**: 318-327.
- 2388 569 Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe
 2389 graft-versus-host disease. *N Engl J Med*. 2007; **356**: 335-347.
- Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus
 intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic
 hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. *Annals of internal medicine*. 2003; **138**: 705-713.
- 2394 571 Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole
 2395 antifungals. *Blood*. 2004; **103**: 1557-1559.

- Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for
 fungal infections in neutropenic patients with hematologic malignancies: A randomized,
 placebo-controlled, double-blind, multicenter trial. Gimema infection program. Gruppo
 italiano malattie ematologiche dell' adulto. *Clin Infect Dis.* 1999; 28: 250-255.
- 2400 573 Prentice HG, Caillot D, Dupont B, Menichetti F, Schuler U. Oral and intravenous itraconazole
 2401 for systemic fungal infections in neutropenic haematological patients: Meeting report.
 2402 London, united kingdom, 20 june 1998. *Acta Haematol*. 1999; **101**: 56-62.
- Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for
 primary prophylaxis of fungal infections in patients with hematological malignancy and
 profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial
 comparing itraconazole and amphotericin b. *Antimicrob Agents Chemother*. 2000; 44: 18871893.
- 2408575Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic2409granulomatous disease. N Engl J Med. 2003; 348: 2416-2422.
- 2410 576 de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral
 2411 solution of itraconazole in infants and children. *Antimicrob Agents Chemother*. 1998; **42**: 4042412 408.
- Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of
 cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. *Antimicrob Agents Chemother*. 2002; **46**: 2554-2563.
- 578 Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children
 undergoing stem cell transplantation or intensive chemotherapy for haematological
 disorders. *Bone Marrow Transplant*. 1999; 24: 1089-1093.
- Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients
 receiving conventional chemotherapy or autologous stem cell transplants. *Support Care Cancer.* 2007; 15: 213-220.
- Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of
 prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute
 myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12year period. *Haematologica*. 2012; **97**: 459-463.

2426	581	Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug
2427		monitoring: A practical approach. Curr Opin Infect Dis. 2012; 25: 605-611.
2428	582	Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral
2429		posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-
2430		host disease. <i>Pharmacotherapy</i> . 2007; 27 : 1627-1636.
2431	583	Welzen ME, Bruggemann RJ, Van Den Berg JM, et al. A twice daily posaconazole dosing
2432		algorithm for children with chronic granulomatous disease. Pediatr Infect Dis J. 2011; 30:
2433		794-797.
2434	584	Döring M, Müller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis
2435		in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
2436		BMC Infect Dis. 2012; 12 : 263.
2437	585	Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric
2438		patients: A multicentre survey. Eur J Clin Microbiol Infect Dis. 2010; 29: 1043-1045.
2439	586	Vanstraelen K, Colita A, Bica AM, et al. Pharmacokinetics of posaconazole oral suspension in
2440		children dosed according to body surface area. <i>Pediatr Infect Dis J</i> . 2016; 35 : 183-188.
2441	587	Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and
2442		intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous
2443		leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011; 19: 19-26.
2444	588	Barreto JN, Beach CL, Wolf RC, et al. The incidence of invasive fungal infections in
2445		neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary
2446		antifungal prophylaxis with voriconazole. Am J Hematol. 2013; 88: 283-288.
2447	589	Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous
2448		voriconazole in children after single- or multiple-dose administration. Antimicrob Agents
2449		<i>Chemother</i> . 2004; 48 : 2166-2172.
2450	590	Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole
2451		plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009; 53:
2452		935-944.

- 2453 591 Driscoll TA, Frangoul H, Nemecek ER, et al. Comparison of pharmacokinetics and safety of
 2454 voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy
 2455 adults. Antimicrob Agents Chemother. 2011; 55: 5780-5789.
- 2456 592 Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of
 2457 voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
 2458 Antimicrob Agents Chemother. 2011; 55: 5770-5779.
- 2459593Molina JR, Serrano J, Sanchez-Garcia J, et al. Voriconazole as primary antifungal prophylaxis2460in children undergoing allo-sct. *Bone Marrow Transplant*. 2012; **47**: 562-567.
- 2461594Tollemar J, Ringden O, Andersson S, et al. Prophylactic use of liposomal amphotericin b2462(ambisome) against fungal infections: A randomized trial in bone marrow transplant2463recipients. *Transplant Proc.* 1993; **25**: 1495-1497.
- 2464595Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-2465blind study of liposomal amphotericin b (ambisome) prophylaxis of invasive fungal infections2466in bone marrow transplant recipients. *Bone Marrow Transplant*. 1993; **12**: 577-582.
- Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (ambisome) in the
 prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind,
 placebo-controlled study. *Bone Marrow Transplant*. 1999; 23: 163-168.
- 2470597Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin b in2471pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006; 50: 935-942.
- 2472 598 Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin b encapsulated in liposomes
 2473 (ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J
 2474 Antimicrob Chemother. 1991; 28 Suppl B: 73-82.
- Kolve H, Ahlke E, Fegeler W, Ritter J, Jurgens H, Groll AH. Safety, tolerance and outcome of
 treatment with liposomal amphotericin b in paediatric patients with cancer or undergoing
 haematopoietic stem cell transplantation. *J Antimicrob Chemother*. 2009; 64: 383-387.
- 2478600Huang X, Chen H, Han M, et al. Multicenter, randomized, open-label study comparing the2479efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal2480infections in patients undergoing hematopoietic stem cell transplant. *Biology of blood and*

- 2481 marrow transplantation : journal of the American Society for Blood and Marrow
 2482 Transplantation. 2012; 18: 1509-1516.
- Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of
 micafungin (fk463) in febrile neutropenic pediatric patients. *Antimicrob Agents Chemother*.
 2005; **49**: 3317-3324.
- Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in
 pediatric patients and implications for antifungal dosing. *Antimicrob Agents Chemother*.
 2007; **51**: 3714-3719.
- Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. *Pediatr Infect Dis J.* 2011; **30**: e97-e102.
- 2491604Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in2492pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic2493study. Biology of blood and marrow transplantation : journal of the American Society for2494Blood and Marrow Transplantation. 2010; 16: 1458-1462.
- 2495605Beaute J, Obenga G, Le Mignot L, et al. Epidemiology and outcome of invasive fungal diseases2496in patients with chronic granulomatous disease: A multicenter study in france. Pediatr Infect2497Dis J. 2011; **30**: 57-62.
- 2498 606 Mouy R, Veber F, Blanche S, et al. Long-term itraconazole prophylaxis against aspergillus
 2499 infections in thirty-two patients with chronic granulomatous disease. *J Pediatr*. 1994; **125**:
 2500 998-1003.
- 2501607Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold2502infections in transplant recipients. *Eur J Clin Microbiol Infect Dis*. 2003; **22**: 408-413.
- Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. Superiority of voriconazole over
 amphotericin b in the treatment of invasive aspergillosis after heart transplantation. *J Heart Lung Transplant*. 2005; 24: 102-104.
- 2506 609 Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive
 2507 aspergillosis in kidney transplant recipients. *Transplant Proc.* 2007; **39**: 1838-1840.

- Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of
 voriconazole in immunocompromised children. *Antimicrob Agents Chemother*. 2010; 54:
 4116-4123.
- 2511 611 Doby EH, Benjamin DK, Jr., Blaschke AJ, et al. Therapeutic monitoring of voriconazole in
 2512 children less than three years of age: A case report and summary of voriconazole
 2513 concentrations for ten children. *Pediatr Infect Dis J.* 2012; **31**: 632-635.
- Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the
 management of invasive fungal infection in immunocompromised children: A prospective
 study. J Antimicrob Chemother. 2012; 67: 700-706.
- Bartelink IH, Wolfs T, Jonker M, et al. Highly variable plasma concentrations of voriconazole
 in pediatric hematopoietic stem cell transplantation patients. *Antimicrob Agents Chemother*.
 2013; **57**: 235-240.
- 2520614Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA, Pandya SK. A comparative2521study of plasma concentrations of liposomal amphotericin b (I-amp-Irc-1) in adults, children2522and neonates. Int J Pharm. 2002; 238: 11-15.
- 2523 615 Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin b twice weekly as
 2524 antifungal prophylaxis in paediatric haematological malignancy patients. *Clin Microbiol*2525 *Infect*. 2011; **17**: 1868-1874.
- Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of
 caspofungin, liposomal amphotericin b, and the combination of both in allogeneic
 hematopoietic stem cell recipients. *Antimicrob Agents Chemother*. 2010; **54**: 4143-4149.
- 2529617Sunakawa K, Tsukimoto I, Tsunematsu Y, et al. Evaluation of the safety and efficacy of2530liposomal amphotericin b (I-amb) in children. J Infect Chemother. 2012; 18: 456-465.
- Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis
 in allogeneic hematopoietic stem cell transplant patients: An european organisation for
 research and treatment of cancer study. *Bone Marrow Transplant*. 2010; **45**: 1227-1233.
- Viscoli C, Herbrecht R, Akan H, et al. An eortc phase ii study of caspofungin as first-line
 therapy of invasive aspergillosis in haematological patients. *J Antimicrob Chemother*. 2009;
 64: 1274-1281.

Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase ii dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother. 2011; 55: 5798-5803. Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008; : 1-6. Winkler M, Pratschke J, Schulz U, et al. Caspofungin for post solid organ transplant invasive fungal disease: Results of a retrospective observational study. Transpl Infect Dis. 2010; 12: 230-237. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005; 49: 4536-4545. Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009; 53: 1450-1456. Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis. 2007; 7: 28. Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009; 28: 1132-1135. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented candida or aspergillus infections in pediatric patients. *Pediatrics*. 2009; 123: 877-884. Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA. Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: A brief report. Int J Antimicrob Agents. 2011; 38: 540-544. Manzoni P, Rizzollo S, Farina D. Response to "is liposomal amphotericin b really safety in neonates?". Early Hum Dev. 2013; 89: 37. Karadag-Oncel E, Ozsurekci Y, Yurdakok M, Kara A. Is liposomal amphotericin b really safety in neonates? Early Hum Dev. 2013; 89: 35-36.

2565 2566	631	Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, de Lucia A. Liposomal amphotericin b treatment for neonatal fungal infections. <i>Pediatr Infect Dis J</i> . 1998; 17 : 146-148.
2567	632	Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose
2568		liposomal amphotericin b in the therapy of systemic candidiasis in neonates. Eur J Clin
2569		Microbiol Infect Dis. 2003; 22 : 603-607.
2570	633	Mellinghoff SC, Bassetti M, Dorfel D, et al. Isavuconazole shortens the qtc interval. Mycoses.
2571		2017.
2572	634	Cornely OA. Isavuconazole: Is there a need for a new antifungal? J Antimicrob Chemother.
2573		2017; 72 : i2-i4.
2574	635	Neofytos D, Ostrander D, Shoham S, et al. Voriconazole therapeutic drug monitoring: Results
2575		of a prematurely discontinued randomized multicenter trial. Transpl Infect Dis. 2015; 17:
2576		831-837.
2577	636	Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin b lipid complex
2578		(ablc) treatment in allogeneic hematopoietic cell transplant (hct) recipients with invasive
2579		aspergillosis (ia). Bone Marrow Transplant. 2005; 36 : 873-877.
2580	637	Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of
2581		micafungin (fk463) in the treatment of deep-seated mycosis in japan. Scand J Infect Dis.
2582		2004; 36 : 372-379.
2583	638	Denning DW, Marr KA, Lau WM, et al. Micafungin (fk463), alone or in combination with other
2584		systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;
2585		53 : 337-349.
2586	639	Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination
2587		with other systemic antifungal therapies in hematopoietic stem cell transplant recipients
2588		with invasive aspergillosis. Transpl Infect Dis. 2009; 11: 89-93.
2589	640	Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin b in combination with
2590		caspofungin for invasive aspergillosis in patients with hematologic malignancies: A
2591		randomized pilot study (combistrat trial). <i>Cancer</i> . 2007; 110 : 2740-2746.
2592	641	Dohen-Becue F, Salez F, Ramon P, et al. [management of hemoptysis in invasive pulmonary
2593		aspergillosis]. Revue des maladies respiratoires. 1998; 15: 791-796.

- Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. *Blood*. 2005; **106**: 2641-2645.
 Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: A series of 14 cases from a general hospital and review of 123 cases from the literature. *Medicine (Baltimore)*. 2012; **91**: 328-336.
 Rüping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central
- 2599644Rüping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central2600nervous system. J Antimicrob Chemother. 2008; 62: 1468-1470.
- 2601 645 Coleman JM, Hogg GG, Rosenfeld JV, Waters KD. Invasive central nervous system
 2602 aspergillosis: Cure with liposomal amphotericin b, itraconazole, and radical surgery--case
 2603 report and review of the literature. *Neurosurgery*. 1995; **36**: 858-863.
- 2604 646 Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional
 2605 amphotericin b, liposomal amphotericin b (ambisome), caspofungin, micafungin, and
 2606 voriconazole alone and in combination against experimental murine central nervous system
 2607 aspergillosis. Antimicrob Agents Chemother. 2005; 49: 4867-4875.
- 2608 647 Ellis M, Spence D, de Pauw B, et al. An eortc international multicenter randomized trial (eortc
 2609 number 19923) comparing two dosages of liposomal amphotericin b for treatment of
 2610 invasive aspergillosis. *Clin Infect Dis.* 1998; **27**: 1406-1412.
- 2611648Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin b-2612based therapy in cns aspergillosis. *Mycoses*. 2007; **50**: 196-200.
- 2613 649 Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin b formulations in
 2614 immunocompromised patients in 4 european countries. *Clin Infect Dis.* 2006; **43**: e29-38.
- 2615 650 Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated
 2616 with amphotericin b for suspected or proven aspergillosis. *Clin Infect Dis.* 1999; **29**: 14022617 1407.
- 2618 651 Girmenia C, Pizzarelli G, Pozzi E, Cimino G, Gentile G, Martino P. Improving outcomes of
 2619 acute invasive aspergillus rhinosinusitis in patients with hematologic malignancies or aplastic
 2620 anemia: The role of voriconazole. *Haematologica*. 2008; **93**: 159-160.

- 2621 652 Thurtell MJ, Chiu AL, Goold LA, et al. Neuro-ophthalmology of invasive fungal sinusitis: 14
 2622 consecutive patients and a review of the literature. *Clin Experiment Ophthalmol*. 2013; 41:
 2623 567-576.
- 2624 653 Daudia A, Jones NS. Advances in management of paranasal sinus aspergillosis. *J Laryngol*2625 *Otol*. 2008; **122**: 331-335.
- 2626 654 Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive
 2627 fungal infections in allogeneic stem cell transplant recipients: Results of the vosifi study.
 2628 Haematologica. 2010; 95: 1762-1768.
- Liu F, Wu T, Wang JB, et al. Risk factors for recurrence of invasive fungal infection during
 secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
 Transpl Infect Dis. 2013; **15**: 243-250.
- 2632 656 Gerlach S, Vehreschild JJ, Ruping MJTG, Fischer G, Cornely OA. Epidemiology of aspergillus
 2633 spp. At the university hospital of cologne: Molecular typing of environmental and clinical
 2634 isolates. In: *Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerichen*2635 *GHO*. Wien, Österreich: Onkologie, 2008.
- 2636 657 Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal
 2637 prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. *J Antimicrob*2638 *Chemother*. 2008; **61**: 734-742.
- de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary
 prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary
 and/or systemic fungal infection. *Bone Marrow Transplant*. 2007; **40**: 245-249.
- Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation
 conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic
 hematopoietic stem cell transplantation: A retrospective survey of the infectious diseases
 working party of the european group for blood and marrow transplantation. *Blood*. 2006;
 108: 2928-2936.
- Kruger WH, Russmann B, de Wit M, et al. Haemopoietic cell transplantation of patients with
 a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin
 b. Acta Haematol. 2005; 113: 104-108.

- 2650 661 Nosari A, Ravini M, Cairoli R, et al. Surgical resection of persistent pulmonary fungus nodules
 2651 and secondary prophylaxis are effective in preventing fungal relapse in patients receiving
 2652 chemotherapy or bone marrow transplantation for leukemia. *Bone Marrow Transplant*.
 2653 2007; **39**: 631-635.
- 2654 662 Eliashar R, Resnick IB, Goldfarb A, Wohlgelernter J, Gross M. Endoscopic surgery for sinonasal
 2655 invasive aspergillosis in bone marrow transplantation patients. *The Laryngoscope*. 2007; **117**:
 2656 78-81.
- 2657 663 Cesaro S, Cecchetto G, De Corti F, et al. Results of a multicenter retrospective study of a
 2658 combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic
 2659 patients. *Pediatric blood & cancer*. 2007; 49: 909-913.
- 2660664Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive2661pulmonary aspergillosis in patients with neutropenia. *Chest*. 2004; **126**: 1783-1788.
- 2662 665 Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis
 2663 in neutropenic patients with hematologic diseases. *Am J Respir Crit Care Med*. 1998; **158**:
 2664 885-890.
- 2665 666 Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous
 amphotericin b deoxycholate as empirical antifungal therapy for persistent fever in
 neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A
 randomized, controlled trial. *Annals of internal medicine*. 2001; **135**: 412-422.
- Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial
 evaluating the safety of liposomal amphotericin b versus amphotericin b lipid complex in the
 empirical treatment of febrile neutropenia. L amph/ablc collaborative study group. *Clin Infect Dis.* 2000; **31**: 1155-1163.
- 2673 668 White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of
 2674 amphotericin b colloidal dispersion vs. Amphotericin b in the empirical treatment of fever
 2675 and neutropenia. *Clin Infect Dis.* 1998; **27**: 296-302.
- 2676 669 Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety of micafungin, an echinocandin
 2677 antifungal agent, on invasive fungal infections in patients with hematological disorders. *Leuk*2678 *Lymphoma*. 2009; **50**: 92-100.

- 2679 670 Lass-Florl C. Triazole antifungal agents in invasive fungal infections: A comparative review.
 2680 Drugs. 2011; **71**: 2405-2419.
- 2681 671 Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive
 2682 aspergillosis. *Clin Infect Dis.* 2004; **39**: 797-802.
- 2683 672 Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or
 2684 refractory fungal infections. *Clin Infect Dis*. 2003; **36**: 1122-1131.
- 2685 673 Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal
 2686 infections in patients failing or intolerant to standard antifungal therapy. *Transplantation*.
 2687 2003; **76**: 1632-1637.
- 2688 674 Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary
 2689 invasive fungal infections in 32 immunocompromised patients with hematologic
 2690 malignancies. *Eur J Haematol*. 2005; **75**: 227-233.
- 2691 675 Ng TT, Denning DW. Liposomal amphotericin b (ambisome) therapy in invasive fungal
 2692 infections. Evaluation of united kingdom compassionate use data. *Archives of internal*2693 *medicine*. 1995; **155**: 1093-1098.
- 2694 676 Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin b lipid complex versus liposomal
 2695 amphotericin b monotherapy for invasive aspergillosis in patients with hematologic
 2696 malignancy. *Cancer.* 2008; **112**: 1282-1287.
- 2697 677 Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin b lipid complex for invasive fungal
 2698 infections: Analysis of safety and efficacy in 556 cases. *Clin Infect Dis.* 1998; **26**: 1383-1396.
- 2699 678 Chandrasekar PH, Ito JI. Amphotericin b lipid complex in the management of invasive
 2700 aspergillosis in immunocompromised patients. *Clin Infect Dis.* 2005; **40 Suppl 6**: S392-400.
- 2701 679 Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin b colloidal
 2702 dispersion in the treatment of invasive mycoses. *Clin Infect Dis.* 1995; **21**: 1145-1153.
- 2703 680 Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin b colloidal
 2704 dispersion. An overview. *Chemotherapy*. 1999; **45 Suppl 1**: 67-76.
- 2705681Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive candida or2706invasive aspergillus infections in neutropenic patients. *Cancer*. 2006; **106**: 466-473.

- Egerer G, Reichert D, Pletz MW, Kaskel P, Krobot KJ, Maertens J. Caspofungin for treatment
 of invasive aspergillosis in germany: Results of a pre-planned subanalysis of an international
 registry. *Eur J Med Res.* 2012; **17**: 7.
- Hiemenz JW, Raad, II, Maertens JA, et al. Efficacy of caspofungin as salvage therapy for
 invasive aspergillosis compared to standard therapy in a historical cohort. *Eur J Clin Microbiol Infect Dis.* 2010; 29: 1387-1394.
- Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for
 invasive aspergillosis: Results from the caspofungin compassionate use study. *J Infect*. 2005;
 50: 196-205.
- Morrissey CO, Slavin MA, O'Reilly MA, et al. Caspofungin as salvage monotherapy for invasive
 aspergillosis in patients with haematological malignancies or following allogeneic stem cell
 transplantation: Efficacy and concomitant cyclosporin a. *Mycoses*. 2007; **50 Suppl 1**: 24-37.
- 2719 686 Maertens J, Egerer G, Shin WS, et al. Caspofungin use in daily clinical practice for treatment
 2720 of invasive aspergillosis: Results of a prospective observational registry. *BMC Infect Dis.* 2010;
 2721 10: 182.
- 2722687Leon-Gil C, Ubeda-Iglesias A, Loza-Vazquez A, et al. Efficacy and safety of caspofungin in2723critically ill patients. Procas study. *Rev Esp Quimioter*. 2012; **25**: 274-282.
- 2724688Enoch DA, Idris SF, Aliyu SH, Micallef C, Sule O, Karas JA. Micafungin for the treatment of2725invasive aspergillosis. J Infect. 2014; 68: 507-526.
- 2726 689 Hachem RY, Langston AA, Graybill JR, et al. Posaconazole as salvage treatment of invasive
 2727 fungal infections in patients with underlying renal impairment. *J Antimicrob Chemother*.
 2728 2008; 62: 1386-1391.
- Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal
 therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective
 analysis. *Mycoses*. 2013; 56: 304-310.
- 2732 691 Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of
 2733 amphotericin-b-refractory invasive pulmonary aspergillosis. *Acta Haematol.* 2003; 109: 1112734 118.

- 2735 692 Luong ML, Chaparro C, Stephenson A, et al. Pretransplant aspergillus colonization of cystic
 2736 fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.
 2737 *Transplantation*. 2014; **97**: 351-357.
- Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin b prophylaxis for aspergillus
 infection in lung transplantation: Study of risk factors. *J Heart Lung Transplant*. 2001; 20:
 1274-1281.
- 2741 694 Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients:
 2742 Incidence and prognosis. *Eur J Clin Microbiol Infect Dis.* 2007; 26: 879-886.
- Hsu JL, Khan MA, Sobel RA, et al. Aspergillus fumigatus invasion increases with progressive
 airway ischemia. *PLoS One*. 2013; 8: e77136.
- Sole A, Morant P, Salavert M, Peman J, Morales P, Valencia Lung Transplant G. Aspergillus
 infections in lung transplant recipients: Risk factors and outcome. *Clin Microbiol Infect*. 2005;
 11: 359-365.
- 2748 697 Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal
 2749 infection within the first year after pediatric lung transplantation. *J Heart Lung Transplant*.
 2750 2008; **27**: 655-661.
- Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yanez J, et al. Igg monitoring to identify the risk
 for development of infection in heart transplant recipients. *Transpl Infect Dis.* 2006; 8: 49-53.
- 2753 699 Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections
 2754 complicating orthotopic liver transplantation. *The Journal of infectious diseases*. 1994; **170**:
 2755 644-652.
- 2756 700 Singh N, Husain S, Practice ASTIDCo. Invasive aspergillosis in solid organ transplant recipients.
 2757 Am J Transplant. 2009; **9 Suppl 4**: S180-191.
- 2758 701 Singh N, Pruett TL, Houston S, et al. Invasive aspergillosis in the recipients of liver
 2759 retransplantation. *Liver Transpl.* 2006; **12**: 1205-1209.
- 2760 702 Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: Outcomes and
 2761 risk factors revisited in the meld era. *Clin Transplant*. 2013; 27: E454-461.

- 2762 703 He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchial-pulmonary aspergillosis in
 critically ill patients with chronic obstructive respiratory diseases: A prospective study. *Crit Care.* 2011; **15**: R5.
- 2765 704 Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive
 pulmonary disease. *Eur Respir J*. 2007; **30**: 782-800.
- Kistemann T, Huneburg H, Exner M, Vacata V, Engelhart S. Role of increased environmental
 aspergillus exposure for patients with chronic obstructive pulmonary disease (copd) treated
 with corticosteroids in an intensive care unit. *Int J Hyg Environ Health*. 2002; **204**: 347-351.
- 2770 706 Murray CK, Loo FL, Hospenthal DR, et al. Incidence of systemic fungal infection and related
 2771 mortality following severe burns. *Burns*. 2008; **34**: 1108-1112.
- 2772 707 Lahmer T, Messer M, Schwerdtfeger C, et al. Invasive mycosis in medical intensive care unit
 2773 patients with severe alcoholic hepatitis. *Mycopathologia*. 2014; **177**: 193-197.
- 2774 708 Ballard J, Edelman L, Saffle J, et al. Positive fungal cultures in burn patients: A multicenter
 2775 review. *J Burn Care Res.* 2008; 29: 213-221.
- 2776 709 Horvath EE, Murray CK, Vaughan GM, et al. Fungal wound infection (not colonization) is
 2777 independently associated with mortality in burn patients. *Annals of surgery*. 2007; 245: 9782778 985.
- Guinea J, Jensen J, Pelaez T, et al. Value of a single galactomannan determination (platelia)
 for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation
 of aspergillus spp. *Medical mycology*. 2008; **46**: 575-579.
- Acosta J, Catalan M, del Palacio-Perez-Medel A, et al. Prospective study in critically ill nonneutropenic patients: Diagnostic potential of (1,3)-beta-d-glucan assay and circulating
 galactomannan for the diagnosis of invasive fungal disease. *Eur J Clin Microbiol Infect Dis*.
 2012; **31**: 721-731.
- He H, Ding L, Sun B, Li F, Zhan Q. Role of galactomannan determinations in bronchoalveolar
 lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for
 the diagnosis of invasive pulmonary aspergillosis: A prospective study. *Crit Care*. 2012; 16:
 R138.

- 2790 713 Khorvash F, Meidani M, Babaei L, Abbasi S, Ataei B, Yaran M. Galactomannan antigen assay
 2791 from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in
 2792 intensive care units patients. *Adv Biomed Res.* 2014; **3**: 68.
- 2793 714 Steinmann J, Buer J, Rath PM. Detection of aspergillus fumigatus in blood samples from
 2794 critically ill patients in intensive care units by use of the septifast assay. *Journal of clinical*2795 *microbiology*. 2016; **54**: 1918-1921.
- Westh H, Lisby G, Breysse F, et al. Multiplex real-time pcr and blood culture for identification
 of bloodstream pathogens in patients with suspected sepsis. *Clin Microbiol Infect*. 2009; 15:
 544-551.
- Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of
 invasive pulmonary aspergillosis among solid-organ transplant recipients. *Journal of clinical microbiology*. 2007; 45: 1759-1765.
- 2802 717 Gazzoni FF, Hochhegger B, Severo LC, et al. High-resolution computed tomographic findings
 2803 of aspergillus infection in lung transplant patients. *Eur J Radiol.* 2014; 83: 79-83.
- Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for
 invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ
 transplant patients. *J Infect*. 2012; 65: 588-591.
- Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3){beta}-d-glucan test as an
 aid to early diagnosis of invasive fungal infections following lung transplantation. *Journal of clinical microbiology*. 2010; **48**: 4083-4088.
- Husain S, Kwak EJ, Obman A, et al. Prospective assessment of platelia aspergillus
 galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant
 recipients. *Am J Transplant*. 2004; **4**: 796-802.
- Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the
 bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant
 recipients. *Transplantation*. 2007; 83: 1330-1336.
- Ambrosioni J, Coll S, Manzardo C, et al. Voriconazole and cobicistat-boosted antiretroviral
 salvage regimen co-administration to treat invasive aspergillosis in an hiv-infected patient. J
 Antimicrob Chemother. 2016; **71**: 1125-1127.

- 2819 723 Utili R, Zampino R, De Vivo F, et al. Improved outcome of pulmonary aspergillosis in heart
 2820 transplant recipients with early diagnosis and itraconazole treatment. *Clin Transplant*. 2000;
 2821 14: 282-286.
- Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin b after
 aerosolized delivery of amphotericin b lipid complex (abelcet; ablc) in lung transplant
 recipients. *Transplantation*. 2010; **90**: 1215-1219.
- 2825 725 Mucha K, Foroncewicz B, Orlowski T, et al. Atypical presentation of invasive pulmonary
 2826 aspergillosis in a liver transplant recipient. *Ann Transplant*. 2013; **18**: 238-242.
- 2827 726 Lopez-Medrano F, Fernandez-Ruiz M, Silva JT, et al. Clinical presentation and determinants of
 mortality of invasive pulmonary aspergillosis in kidney transplant recipients: A multinational
 cohort study. *Am J Transplant*. 2016; 16: 3220-3234.
- 2830 727 Kleinberg M. Aspergillosis in the clear outcomes trial: Working toward a real-world clinical
 2831 perspective. *Medical mycology*. 2005; 43 Suppl 1: S289-294.
- 2832728Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant2833recipients: Outcome comparison of therapy with amphotericin b lipid complex and a2824bistorical schedulith comparison of therapy and schedulith approximation by Clip (affort Dis 2002) 27: 47-25
- historical cohort treated with conventional amphotericin b. *Clin Infect Dis.* 2003; **37**: 17-25.
- Walter J, Sobottka I, Rogiers X, Broering D, Fischer L. Invasive aspergillosis caused by
 aspergillus terreus in a living donor liver transplant recipient successfully treated by
 caspofungin. *Mycoses*. 2011; 54: e220-222.
- 2838730Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the2839resitra cohort: A multicenter prospective study. Am J Transplant. 2007; 7: 1989-1996.
- 2840 731 Neoh CF, Snell GI, Levvey B, et al. Preemptive treatment with voriconazole in lung transplant
 2841 recipients. *Transpl Infect Dis.* 2013; 15: 344-353.
- 2842 732 Drew RH, Dodds Ashley E, Benjamin DK, Jr., Duane Davis R, Palmer SM, Perfect JR.
- 2843 Comparative safety of amphotericin b lipid complex and amphotericin b deoxycholate as
- 2844 aerosolized antifungal prophylaxis in lung-transplant recipients. *Transplantation*. 2004; 77:
 2845 232-237.

- 2846 733 Monforte V, Ussetti P, Gavalda J, et al. Feasibility, tolerability, and outcomes of nebulized
 2847 liposomal amphotericin b for aspergillus infection prevention in lung transplantation. *J Heart*2848 *Lung Transplant*. 2010; **29**: 523-530.
- 2849 734 Monforte V, Lopez-Sanchez A, Zurbano F, et al. Prophylaxis with nebulized liposomal
 amphotericin b for aspergillus infection in lung transplant patients does not cause changes in
 the lipid content of pulmonary surfactant. *J Heart Lung Transplant*. 2013; **32**: 313-319.
- 2852 735 Borro JM, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin b lipid
 2853 complex (abelcet) in the prophylaxis of invasive fungal infections following lung
 2854 transplantation. *Transplant Proc.* 2008; **40**: 3090-3093.
- Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous
 malignancy: A literature review on photocarcinogenesis in organ transplant recipients. *Clin Infect Dis.* 2014; 58: 997-1002.
- 2858 737 Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac
 2859 transplantation. *Clin Infect Dis.* 2003; **37 Suppl 3**: S281-292.
- 2860 738 Paniagua Martin MJ, Marzoa Rivas R, Barge Caballero E, et al. Efficacy and tolerance of
 2861 different types of prophylaxis for prevention of early aspergillosis after heart transplantation.
 2862 Transplant Proc. 2010; 42: 3014-3016.
- Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a
 lipid preparation of amphotericin b for invasive fungal infections in liver transplant recipients
 requiring renal replacement therapy. *Transplantation*. 2001; **71**: 910-913.
- 2866 740 Castroagudin JF, Ponton C, Bustamante M, et al. Prospective interventional study to evaluate
 2867 the efficacy and safety of liposomal amphotericin b as prophylaxis of fungal infections in
 2868 high-risk liver transplant recipients. *Transplant Proc.* 2005; **37**: 3965-3967.
- Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for
 high-risk liver transplant recipients. *Liver Transpl.* 2007; 13: 1743-1750.
- 2871 742 Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal
 2872 infections in high-risk liver transplant recipients. *Transplantation*. 2009; 87: 424-435.
- 2873 743 Chakrabarti A, Sethi S, Raman DS, Behera D. Eight-year study of allergic bronchopulmonary
 2874 aspergillosis in an indian teaching hospital. *Mycoses*. 2002; 45: 295-299.

2875	744	Tashiro T, Izumikawa K, Tashiro M, et al. A case series of chronic necrotizing pulmonary
2876		aspergillosis and a new proposal. Jpn J Infect Dis. 2013; 66: 312-316.
2877	745	Dupont B. Itraconazole therapy in aspergillosis: Study in 49 patients. J Am Acad Dermatol.
2878		1990; 23 : 607-614.
2879	746	Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute
2880		invasive and chronic pulmonary aspergillosis. The American journal of medicine. 2006; 119:
2881		527 e517-524.
2882	747	Saito T, Fujiuchi S, Tao Y, et al. Efficacy and safety of voriconazole in the treatment of chronic
2883		pulmonary aspergillosis: Experience in japan. Infection. 2012; 40: 661-667.
2884	748	Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of
2885		posaconazole for chronic pulmonary aspergillosis. <i>Clin Infect Dis</i> . 2010; 51 : 1383-1391.
2886		

2887 Transparency Declaration: Dr. Cornely reports research grants from Actelion, Amplyx, Arsanis, 2888 Astellas, AstraZeneca, Basilea, Bayer, Cidara, Duke University (NIH UM1AI104681), F2G, Gilead, GSK, 2889 Leeds University, Matinas, Medicines Company, MedPace, Melinta, Merck/MSD, Miltenyi, Pfizer, 2890 Rempex, Roche, Sanofi Pasteur, Scynexis, Seres, is a consultant to Amplyx, Actelion, Astellas, Basilea, 2891 Cidara, Da Volterra, F2G, Gilead, Janssen, Matinas, Menarini, Merck/MSD, Paratek, PSI, Scynexis, 2892 Seres, Summit, Tetraphase, Vical, and received lecture honoraria from Astellas, Basilea, Gilead, 2893 Merck/MSD and Pfizer, outside the submitted work. Dr. Ader has nothing to disclose. Dr. Aguado 2894 received honoraria for speaking at symposia organised on behalf of Pfizer, Merck Sharp & Dohme 2895 (MSD), Schering-Plough and Gilead and was on advisory boards for antifungal agents on behalf of 2896 MSD, Astellas, Pfizer and Gilead. Dr. Akova has nothing to disclose. Dr. Arendrup reports personal 2897 fees from MSD and Pfizer, grants from Basilea, Gilead, Amplyx, F2G and Cidara, outside the 2898 submitted work. Dr. Arikan-Akdagli reports non-financial support from Pfizer, outside the submitted 2899 work. Dr. Barnes reports personal fees from Gilead, Basilia and Biomerieux, grants from EORTC, 2900 outside the submitted work. Dr. Beigelman-Aubry reports personal fees from Gilead, outside the 2901 submitted work. Dr. Blot reports grants from Pfizer, outside the submitted work. Dr. Bouza has 2902 nothing to disclose. Dr. Brüggemann has received grants and consultancy fees as well as speaker 2903 fees from MSD, Pfizer, Gilead and Astellas. All contracts were with Radboudumc and all payments 2904 have been received by Radboudumc. Dr. Buchheidt reports personal fees and non-financial support 2905 from Astellas, personal fees from Basilea, grants, personal fees and non-financial support from 2906 Gliead, personal fees and non-financial support from Merck Sharp & Dohme/Merck, grants, 2907 personal fees and non-financial support from Pfizer, outside the submitted work. Dr. Cadranel 2908 reports personal fees from MSD, outside the submitted work. Dr. Castagnola reports personal fees 2909 from Astellas Pharma, non-financial support from Gilead, outside the submitted work. Dr. 2910 Chakrabarti has nothing to disclose. Dr. Cuenca-Estrella reports grants and other from Gilead and 2911 MSD, grants from Amplyx, Cidara, Scynexis and F2G, other from Astellas, outside the submitted 2912 work. Dr. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out 2913 antifungal discovery company. He acts or has recently acted as a consultant to Astellas, Sigma Tau, 2914 Basilea, Scynexis, Cidara, Biosergen, Quintiles, Pulmatrix, Pulmocide and Zambon. In the last 3 years, 2915 he has been paid for talks on behalf of Astellas, Dynamiker, Gilead, Merck and Pfizer. He is a 2916 longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, 2917 the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines 2918 group and the British Society for Medical Mycology Standards of Care committee. In addition, Dr. 2919 Denning has a patent Assays for Fungal Infection licensed. Dr. Dimopoulos has nothing to disclose. 2920 Dr. Fortún has nothing to disclose. Dr. Gangneux reports grants and personal fees from Pfizer, MSD, 2921 Gilead and Astellas during the conduct of the study. Dr. Garbino has nothing to disclose. Dr. Groll 2922 reports grants and personal fees from Gilead, Merck, Sharp & Dohme and Pfizer, personal fees from 2923 Astellas and Basilea, outside the submitted work. Dr. Heinz reports personal fees from Astellas, 2924 Gilead and Basilea, grants and personal fees from MSD Sharp & Dohme / Merck and Pfizer, outside 2925 the submitted work. Dr. Herbrecht reports personal fees from Astellas, Basilea, Gilead, MSD and 2926 Pfizer, outside the submitted work. Dr. Heussel reports personal fees from Boehringer Ingelheim, 2927 Novartis, Gilead, Intermune and Fresenius, grants from Siemens, Pfizer and Boehringer Ingelheim, 2928 lecture fees from Gilead, MSD, Pfizer, Intermune, Novartis, Basilea and Bayer, outside the submitted 2929 work. Dr. Heussel has a patent for Method and Device For Representing the Microstructure of the 2930 Lungs licensed. Dr. Kibbler reports personal fees from Gilead, outside the submitted work. Dr. 2931 Klimko reports personal fees from Astellas and Pfizer, and grants and personal fees from Merck, 2932 outside the submitted work. Dr. Kullberg reports personal fees from Astellas, Amplyx, Cidara, Gilead, 2933 Pfizer and Scynexis, outside the submitted work. Dr. Lagrou reports grants, personal fees and non-2934 financial support from MSD, Pfizer and Gilead, personal fees from Abbott, outside the submitted 2935 work. Dr. Lange reports personal fees from Chiesi, Gilead, Abbvie, MSD, Becton Dickinson, Janssen, 2936 Lucane, Novartis, Thermofisher, and Transgene, outside the submitted work. Dr. Lass-Flörl reports 2937 grants, personal fees and other from Astellas Pharma and Gilead, personal fees and other from 2938 Pfizer, other from Merck Sharp and Dohme and Basilea, outside the submitted work. Dr.

2939 Lehrnbecher reports grants, personal fees and non-financial support from Gilead Sciences, personal 2940 fees and non-financial support from Astellas and Merck/MSD, personal fees from Basilea, outside 2941 the submitted work. Dr. Lewis reports personal fees from Gilead, grants and personal fees from 2942 Merck, personal fees from Cidara, outside the submitted work. Dr. Loeffler has nothing to disclose. 2943 Dr. Lotholary has nothing to disclose. Dr. Maertens reports grants, personal fees and non-financial 2944 support from MSD, Astellas, Pfizer and Gilead, personal fees and non-financial support from Basilea 2945 and F2G, personal fees from Scynexis, during the conduct of the study. Dr. Marchetti has nothing to 2946 disclose. Dr. Meis reports personal fees and grants for consultancy from Astellas, MSD and Scynexis, 2947 grants from F2G and Pulmozyme, personal fees and grands for lectures including service on speakers 2948 bureaus from Merck, Gilead and TEVA, grants for travel and accommodation from Nordic-Pharma, 2949 outside the submitted work. Dr. Muñoz has nothing to disclose. Dr. Pagano reports grants and 2950 personal fees from Gilead, personal fees from MSD, Pfizer, Novartis, Janssen and Basilea, outside 2951 the submitted work. Dr. Ribaud has nothing to disclose. Dr. Richardson reports other from 2952 Associates of Cape Cod, personal fees from Gilead and MSD, other from Gilead, during the conduct 2953 of the study. Dr. Roilides reports grants, personal fees and non-financial support from Astellas, 2954 Gilead Merck and Pfizer, outside the submitted work. Dr. Ruhnke reports personal fees from Basilea 2955 and Scynexis for board membership, personal fees from Basilea and Janssen for lectures including 2956 service on speakers bureaus, personal fees from Janssen for development of educational 2957 presentation, outside the submitted work. Dr. Sanguinetti has nothing to disclose. Dr. Sheppard 2958 reports grants and personal fees from Merck, outside the submitted work. Dr. Sinko reports 2959 personal fees (honoraria, fees for consulting, lectures, speakers bureaus) from Pfizer, Merck, 2960 Astellas. Dr. Skiada has nothing to disclose. Dr. Ullmann reports personal fees from Pfizer, Astellas, 2961 MSD and Gilead, outside the submitted work. Dr. Vehreschild reports personal fees, non-financial 2962 support and other from Astellas, during the conduct of the study; grants and personal fees from 2963 Astellas and Merck/MSD, grants from Seres Therapeutics and DaVolterra, grants and personal fees 2964 from Gilead, personal fees from Berlin Chemie, Falk Foundation, Organobalance and Pfizer, outside

the submitted work. Dr. Verweij reports grants from Gilead Sciences, MSD and F2G, outside the
submitted work. Dr. Viscoli reports personal fees from MSD, Gilead, Pfizer, Angelini, Astellas and
Basilea, outside the submitted work. Dr. Warris reports grants from Gilead, other from Gilead and
Basilea, outside the submitted work.